DNAPrint Genomics ...... wann, wenn nicht 2004! - 500 Beiträge pro Seite

[ge4teilter]

Moin!

Auf Wunsch unseres verdienten Alt- aber seit 3. März 2004 leider auch Ex-Aktionärskollegen cariocca aus der Schweiz möchte ich nun einen neuen DNAP-Thread für 2004 eröffnen.

Obwohl ich ein sehr positives und optimistisches Kerlchen bin, will ich gleich vorausschicken, daß auch ich nicht mehr länger als bis 31.12.2004 Geduld haben werde.

Denn, wie der Threadtitel schon sagt: Wann, wenn nicht 2004?!

Ich wünsch´ Euch was!

ge4teilter

[hvs1]

g4,

wird schon werden.
Leider wird es wohl auch bis zum Ende des Jahres dauern.
Aber ich hoffe,Du stellst öfter wichtige Dinge hier rein.
Möglichst in deutscher Übersetzung oder sinngemäße Wieder-
gabe.
Viel Glück!

hvs1

[Michiko]

PHIUUU!

Ist der Kelch der Thread-Eröffnung doch an mir vorüber gegangen!

So ganz abschreiben sollten wir DNAP und Co noch nicht. Es kamen schon öfter Überraschungen aus dem OFF. Ich selbst werde noch eine Weile (schätze mal bis ca. Herbst) geduldig bleiben; erwarte aber dann schon deutliche(!) Zeichen, wie es weitergehen kann.
Von daher gesehen, G4, hast Du eine gute Thread-Überschrift gewählt.

Schaun wir, wie sich die Geschichte weiter entwickelt und was wir von "drüben" (z.B. ihub) erfahren.

Gruß an alle Investierten

Michi

[hvs1]

Vielleicht kann ja mal jemand den derzeitigen Stand
von DNAP darstellen und welche Erwartungen in der Pipeline
sind.

hvs1

[hvs1]

DNAP,

was ist bloß mit dir los?
Das ist ja schrecklich.

hvs1

[Michiko]

Auszug aus einer press release im letzten Dezember:

We are extremely excited about the prospects for DNAPrint™ now that we have established a reliable source of capital for the foreseeable future,” said Richard Gabriel, CEO and President of DNAPrint. “This financing, once it completes the registration process at the SEC, should allow management to build shareholder value.

Ein wenig auf den Arm genommen wird man ja schon von diesen Herren!

Michi

[hvs1]

Michi,

bist Du noch voll investiert?

hvs1

[Michiko]

hvs1,

einen Teil habe ich verscherbelt.
Halte aber immer noch ca. 700k Stück.
Die liegen irgendwo in einer Ecke rum und bleiben vorerst auch dort.
Wie sieht´s bei Dir aus?

Michi

[hvs1]

Michi,

halte 650K bis zum bitteren Ende.
Mahastock im RB hat ein Email von Frudakis erhalten,
daß sie an diversen Sachen arbeiten aber keine News ver-
melden können.
Also abwarten.
Ich wollte auf 1,0 M aufstocken,warte erstmal ab.

hvs1

[Michiko]

hvs1,

und prompt geht´s in Amiland hoch!

Gruß

Michi

[ge4teilter]

NEWS (....und keine schlechte, wie ich finde!)

DNAPrint(TM) Invited to Present at the National District Attorney Association Board of Directors Meeting
DNAPrint(TM) Invited to Present at the National District Attorneys Association Board of Directors Meeting
SARASOTA, Fla., March 18 /PRNewswire/ -- DNAPrint(TM) genomics, Inc. ("DNAPrint" or the "Company") has been invited to present its flagship product, DNAWitness(TM), at the National District Attorneys Association Board
of Directors Meeting to be held March 18-20, 2004 at the Radisson Bahia Mar in Ft. Lauderdale, Florida. The company`s Technical Director of Forensics, Zach
Gaskin, will discuss how DNAWitness(TM) can aid in investigations and will describe recent cases in which the technology has been applied. DNAWitness(TM)
is an advanced presumptive DNA test that gives an investigator a reasonably good eyewitness at the crime scene by using the genetic code of the donor. The
test determines the Biogeographical Ancestry (BGA) of an individual giving the percentages of East Asian, Native American, European, and Sub-Saharan African.
"Meetings such as this are helping us reach into all areas of the justice system. Primarily, DNAWitness(TM) cases come from the crime labs, detectives and prosecutors, so it is important to provide each of these areas with
information about the test," said Zach Gaskin, Technical Director of Forensics with DNAPrint(TM). "Every agency in the U.S. has at least one case, if not more, where this technology can, and should, be applied. Educating people
about DNAWitness(TM) is the first step to helping solve these crimes. Imagine for a second if a fuzzy photo ID was left at each crime scene. That`s what this test can do for an investigation."
"Our long-term goal with this technology is to bring all crime scene donors` DNA to the detectives. The fuzzy photos that we provide will help investigators sort through the hundreds, sometime thousands, of bits of
information, helping them and the prosecutors determine who is and who is not likely to be a suspect in a crime," said Richard Gabriel, the Company`s CEO and President. "DNAWitness(TM) is a flagship product that provides stunning results that can help detectives and prosecutors by matching donor crime scene DNA to eyewitness reports. That`s just one example of its application, and because it is a presumptive test, it can be used wherever DNA is found at a crime scene. The test kit used to collect the evidence is free from DNAPrint(TM) genomics and through the Lynn Peavey Company catalog. We perform all of our analysis under the strictest confidentiality and highest quality control and quality assurance. We are delighted and honored to be selected as
a guest speaker at the National District Attorneys Association Board of Directors Meeting."

About DNAPrint(TM) genomics, Inc.
DNAPrint(TM) genomics, Inc. was founded by a team of scientists with
research and commercial experience in high-level mathematical modeling,
programming and molecular genetics. The DNAWitness(TM) and the
ANCESTRYbyDNA(TM) analysis is a direct result of focused research by the DNAP research and development team.
In addition, using proprietary human genome research methods, the Company develops pharma-predictive tests for matching patients with drugs based on their genetic constitution, discovers disease genes for the development of new drugs and develops new forensic genomics and consumer genomics testing products. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit
www.dnaprint.com. For more information on our genealogical DNA-derived test, ANCESTRYbyDNA(TM) 2.5, visit us on line at www.ancestrybydna.com helping everyone to understand their genetic heritage.
All statements in this press release that are not historical and are forward-looking statements within the meaning of Section 21E of the Securities
Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s(TM) products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint(TM) genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in DNAPrint`s(TM) expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Media and Press Contacts
Richard Gabriel
DNAPrint(TM) genomics, Inc.
CEO/President
[phone]

SOURCE DNAPrint genomics, Inc.
-0- 03/18/2004
/CONTACT: Richard Gabriel, CEO - President, DNAPrint(TM) genomics,
[phone]/
/Web site: http://www.dnaprint.com
http://www.ancestrybydna.com /
(DNAP)

CO: DNAPrint genomics, Inc.; National District Attorneys Association
ST: Florida
IN: MTC OTC
SU:
*** end of story ***


g4

[Michiko]

Ist schon in Ordnung g4!

Erklärt auch den kurzen Uptrend.

Aber konkret?

Wenn da nix nachkommt, setzt sich die uns hinlänglich bekannte Linie weiter fort.

GCBR will bei 3 Cents nachkaufen, wenn ich das richtig in Erinnerung habe!!!

Take care!

[cariocca]

Hmmmm...

Habt ihr auf mich gehört? Hmmm...? PRIM ist am Durchstarten.
Toller CEO. Kommunikation PUR. DNAP wird ihre Zeit haben...
Die Frage ist: WANN?

Viel Glück an Alle.

Roger (ein Raum in der Toscana-Villa ist im Körbchen)

[Michiko]

Ein wenig Neues:

DNAPrint(TM) genomics, Inc. Forms Joint Research Program With the H. Lee Moffitt Cancer Center and Research Institute
3/29/2004 11:40:00 AM

SARASOTA, Fla., Mar 29, 2004 /PRNewswire-FirstCall via COMTEX/ -- DNAPrint genomics (DNAP) (the "Company") of Sarasota, FL today announced that it has formed a multi-faceted pharmacogenomics program with the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida. The program will aim to develop and implement new clinical tests for predicting patient response to various cancer chemotherapies.


CBS MARKETWATCH TOP NEWS
U.S. stocks in broad rally as Dow jumps triple digits
Amgen reaches $1.3 billion deal to acquire Tularik
Lyondell to buy Millennium Chemicals in stock swap
Russian firm buys Gold Fields stake for $1.16 billion
BP to return cash from oil prices over $20/bbl





Create A Portfolio | Create An Alert

Moffitt physicians and scientists are teaming with DNAPrint to identify genetic variants that underlie poor patient response to various chemotherapies, and to implement new clinical tests at the Center combining these variants with other biomarkers from gene-expression, proteomics and epidemiological research. The aim of the tests will be to predict patient chemotherapy response from the DNA before the commencement of the chemotherapy, so that patients with a genetic proclivity for poor or non- response can be spared from exposure to ineffective therapy. With the newly signed agreement, both organizations have teamed to make an important stride towards their goal of enabling a more personalized, safe and effective modality of cancer treatment for our current generation of cancer patients.

The program is multi-faceted and presently defines study in several cancer areas and clinical programs. Research will draw from several ongoing clinical trials and epidemiology research projects underway at the Center. A primary area of focus for the program is colorectal cancer, where DNAPrint will work with primary investigator Dr. Timothy Yeatman, Moffitt`s Associate Center Director for Clinical Investigations. DNAPrint will implement its proprietary ADMIXMAP genetic discovery platform to define gene sequences predictive for response to two anti-cancer treatments, XELOX and XELIRI. Though representing current FDA-approved therapies for metastatic colon cancer, approximately 50% of patients fail to respond and given the poor prognosis associated with non- response, there is a dire need for tools capable of predicting response beforehand. The study design will aim to first discover and then evaluate the predictive power of predictive Single Nucleotide Polymorphism (SNP) markers in tandem with biomarkers from gene expression chip and proteomics research currently under way at Moffitt. The first colon cancer study will involve 100 patients. Other phases of this particular project will permit a retrospective alignment of genetic risk and epidemiologic factors, and prospective evaluation of chemotherapy response prediction in the setting of GLP and FDA-approved clinical trial setting.

Over all of the program areas, the collaboration will combine Moffitt oncologists, research scientists, mathematicians and software engineers with DNAPrint computer scientists, molecular biologists and population geneticists, and draw upon DNAPrint`s pharmaceutical, clinical and regulatory expertise. Moffitt will contribute gene expression and proteomics data resources currently in development and DNAPrint will contribute its ADMIXMAP platform and SNP analysis for mapping the genetic determinants of variable drug response by harnessing the power of human population genetic structure. "We have identified several clinical projects at the Moffitt that are of keen commercial and social interest," said Dr. Hector J. Gomez, MD, PhD, Chairman of the BOD and Chief Medical Officer of DNAPrint genomics, Inc. "Each of these programs offers us the opportunity to advance cancer treatment in a significant way," he said. Recent (November 2003) FDA guidance regarding pharmacogenomics technologies promulgate that if markers are validated using well understood markers in legitimate clinical environments, genetic tests derived from those markers should be included in new drug applications.

Moffitt sees thousands of cancer patients each year, and ranks with M.D. Anderson (Univ. Texas), Johns Hopkins (Baltimore, MD) and Fred Hutchinson (Seattle, WA) as among the nation`s busiest and most prestigious cancer research centers. The center has established a domestic and international network of collaborating physicians to build patient registries and implement cutting-edge methods for reducing, treating or preventing the onset of cancer diseases.

"Moffitt scientists and physicians were impressed with DNAPrint`s ADMIXMAP approach for using a population`s structure as a fuel for mapping drug response gene variants. We recognized its profound potential for contributing to the enhancement of cancer treatment," said Moffitt`s Dr. Timothy Yeatman.

Dr. Tony Frudakis, the scientific leader of DNAPrint and founder says, "By virtue of its broad scope and scale, and given its clinical setting, this is by far the most exciting research and product development opportunity yet for our young company. Our goal is simple -- to present the FDA with what we can do and to pave the way for our brand of personalized medicine as the gold standard for drug development and use." He added, "The signing of this deal illustrates Dr. Gomez`s regulatory experience and leadership in the clinical development and pharmaceutical product approval process. This is invaluable to us as a company, as he brings a real world experience to our development programs."

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. uses proprietary human genome research methods to develop and sell genomic-based services. The Company introduced AncestrybyDNA in the consumer market and DNA Witness in the forensic market in 2003. DNAPrint is developing products in the pharmacogenomic market and has a disease gene discovery program. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com.

All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Media and Press Contacts
Richard Gabriel
DNAPrint genomics, Inc.CEO/President(941) 366-3400


SOURCE DNAPrint genomics, Inc.

Richard Gabriel, CEO and President, DNAPrint genomics, Inc.,
[phone]
(DNAP)


Copyright (C) 2004 PR Newswire. All rights reserved.

[hvs1]

Jungs,

es gibt Neuigkeiten bei DNAP.

hvs1

[Michiko]

HE! hvs1

Ich habe 3 Sekunden VOR dir gepostet und stehe trotzdem hintendran?

Michi

[hvs1]

Hallo Michi,

aber mit den Shares bist Du vor mir.
Wir sind ja auch nicht verwöhnt und mit Kleinigkeiten zufrieden.

hvs1

[hvs1]

Na bitte,

es geht ja langsam nach Norden.

hvs1

[Michiko]

Hallo hvs1,

hast Du schon diesen Teil der News gewürdigt?:

Dr. Tony Frudakis, the scientific leader of DNAPrint and founder says, " By virtue of its broad scope and scale, and given its clinical setting, this is by far the most exciting research and product development opportunity yet for our young company. Our goal is simple -- to present the FDA with what we can do and to pave the way for our brand of personalized medicine as the gold standard for drug development and use." He added, " The signing of this deal illustrates Dr. Gomez`s regulatory experience and leadership in the clinical development and pharmaceutical product approval process. This is invaluable to us as a company, as he brings a real world experience to our development programs."

Sieht wahrlich nicht schlecht aus!

Plötzlich wach geworden:

Michi

[marterpfahl]

Hallo zusammen,
die heutige PR beinhaltet viel mehr vom ungeheuren Potential von DNAP als die bisherigen forensischen Einzelerfolge oder die bisherigen kommerziellen Angebote zur genetisch / rassischen Herkunft. Die personalisierte pharmakogenetische Therapie gerade bei verschiedenen Karzinomen ist ein wichtiger Zukunftsschritt in der Onkologie und hier werden die ersten zwei konkreten Medikamente für Darmkrebs geprüft.
Wenn hier mehr kommt, wo von ich trotz vieler Enttäuschungen immer noch ausgehe, werden wir noch mächtig Freude am DNAP-Kurs haben !
Was mich nur wundert, ist die geringe Auswirkung auf den Kurs !
Nachkaufen ?
Nachkaufen !!!

marterpfahl

[hvs1]

Michi,

hatte ich bereits im RB gelesen,aber doppelt hält besser.
Habe leider zur Zeit keine Kohle mehr frei,sonst hätte ich die fehlenden 350K nachgelegt.

hvs1

[ge4teilter]

hvs1,

laß uns doch zusammenlegen, paßt zufällig ganz genau!

Aber wenn ich heute noch nachkaufe, dann paßt´s leider nicht mehr, also mußte doch selber ran!

Gruß an Alle!

g4

[Michiko]

g4,

der 100k-Kauf eben, war der von Dir?

Michi

[hvs1]

Glückwunsch G4.

Ich kann zwar teilen,aber meine 650K bleiben bei mir,schon
im 4 Jahr.Es wird wirklich Zeit,daß etwas geschieht mit dem
Kurs.Am 1. April soll ja noch was kommen.

hvs1

[ge4teilter]

Irgendwie freaky, der Typ, findet Ihr nicht?

g4

P.S. Michiko, ich war das nicht mit den 100k. Konnte mich noch nicht mit mir einigen, ob, wann und wieviel

[cariocca]

...von einem besoffenen Fotografen mit Gelbsucht...

[Michiko]

Irgendwie erwarte ich, dass die beiden freundlichen Herren im Hintergrund gleich ne Zwangsjacke bereithalten

RAUUUUUUUUUUUUUUUUUUS!!!

[hvs1]

Michi,

raus aus der Aktie oder was?

hvs1

[cariocca]

[hvs1]

Roger,

was bedeutet das!

hvs1

[Michiko]

hvs1

also erstmal kriegste von mir ne Antwort:

War natürlich ein Joke. Selbstverständlich bin und bleibe ich voll investiert.
Long, leider vermutlich sehr long, so ne Art Altersversicherung

Gruß

Michi

[cariocca]

Der mit der Zwangsjacke hat mit sehr gefallen!
Darum die Smilies.

[ge4teilter]

Tach zusammen!

Heute scheint ja mal ein bisschen Bewegung reinzukommen:

13 Apr 2004, 10:25am ET

Last price:0.05
0.008 or (19.04%)

Gruß ... g4

[Michiko]

Tach g4,

ich denke, bei diesen dürren Volumina hat das (leider) nicht viel zu sagen.

Gruß Michi

[hvs1]

Hallo Michiko,
hallo G4,

sind wir die letzten Mohik.... eh DNAPler?
Kleines Strohfeuerchen.Aber unsere Zeit kommt noch,ganz be-
stimmt.

Ich grüße euch.

hvs1

[wsperber]

Zumindest sind wir noch zu viert. Hab letztens sogar
noch nachgekauft.

Gruß

Wolfgang

[Blackjack2000]

Ihr seid nicht alleine....

Immer noch LONG

Gruß an alle

Blackjack

[Michiko]

Also meine Meinung (völlig unverbindlich natürlich):

Irgendwann werden wir uns in den rückwärtigen Bauch beißen, dass wir uns zu den momentanen Kursen nicht noch weitaus "heftiger" vollgesaugt haben.

Gruß Michi

[Michiko]

Na! Das ist doch ein versöhnlicher Ausklang des Börsentages.
Auch was das Volumen angeht!

Michi

[ge4teilter]

Michiko,

noch ist´s doch nicht zu spät! Morgen mal Konto ansehen und zuschlagen oder nicht

Gut´s Nächtle!

g4

[Michiko]

g4

ich habe kürzlich ein Schreiben meiner Bank erhalten, sinngemäß mit dem Inhalt, ich solle doch mal über eine breitere Risiko-Streuung nachdenken (nur gut gemeint natürlich )

Vom Bauch her würde ich am liebsten alles in DNAP schmeißen, ein, zwei oder drei Jahre nicht mehr hinkucken und dann in Rente gehen.

Aber wie sagte meine Mutter selig: Kühler Kopf und warme Füße!

Wenn eines meiner übrigen Harakiri-Invests boomen sollte (Obducat, Qt5, etc), wirst Du Mich(i) nachkaufen sehen.

Aber erst dann!

Gruß Michi

[Pushi2]

Wer spricht hier von langfristigen Engagements oder sogar Altersversorgung?
Schaut ihr euch die Annual Reports nicht an?
Zocke selbst gerne und freu mich - wie letzten Sommer - wenn Werte wie DNAP sich vervielfachen.
Vergesst jedoch nicht die Gewinne mitzunehmen.
Vermutlich wird DNAP nie Geld verdienen.
Wäre vorerst schön, wenn DNAP bis Ende des Jahres durchhält.

Hier ein Auszug der Wirtschaftsprüfer:

The accompanying consolidated financial statements of DNAPrint genomics, Inc. and Subsidiary have been prepared assuming that the Company will continue as a going concern. As more fully described in Note B, the Company has had recurring operating losses since inception, has negative working capital as of December 31, 2003, and has used approximately $1,530,000 of cash in operations for the year ended December 31, 2003. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans regarding these matters are also described in Note B. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Pender Newkirk & Company
Certified Public Accountants
Tampa, Florida
February 20, 2004

Hier die Überlebensstrategie der DNAP:

Our consolidated financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. We have incurred losses since our inception, and have experienced and continue to experience negative cash flows from operations. In addition, we have working capital and stockholders’ deficiencies of approximately $1,540,922 and $2,037,095 at December 31, 2003, and will continue to have ongoing requirements for substantial additional capital investment to accomplish our business plan over the next several years. Over the past two years, our operations have been funded through related party funding, sales of common stock and the issuance of a convertible debenture. We continue to experience some success generating operating revenues; however, we do not expect our revenue stream to be sufficient to cover costs of operations in the immediate future. We anticipate that the funding we expect to receive from the minimum conversions of the outstanding debenture into common stock and the related exercise of the non-detachable warrants will fund our operating activities through 2004. However, there can be no assurance the minimum conversions of the outstanding debenture into common stock and the related exercise of the non-detachable warrants will be exercised and/or that we will have the cash flow to meet our operating requirements. These factors, among others, indicate that we may be unable to continue as a going concern for a
reasonable period of time.

[cariocca]

Aber Hoppala...

[Pushi2]

Was heisst "Aber Hoppala..."?
Überrascht ganz Du nach vier Jahren in DNAP doch nicht sein?
Du kennst DNAP doch besser als wir alle.
Bin nur verwundert, dass Du zum jetztigen Zeitpunkt ausgestiegen bist und bei Kursen von > 0.12 USD von Langfristinvestition gesprochen hast.
Ich warte mit meinen Restbeständen auf die nächsten interessanten Gerüchte (derzeit passiert ja nicht viel ...) und beobachte die schwierige Finanzsituation weiter.

[Pushi2]

Kann doch nicht sein, dass es Euch die Sprache verschlagen hat!
Dass derartige Werte kein Geld verdienen, ist doch bekannt.
Und dass man immer hoffen muss, dass sich neue Geldgeber finden, um weiterzuspielen (-forschen), ist doch auch klar.
Also hoffen wir gemeinsam auf die nächsten Gerüchte, damit wir mal wieder ein paar Gewinne mitnehmen können ...

Hallo, hallo?
Keiner da? Keiner eine Meinung???

[Pushi2]

Hallo???
Wirklich keiner eine Meinung zu DNAP.
Immerhin reden wir über eine Perle mit einer Marktkapitalisierung von 750.000 USD ...

[Blackjack2000]

Hallo @ all Longs,

habe von Dave Moskowitz (Genomed) heute eine Antwort auf meine Fragen bekommen.



> I have two questions:
>
> Can you tell me exactly what the partnership beetween Dnaprint Genomics and
> Genomed contains?What are they doing for Genomed?

Now that we have funding, finally, we`re in the process of redefining the
relationship, since it had to be put on hold for 2 years.

>
>
> "We use the least expensive, fastest throughput genotyping currently
> available in the world. "
>
> Who is doing this genotyping for Genomed?

Look for a press release soon.

Thanks for your interest in GenoMed.

Dave


Hört sich gut an!


Gruss

Blackjack

[wsperber]

An Pushi2

Marktkapitalisierung liegt wesentlich höher. Momentan über
25 Millionen. Ich weiß nicht genau wieviele Aktien es
im Moment gibt, dürften aber deutlich über 600 Millionen
sein.

Siehe dazu z.B. (die Zahl der Aktien dort ist veraltet)

http://www.pinksheets.com/quote/company_profile.jsp?symbol=D…

[Pushi2]

Wollte mal Antworten provozieren ...


Gebe Dir recht:
Nach dem Annual Report waren es am 20.02.04
547,238,171 (State the number of shares outstanding of each of the issuer’s classes of common equity)
Demnach bei aktuellem Börsenstand eine Marktkapitalisierung von 21,9 Mio USD

[Put_or_Call]

das Teil ist töter als tot nur Insider Verkäufe

http://clearstation.etrade.com/cgi-bin/fundamentals?Event=in…

[cariocca]

Ist sehr ruhig hier...

Hat noch jemand DNAP`s?
Ist das wirklich noch normal? 5 Jahre... NICHTS!
Beschämend. Pfui-Deibel, Tony.

Bin wirklich froh, aus-und umgestiegen zu sein.

Roger

[ge4teilter]

Rogi,

ich hab´ sie nicht mehr alle weil ich sie noch alle hab´!

Bin ja noch jung und kann warten.

Hoffe aber, wir lernen uns trotzdem irgendwann mal persönlich kennen, auch wenn Du kein DNAPper mehr bist. Letztlich ist es ja auch egal, mit welcher Aktie man irgendwann Millionär wird.

Lieben Gruß!

g4

[Michiko]

cari,

da ich erst seit gut einem Jahr in DNAP bin, habe ich noch etwas mehr Geduld. Der "Hüpfer" im letzten Juni hat meinem Konto gut getan; jetzt kann ich mir vorstellen, noch ein oder zwei Jahre zu warten.
Im Zweifelsfalle: Meine älteste Tochter zieht demnächst aus, da wäre das Problem mit den Tapeten schon mal geklärt

Bin im Sommer wieder in Engelberg; ein Hoch auf die Schweiz!

Michi

[cariocca]

Michi

OK... Treffen wir uns in Engelberg.

Gell kommst auch, ge4teilter. Datum / Zeit bitte via EMail.

PS:
Am 26. Mai treffe ich mich mit Bob (justswell) bei mir im Garten in Adliswil. Er war in Rammstein stationiert, der alte Krieger und besucht anscheinend einen Bekannten am Bodensee.! Ich hoffe er kann noch ein paar Bröckchen Deutsch, sonst wirds zappenduster mit der Unterhaltung.


Roger

[hvs1]

Hallo Freunde,

auch ich habe sie nicht mehr alle,weil ich noch alle habe.
Aber ein wenig frustriert bin ich schon.Mit DNAP geht ja
aber auch wirklich nichts.Ich kann Roger verstehen.Ich steige nur nicht aus,weil sie abgeht wie Schmidt`s Katze,
wenn ich raus bin.
Wie heißt es so schön,die Hoffnung stirbt zuletzt.

Also hoffen wir weiter.
Hallo Roger,
QBID und Prim nehmen auch ne kleine Pause,oder?

hvs1

[cariocca]

Ja, hvs1....

Aber die Pausen sind nicht soooo lang wie bei DNAP. Ausserdem ein ver-7facher bei PRIM und ein ver-184facher bei QBID sind ein hübsches Polster.

[hvs1]

Roger,da stimme ich Dir zu.
Habe in den letzten Jahren doch ne Menge minus gemacht.
Trotzdem habe ich mir heute den Tuareg 3.2 tiptronic mit
162 kw gegönnt.Für schlappe 55.000,- Euronen
Auch wenn er ein wenig mehr Sprit verbraucht als der Diesel.

Gruß hvs1

[Michiko]

* S Ä U F F Z Z ! ! ! *

Meiner einer ist leider nur ein gebrauchter Punto für 8,5k.

Na ja, es gibt halt Krösusse und andere!

Michi

[hvs1]

Michiko,

mein alter ging in Zahlung,der Rest über Leasing.
Habe eine GmbH und muß Kosten produzieren,damit ich nicht
soviel Steuern zahlen muß.

Gruß hvs1

[cariocca]

Info für Interessierte:

Am Samstag, 22. Mai besucht mich Bob (justswell84) aus dem DNAP-RB-Bord bei mir zu Hause. Er wird mit einem Freund (aus Deutschland) zu einer Barbecue-Party im Garten vorbeikommen.

US-Bob hat Aktivdienst in Rammstein geleistet und spielt dort mit seinen alten Freunden in einer Rock-Band! Bob ist etwa Jahrgang 55 und ein wirklich spassiges Kerlchen! Das wird lustig...

Vielleicht hat jemand von euch alten DNAPstern, Zeit und Lust sich diesem Treffen anzuschliessen. Ihr seid herzlich eingeladen.

Samstag, 22.Mai ab 11:00 Uhr


Für genauere Infos:

[e-mail]

[hvs1]

Roger,

da könnte ich ja gleich mein neues Auto ausprobieren.
Aber leider habe ich keine Zeit.Terminbauten die bis zum
31.MAI übergeben werden müssen.

Gruß hvs1

[Michiko]

GRRRRRRRRRRRRRRRRRR!!!

Ist den Sarasotanern der Kurs ihrer Aktien denn völlig egal?

*heftiggrummel*

Michi

[HenryR.Mandell]

Hallo Michi,

ich stehe endlich auch mal wieder auf Start...

erstmal auf 30000 DNAPs aufstocken - dann PTSC,SNNW und Raven...

Schön je 25% im Depot

Und dann melde ich mich in einem Jahr nochmal...

Wann kaufen wir eigentlich wieder Spazen ?

Zu 5 oder 3 cent ????

cu Croko

[Michiko]

Nur der Vollständigkeit halber:

DNAPrint Launches New Genealogy Products and Service in Family Tree Legends


SARASOTA, Fla., May 10, 2004 /PRNewswire-FirstCall via COMTEX/ -- DNAPrint
genomics (OTC Bulletin Board: DNAP) of Sarasota, FL announced that it is
launching a new product -- "STR Map" -- to be used for determining paternity and
identity in genealogy testing in the Family Tree Legends web site:
www.familytreelegends.com along with its ANCESTRYbyDNA(TM) 2.5
DNAPrint genomics is pleased to announce the release of its STR Map service in
conjunction with Pearl Street Software. STR Map uses the industry`s gold
standard in Human Identity testing, the same test used by forensic and paternity
labs around the world. The test is based on a genetic variation known as short
tandem repeat or "STR." These genetic markers form a unique identifying code for
each individual, statistically powerful enough for human identification. The STR
Map service allows the consumer to have these markers typed for their private
and confidential use.

By teaming up with Pearl Street Software and its highly rated records manager
software, Family Tree Legends, the usefulness of this service to the genealogy
community grows. The STR Map service adds to the tests and services already
offered by DNAPrint genomics including its popular ANCESTRYbyDNA(TM) 2.5 test,
which determines your percentage of Sub-Saharan African, East Asian, European
and Native American.

"We welcome the opportunity to bring customers the benefits of preserving and
further exploring their genetic profiles. This adds a whole new dimension to the
information a genealogist can collect, and by teaming with Pearl Street Software
on this, we add to the value of the information we can provide. This type of
genetic information should enhance our understanding of where we come from and
how our families may interrelate," said Dr. Matt Thomas, Senior Scientist at
DNAPrint(TM).

"As the only records manager that handles DNA, Family Tree Legends continues to
bring genetic genealogy into the fold as a must-have tool for family historians.
With this new release, DNAPrint(TM) has further solidified itself in the DNA
market, and I`m certain the exposure will have more genealogists using their
services," said Cliff Shaw, President and CEO of Pearl Street Software.

To learn more about STR Map and to order a collection kit, please visit
DNAPrint`s web page http://www.ancestrybydna.com/strorder.asp or by phone at
941-366-3400. Information about Pearl Street Software`s Family Tree Legends can
be found at http://www.familytreelegends.com/.

About DNAPrint genomics, Inc.

DNAPrint genomics Inc. uses proprietary human genome research methods to develop
genomic-based services and products. The Company introduced ANCESTRYbyDNA(TM) in
the consumer market and DNAWitness(TM) in the forensic market in 2003.
DNAPrint(TM) is developing products in the pharmacogenomic market and has a
disease gene discovery program. The Company is traded on the Nasdaq OTC Bulletin
Board under the ticker symbol: DNAP. For more information about the company,
please visit www.dnaprint.com.

All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities Exchange
Act as amended. Such statements are subject to risks and uncertainties that
could cause actual results to differ materially from those projected, including,
but not limited to, uncertainties relating to technologies, product development,
manufacturing, market acceptance, cost and pricing of DNAPrint`s products,
dependence on collaborations and partners, regulatory approvals, competition,
intellectual property of others, and patent protection and litigation. DNAPrint
genomics, Inc. expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements contained
herein to reflect any change in DNAPrint`s expectations with regard thereto or
any change in events, conditions, or circumstances on which any such statements
are based.





Media and Press Contacts

Richard Gabriel

DNAPrint genomics, Inc.

CEO/President

[phone]

SOURCE DNAPrint genomics, Inc.



CONTACT: Richard Gabriel, CEO - President, DNAPrint genomics, Inc.,

[phone]



URL: http://www.dnaprint.com

http://www.prnewswire.com


Copyright (C) 2004 PR Newswire. All rights reserved.





KEYWORD: Florida

INDUSTRY KEYWORD: MTC

OTC

CPR

STW

SUBJECT CODE: PDT

OTC

[ge4teilter]

Oh Mann!

[hvs1]

G4,

was machen die bloß mit uns.
Schauffeln sich die Kohle rein und an uns denkt kein Schwein.

hvs1

[Michiko]

Ich erinnere immer wieder mal gerne an die PR vom Dezember 03:

We are extremely excited about the prospects for DNAPrint™ now that we have established a reliable source of capital for the foreseeable future,” said Richard Gabriel, CEO and President of DNAPrint. “This financing, once it completes the registration process at the SEC, should allow management to build shareholder value.

Hoffen und harren . . .

Michi

[hvs1]

Michi,

was ist mit Nachkauf bei diesen Kursen 0,025 Euro.

hvs1

[Michiko]

hvs

ich habe gerade eine Überweisung von meinem Giro- aufs Trading-Konto getätigt (Ausführung vermutlich am Montag).
Werde dann evtl auf 770k shares aufstocken.
Vielleicht steht das ask dann auf 0,03 Dollar

Michi

[ge4teilter]

Guten Morgen!

Gibt´s hier außer mir eigentlich noch mehr Bekloppte, die gerade nachkaufen?

Ich habe mir gestern nochmal 70.000 gegönnt

Alles wird gut!

g4

[Michiko]

Moin g4!

Bekloppte unter sich: Ich habe 76k nachgekauft.

Ist vielleicht bei einem fallenden OTC-Wert nicht gerade das Beste, aber bei einem ask von 0,03 Dollar konnte ich nicht widerstehen!

Todamooooon!

Michi

[Michiko]

Dumm - didumm - didumm!

2,7 - 2,8

Michi

[hvs1]

Jungs,

ich warte nun erst einmal ab.Es liegen noch ein paar
Groschen in der Schachtel,die investiert werden wollen.
Die Talfahrt muß doch bald ein Ende haben.
Shareholder-Meeting am 29 July.Bis dahin muß DNAP sich ge-
fangen haben.Wir sind bei 0,022 Eurocent.

hvs1

[Michiko]

Press Release Source: DNAPrint Genomics, Inc.


DNAPrint Introduces New STRmap Technology for Forensic Cases
Monday June 7, 1:13 pm ET


SARASOTA, Fla., June 7 /PRNewswire-FirstCall/ -- DNAPrint (OTC Bulletin Board: DNAP - News; the "Company") will now provide a suspect`s genetic fingerprint to law enforcement agencies that use its DNAWitness test as an investigative tool. The combination of DNAWitness and the STRmap service promises to fill an important niche in the investigative process and represents one of the most powerful tools available to investigators.
ADVERTISEMENT


Every person has within his or her genes a pattern of genetic variation that produces a fingerprint or barcode, which is unique to each person (unless they have an identical twin). Although the benchmark test method can determine whether the sample left at a crime scene was left by a previously identified felon, many samples can take up to one year to complete.

By offering the new STRmap service with each DNAWitness order, DNAPrint seeks to allow investigators to rapidly obtain an entirely free STR fingerprint for their crime scene sample, while at the same time, provide them the confidence that the ancestry profile determined by DNAWitness has come from the proper sample (to eliminate the possibility of laboratory error, or mix-up). In addition, with DNAPrint`s forensics group currently receiving evidence from across the United States, Canada, and the United Kingdom, the new service fulfills a Company need to ensure that the results match the sample.

While investigators will still need to run the STR test in an ASCLD accredited environment before it can be used in court to identify a suspect or obtain a warrant, the free and rapid STRmap service will allow DNAWitness customers to accelerate their CODIS database searching, often by days or weeks. This promises to be attractive for investigators because the time taken to identify could determine the difference between life and death in some cases. The new offering is designed to accelerate the already encouraging rate of adoption by law enforcement of DNAWitness service technology.

DNAWitness continues to shine light on the most likely ancestry mix for DNA samples left by unknown donors at crime scenes, described by us as, "DNA donors." The ancestry (sub Saharan African, East Asian, Indo-European and Native American) determined from most DNAWitness cases is predominantly of a single type, allowing the exclusion of other types. For example, 98% of one group would eliminate the three other groups. Since ancestry mix can be directly related to some characteristics of physical appearance, DNAWitness results can save valuable investigative time and money spent characterizing a crime scene and describing "interested parties or donors of DNA at the crime scene." The product can also be used to corroborate an eyewitness report, confirm a fuzzy video or shed light on a potential donor if no witnesses are available. In the event a DNA donor was known to the victim or the victim`s family, the new STRmap service component of DNAWitness could help bring a quicker resolution, possibly assisting in the prevention of additional crimes.

"There is absolutely no question that DNAWitness and STRmap can help investigators shorten the lead to identification and along with other confirmatory ASCLD testing, lead to arrest, conviction and prosecution," said Richard Gabriel, CEO and President of DNAPrint genomics, Inc. "Our test is not a short cut for the investigative process -- investigators still need to do all the hard work of pulling the evidence together, and confirming that evidence so that it stands up to defense challenges -- but it sure can help focus an investigation. We are continuing to invest in our forensics products because it helps us build our knowledge base and provide the community with an added benefit of helping law enforcement do its job just a little bit better and faster. Our customers, the investigators and prosecutors, can continue to expect improvements of the DNAWitness service line. STRmap will be followed by other even more innovative technologies," he concluded.

About DNAPrint genomics, Inc.

DNAPrint genomics Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company introduced ANCESTRYbyDNA in the consumer market in 2001 and DNAWitness in the forensic market in 2003. DNAPrint is developing products in the pharmacogenomic market and has a disease gene discovery program. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit http://www.dnaprint.com.

All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Media and Press Contacts
Richard Gabriel
DNAPrint Genomics, Inc.
CEO/President
[phone]


The new STRmap test measures the same thirteen genetic locations that are used in the FBI`s CODIS national database of felons, and uses an additional two genetic locations making it extremely powerful.



Letzten Juni war´s nicht übel, und diesmal?

Gruß an alle Investierten

Michi

[Michiko]

. . . und gleich noch einer!: (Wer sagt´s denn )
Auch wenn die News schon an anderer Stelle veröffentlicht wurden, hier gehören sie auch hin.


June 08, 2004 10:30 AM US Eastern Timezone

J.M. Dutton & Associates Announces Investment Opinion: DNAPrint genomics Speculative Buy Rating in Initiating Coverage by Dutton & Associates

NOTE TO EDITORS: The following is an investment opinion issued
by J.M. Dutton & Associates

EL DORADO HILLS, Calif.--(BUSINESS WIRE)--June 8, 2004--J.M. Dutton & Associates initiates coverage of DNAPrint genomics (OTCBBNAP) with a Speculative Buy rating. The 22-page report by J.M. Dutton senior analyst Sherry Grisewood, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Multex, and other leading financial portals.


DNAPrint genomics is a late-stage development company with patented leading-edge quantitative genomics classification and analysis technology. The Company`s technology enables the rapid and cost-effective analysis of DNA material to determine frequency probabilities of gene locations, and therefore, predict specific genetic traits in individuals such as Bio-Geographical Ancestry Admixture or pharmacogenomic profile based upon the frequency of gene location and other markers present in DNA. The Company has developed two commercial products from its state-of-the-art proprietary ADMIXMAP(TM) technology platform for use in forensics and consumer-oriented genealogy analysis. Both products are now beginning to generate revenue and will support future product development in pharmacogenomics diagnostics. The Company is expected to move its first pharmacogenomic profiling diagnostic product, OVANOME(TM), into US. clinical trials during 2004. Further, DNAPrint genomics is one of only a few companies capable of performing high-throughput (25,000 genotypes per day) genotyping analysis. The Company will have to gain greater acceptance in the forensics market to generate revenues. DNAPrint genomics faces a number of challenges that are typical of small capitalization companies.

About Dutton & Associates

Dutton & Associates is one of the largest independent investment research firms in the U.S. Its 24 senior analysts are primarily CFAs, and have expertise in many industries. Dutton & Associates provides continuing analyst coverage of over 70 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.

The cost of enrollment in our one-year continuing research program is US $28,000 prepaid before commencement of our research activities. We received $28,000 from the Company for coverage for the year, and do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst`s personal views about the subject securities or issuer. Neither the analyst`s compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.

[wilfonx]

moin., hatte den thread nicht gesehen , ziehe meinen natürlich zurück....
gehn wir to da moooon --baby ??
gruss willy the fonx..

[Michiko]

Und hier der Kommentar vom CEO R. Gabriel:
(Wenn ich Zeit habe, werde ich versuchen, einige Teile daraus zu übersetzen):

DNAPrint(TM) Announces Coverage by JM Dutton

SARASOTA, Fla., Jun 9, 2004 /PRNewswire-FirstCall via COMTEX/ -- DNAPrint(TM) (the "Company") announces that it is being covered by JM Dutton Associates. The JM Dutton report can be found by visiting JM Dutton at www.duttonassociates.com . The report is an extensive, independent analysis of the Company and its technology. The report, written by Sherry Grisewood, CFA, one of JM Dutton`s senior analysts, covers all aspects of DNAPrint(TM), its technology and markets.

"We are pleased to be covered by JM Dutton Associates. It is an independent review that reinforces what I saw at DNAPrint(TM) when I was invited to join the board of directors and then lead the Company as its Chief Executive Officer and President," said Richard Gabriel, CEO and President of DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP). "Over the last year, we have been reorganizing and strengthening our Company with much-needed cash flow. There is no doubt that DNAPrint has been on the cutting edge of the genomics revolution, proving that you don`t need to burn hundreds of millions of dollars to build a technology foothold in an emerging market. What you do need is a dedicated team of smart researchers and managers, committed to the health and success of the Company. We are beginning to emerge from a very difficult period in the Company`s development, and we are aggressively seeking opportunities to put our capital to work. What our shareholders should realize is that our recent capital raising transaction is well within line of what a traditional Venture Capital deal would take in terms of equity dilution. We are doing everything we can to help boost our shareholders` confidence and build real underlying stock values."

"Ms. Grisewood`s independent assessment of our technology and our position in the market is spot on," said Dr. Tony Frudakis, Chief Scientific Officer and founder of DNAPrint genomics. "It`s confirmation that what we discovered, invented and were the first to put into the marketplace -- products and services that customers could actually use -- is just the beginning of what DNAPrint(TM) can bring to the table for its customers, employees and shareholders. We are pleased that someone else has looked at our Company and confirmed in a report some of the things we as management know about DNAPrint(TM)."

JM Dutton & Associates has started coverage of DNAPrint genomics, Inc. (DNAP) with its rating maintained at Speculative Buy and a price target of $0.06. The 7-page report by JM Dutton senior analyst Sherry Grisewood, CFA, is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Multex and other leading financial portals.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company introduced ANCESTRYbyDNA(TM) in the consumer market in 2001 and DNAWitness(TM) in the forensic market in 2003. DNAPrint is developing products in the pharmacogenomic market and has a disease gene discovery program. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com.

All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.



Media and Press Contacts
Richard Gabriel
DNAPrint genomics, Inc. CEO/President [phone]

About JM Dutton & Associates

JM Dutton & Associates is one of the largest independent investment research firms in the U.S. Its 24 senior analysts are primarily CFAs and have expertise in many industries. JM Dutton & Associates provides continuing analyst coverage of over 70 enrolled companies, and its research, estimates and ratings are carried in all the major databases serving institutions and online investors.

The cost of enrollment in our one-year continuing research program is US$33,000 prepaid before commencement of our research activities. We received $25,000 from the Company for four reports commencing 6/08/2004, and do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst`s personal views about the subject securities or issuer. Neither the analyst`s compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.

Contact Information: JM Dutton & Associates, LLC, John M. Dutton, 916-941-8119

SOURCE DNAPrint genomics, Inc.


CONTACT: Richard Gabriel, CEO and President, DNAPrint genomics, Inc.,
[phone]; or John M. Dutton, JM Dutton & Associates, LLC,
[phone]

URL: www.dnaprint.com
www.prnewswire.com


Copyright (C) 2004 PR Newswire. All rights reserved.

-0-



KEYWORD: Florida
INDUSTRY KEYWORD: MTC
FIN
OTC
SUBJECT CODE: OTC
INO

STOCK SYMBOLS: [(dnap)]

[Michiko]

Also, hier die angekündigte (Amateur-)Übersetzung:

DNAPrint(TM) gibt ein Gutachten durch JM Dutton bekannt.

SARASOTA, Fla., 9. Juni , 2004
DNAPrint(TM) (die " Company" ) gibt bekannt, dass ein Gutachten von JM Dutton Associates über sie erstellt wurde. Dieser Bericht kann eingesehen werden unter www.duttonassociates.com. Der Bericht beinhaltet eine ausführliche, unabhängige Analyse über die Firma und ihre Technologie. Der Bericht, der von Sherry Grisewood, einem der Chef-Analysten, geschrieben wurde, beleuchtet alle Aspekte von DNAPrint™, deren Technologie und ihrer Märkte.

„Wir freuen uns, von JM Dutton Associates begutachtet worden zu sein. Es ist ein unabhängiger Bericht, der das bestärkt, was ich schon damals sah, als ich zum Mitglied des Direktoriums berufen wurde und dann die Firma als Geschäftsführer und Präsident leitete,“ sagte Richard Gabriel.
“ Im Laufe des letzten Jahres haben wir uns neu organisiert und unsere Gesellschaft mit hochnotwendiger Liquidität ausgestattet. Zweifellos befindet sich DNAPrint an vorderster Front der gentechnischen Entwicklung und hat bewiesen, dass es nicht nötig ist, hunderte Millionen Dollar zu verbraten, um einen Fuß in der Tür eines sich entwickelnden Marktes zu haben. Was man wirklich braucht ist ein entschlossenes Team smarter Forscher und Manager, die sich dem Wohlergehen und dem Erfolg dieser Firma verpflichtet fühlen. Wir kommen gerade aus einer sehr schwierigen Periode der Firmen-Entwicklung und suchen aggressiv nach Möglichkeiten, unser Kapital zum Einsatz zu bringen. Unsere Aktionäre sollten bemerken, dass unsere kürzliche Kapitalerhöhung durchaus ausgewogen und vertretbar ist (Anm: frei und verkürzt von mir übersetzt!) Wir tun alles Menschenmögliche, um das Vertrauen unserer Aktionäre zu stärken und einen echten fundamentalen Wert zu schaffen.“

" Ms. Grisewood`s unabhängige Bewertung unserer Technologie und Marktposition gibt uns grünes Licht,” sagte Dr. Tony Frudakis, Chefwissenschaftler und Gründer von DNAPrint genomics. „Diese Bestätigung, dass wir nämlich Produkte und Dienstleistungen entdeckt und entwickelt haben, die unsere Kunden sofort nutzen konnten, und dass wir die ersten waren, die diese auf den Markt gebracht haben, ist erst der Beginn dessen, was DNAPrint™ seinen Kunden, Angestellten und Aktionären vorweisen kann. Wir freuen uns, dass ein Außenstehender unsere Firma beurteilt hat und uns in diesem Bericht genau das über einige Punkte bestätigt, was wir vom Management schon lange über DNAPrint™ wussten.”


Moooooooooooooooond, wir koooooooooooooooommen!

Nix für ungut

Michi

[hvs1]

Noch jemand da?
DNAP kotzt ja ganz schön ab.
Hat jemand Neuigkeiten?Michi wo bist Du?

hvs1

[malo01]

Aus die Maus

[hvs1]

malo01,

warum das?

hvs1

[hvs1]

Michi,

sammels Du ein?

hvs1

[Michiko]

hvs,

wenn ich das richtig verstanden habe, gibt es in den USA gerade Ärger über Firmen, die sich ein Gutachten bestellen und dies veröffentlichen.

Auf einer Liste (der SEC?) dieser Sünder taucht auch DNAP auf.
Haben vielleicht deshalb einige Aktionäre kalte Füße bekommen?
Wird gerade im iHub diskutiert.

Michi

[hvs1]

Michi,

DNAP soll angeblich $ 28.000,- dafür bezahlt haben.
Wenn da was dran ist,ist das ärgerlich.

hvs1

[Michiko]

hvs1,

selbstverständlich haben sie 28k Dollar bezahlt!

Zitat: We received $28,000 from the Company for coverage for the year, and do not accept payment of our fees in company stock.

Zu Deiner anderen Frage: Ich sammele jetzt nicht mehr ein; es reicht jetzt.

Aber von PRIM habe ich mir heute mal aus Jux und Dollerei ein paar Stück reingelegt. Cariocca war mal ganz begeistert von denen und in letzter Zeit sind sie ziemlich runtergekommen.

Gruß

Michi

[hvs1]

Michi,

habe auch schon mal geliebäugelt.
Wieviele sind ein paar?

hvs1

[smiling]

DNAPrint genomics, Inc. Announces Collaboration With Famous Genetic Epidemiologist Dr. Paul McKeigue
Monday June 28, 5:37 pm ET


SARASOTA, Fla., June 28 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. ("The Company") announced today that it has entered into strategic algorithm development collaboration with famous genetic epidemiologist Dr. Paul McKeigue. The goal of the collaboration is to develop novel statistical genomics algorithms for a new style of genome screening called Admixture Mapping.
ADVERTISEMENT


Dr. McKeigue invented the Admixture Mapping (AM) technique in 1998. The technique is distinct from the Mapping by Admixture Linkage Disequilibrium (MALD) technique introduced by Dr. Ranajit Chakraborty in 1986. Both techniques employ knowledge of population structure to identify genes that underlie complex diseases and drug response, but Admixture Mapping is considerably more sophisticated in a mathematical sense, and uses the power of Bayesian Analysis and an "affecters only" study design to dramatically increase the statistical power for detecting these genes.

Soon after its founding, DNAPrint genomics began consulting with Dr. McKeigue and Mark Shriver of the Pennsylvania State University to augment Admixture Mapping methods and build Ancestry Informative Marker (AIM) libraries for efficient commercial-scale screening of the genome. DNAPrint is already using its own patent-pending variation of the Admixture Mapping method to construct predictive tests for tailoring drugs and doses to patients based on their genetic constitution. This platform has resulted in the identification of numerous genes involved in a number of both positive and negative responses to commonly prescribed drugs. DNAPrint intends to employ the new, improved ADMIXMAP algorithms for a variety of disease gene screens, many of which promise to be the first of their kind ever conducted.

"We believe that the mathematics and advanced computational methods we will be refining and developing will allow us to find elusive disease and drug response genes that others have missed using older, less powerful screening technologies," said Dr. Tony Frudakis, DNAPrint`s Chief Scientific Officer. He continued, "This deal confers a sort of pole position for the Company with respect to this exciting new genome scanning methodology, because it is not just the maps of AIMs that are necessary for Admixture Mapping, but advanced analytical tools that are capable of accommodating parameter uncertainty."

"The mathematics at work here give DNAPrint an advantage because it allows us to research genetic mediated diseases and to develop or license compounds that work to treat the disorders," said Richard Gabriel, DNAPrint`s CEO. "We will extend our reach further into the pharmaceutical industry with advanced mathematical and software programs as well as genomic technologies. We are very pleased to have Dr. McKeigue and his team helping us."

The most common U.S. and European pharmaceutical business model is based on the idea of root genetic causes for disease and small molecule (i.e. drug) targeting of the corresponding defective gene products and their corresponding biological receptors or pathways. DNAP plans to use Admixture Mapping to identify the most likely drug targets, not just the genetic markers of disease or its symptoms. This requires understanding how each individual`s genetic ancestry affects treatment or disease progression.

The agreement announced today will provide support for a Bayesian mathematician in Dr. McKeigue`s Dublin laboratory, and will enable DNAPrint`s computer scientists to improve and augment existing ADMIXMAP code. Paul McKeigue holds joint professorships at the University College London, School of Tropical Medicine and Hygiene and the University of Dublin, Ireland, School of Genetic Epidemiology.

About DNAPrint genomics, Inc.

DNAPrint genomics Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company introduced ANCESTRYbyDNA in the consumer market in 2001 and DNAWitness in the forensic market in 2003. DNAPrint is developing products in the pharmacogenomic market and has a disease gene discovery program. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit http://www.dnaprint.com.

All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Media and Press Contacts
Richard Gabriel
DNAPrint genomics, Inc.
CEO/President
[phone]

[hvs1]

smiling,

bist
Du noch investiert?

Gruß hvs1

[cariocca]

Oi-oi... Michi

Ja PRIM ist momentan am Leiden. Trotz gutem CEO und vielen Infos und Einnahmen im 6-stelligen Bereich. Aber DNAP macht ja auch keine grossen Wellen. Die USA braucht neuen Wind. Das Gerippe Greenspan soll mal endlich beginnen, sein Leben zu geniessen.

Roger

[smiling]

Hallo hvs1!

Kurz und bündig Ja!

.....Ich hatte aber immer nur 57.000 Stück, und die hab ich immer noch.....

...wenn das ganze den Bach runtergeht ist das zwar auch Kohle, aber nicht soviel, daß es mir wehtut.

Wenn ich allerdings zB bei meinem Einkaufspreis von ca 0.05 verkaufen sollte und aus irgendeinem Grund fangen die Dinger später zu fliegen an, würd ich mich wirklich in den Hintern beißen....

Alles Gute Euch Allen!

[hvs1]

Smiling,

ich habe immer noch 650K zu 0,088 und glaube immer noch,daß
die eines Tages fliegen werden und zwar zum Mond und nicht
raus aus der OTCC.

Gruß hvs1

[hvs1]

Roger,

ich habe im RB gelesen,daß Du in der roten Zone bist.
Hast Du noch alle 20M

Gruß hvs1

[ge4teilter]

So, die Hälfte von 2004 wär´ dann mal vorbei ....

Gruß ... g4

[cariocca]

Hvs....

Bin mit 31 Millionen PRIM`s in der ROTEN Zone.

Hihi.. das wird sich ändern.

oger

[hvs1]

Roger,

da hättste ja auch bei DNAP bleiben können.
31M ist ja ne ganze Menge Holz.

Gruß hvs1

[ge4teilter]

July 04 Shareholder Letter (Thanks 4titudinous):

http://www.dnaprint.com/2003/pressreleases/Jul04ShareHolder.…

Dear Shareholder, July 04

The past year your company achieved several significant milestones. Most importantly, we closed a private placement that should provide consistent cash flow for the next 20 plus months and provides the new senior management team with the capital needed to increase our revenues. Although the transaction results in shareholder dilution, the rate of dilution is average to the industry for the size of the investment. Remember, without substantial financing, the company would have been unable to continue its operations. A little over a year ago, the previous management team described this need and considered a funding transaction that they hoped would generate proceeds of $1 million to the company. The private placement that we closed in December should provide $8.0 million, and we have already received $2.1 million. We are using the money to build the business, to add personnel and to increase our research and development.

As you know, our executive management team has just reached its first anniversary at the company. The executive team appointed last May consists of our CFO and COO, Monica Tamborini, our Chief Medical Officer, Hector J. Gomez, MD, PhD and me, your Chief Executive Officer and President. Dr. Gomez is also our Chairman of the Board. Of course, Dr. Tony Frudakis, our founder and scientific visionary is Chief Scientific Officer and continues his aggressive leadership of DNAPrint’s technology future. We have added other staff and now total 14 persons. Outside consulting services add 3 other persons as part time consultants and specialists.

Growth and success can be a double-edged sword if you have not planned for it. We are developing the Company’s foundation to prepare it for future growth. This much-needed infrastructure includes policies, procedures and training. While we remain a development enterprise, we are proactively building towards our future so that as growth occurs, we will be prepared. While it is vital to create awareness and demand for our products and services, we must also be able to deliver what we promise. The foundation that we construct now can ensure our success in the years to come.

As we reach our first anniversary as a management team, I am encouraged by our progress. We improved our consumer product ANCESTRYbyDNA™ and upgraded it from a 71-marker test to a 175-marker test. We intend to continue improving the product, its accuracy and its ability to scan a broader platform of genetic heritage. Our goal is to expand our current 4 categories of inherited genetic markers to 8 and possibly 16 categories. Additionally, we have linked with Family Tree Legends (from Pearl Street Software), a software tool that helps our customers load their DNA results into a family file. Finally, we have added a new test, “STR Map.” It is highly accurate and uses the same underlying technology as our crime scene identification and paternity testing. Our collaboration with Pearl Street Software permits our customers to attach their genetic information to their personal genealogical information.

Our approach allows genealogists to compare a paper trail with a genetic marker history of the family, helping individuals and families identify past and present relatives. We will continue to provide consumer based products to the genealogy market. The information we acquire from our consumer products customers can be leveraged for application in other, potentially more lucrative markets.

For example, we believe the same factors that allow us to understand a person’s heritage can help us to understand a person’s drug response, disease susceptibility and response to various treatment regimes. Similarly, we can use what we learn about genealogy to provide better products for law enforcement in our forensics product line. While the markets we service may seem diverse, the cumulative information we receive is applicable to our entire spectrum of product development. By utilizing all of our markets, we expand awareness and diversify revenue sources. Our goal is to create a product mix that provides future growth and development across a number of chosen markets.

We launched our first product into the forensics market with stunning results. The data we provided to a Louisiana task force from a crime scene donor sample helped redirect the task force’s investigation, culminating in the arrest of the accused. We are currently involved with over 40 ongoing investigations and expect that revenues will continue to grow as more detectives find out about our product and services. DNAWitnessTM 2.0 is the first product offering a presumptive test utilizing crime scene donor DNA. It provides detectives with a ‘fuzzy photograph’ that may confirm an eyewitness report or, in the absence of a witness, act as a “virtual witness” by providing information about the DNA donor. Over the next several years, we will continue to expand our products’ ability to provide an image of the individual that may include eye color, hair color and other phenotypic descriptors unique to the donor’s genetic heritage.

More recently, London’s premier crime organization, the New Scotland Yard, has used our test to help investigate a serial rapist of elderly women. The New Scotland Yard has encouraged the London Metropolitan Police and other police organizations to employ our test to help narrow the investigative field, saving time, money and potentially saving lives.

I recognize that many of our investors downplay the significance of our forensics and genealogy businesses. Indeed, some investors have urged us to focus exclusively on the pharmacogenomics or pharmaceutical markets. As I have noted, however, there is an important connection between these markets. Perhaps most importantly, we believe that the connections are even more valuable than the revenues we derive from forensics and genealogy.

Our forensic products address both the public good in helping to catch criminals and the public defenders in helping innocent people, falsely convicted, prove their innocence. Similarly, our genealogy products help people connect their past and perhaps, in so doing, help them understand more about the present and their relationship to one another.

Our efforts in pharmaceutical development parallel our efforts in genealogy and forensics. Not only do people inherit unique physical markers for common traits, like eye color, hair color, skin shade, height or weight; we also inherit our ancestors’ abilities to respond to medications and to succumb to certain diseases. What do I mean by “parallel our efforts”? The more we learn about a patient’s family history, the more we know about a patient’s potential drug response or lack of response. Similarly, the more we learn about a person’s genetic heritage (eye color, hair color and other markers), the more we will know about a patient’s susceptibility to certain diseases or a patient’s potential response to new or experimental medicines.

Genealogists are not as interested in a person’s eye color or hair color as the forensics community or the police. Similarly, police are not interested in a person’s genetic heritage or family tree. In the pharmaceutical development industry, however, we are interested in both, and in other markers hidden in the complex human gene code.

We live in a new era of drug development, discovery and utilization. DNAPrint’s technology can inform a patient and a physician whether or not the patient will respond positively or negatively to a particular drug. Why is this important? It is important to the patient and the doctor because drug response or the lack of drug response is a key to effective disease management. Our test helps establish a dialogue between the patient, the doctor, the medicine and the disease. We believe that dialogue is a crucial component in successful disease management.

Once we identify patients unlikely to respond to a particular drug, we can focus our efforts on determining why this occurs. Is it a unique genetic marker set? Is it inherited? Do other members of the patient’s family have the same predisposition? With accurate answers to these questions, perhaps we can allow the science of discovery to lead us in the right direction, to a new drug therapy or new treatment regime.

Our recent announcement of a collaboration agreement with the Moffitt Cancer Center in Tampa, Florida is just the beginning of our research collaborations in the pharmaceutical industry. The pharmaceutical segment has great potential rewards but takes longer to achieve market penetration.

We have a dual strategy for this market, first, identifying patients responding to current, approved medications and, second, licensing novel technologies or products that will provide the company with its own product line. As a shareholder, you should not expect revenues from this segment to leap onto the income statement. As I mentioned, this market requires a sustained and committed effort. But each step we take toward receiving approval for a test or a drug brings us closer to our overall objectives, to be the best genomics pharmaceutical company and to deliver high quality, effective drugs to the patients that need them.

Over the course of the last year, you may have seen us on 20/20, Nightline, ABC News, CNN and other news shows, or you may have read about us in a newspaper, magazine or on the internet. These appearances often trigger inquiries or comments on how we communicate with our shareholders and the investment community as a whole, and I would like to address that subject.

We are often asked why we don`t issue more press releases to spread the word about the Company’s activities. As you may know, all companies in the microcap market are frequently placed in a negative light because of the unscrupulous actions of certain microcap companies that attempt to manipulate the price of their stock by issuing frequent press releases. Some of these releases are misleading, and some of them are about immaterial matters – in either case they are an attempt to generate enthusiasm for that company’s stock and to raise its price. In our view, these actions are unethical and often illegal. Because of this public perception of the microcap market, we are very conservative in our communications with the investing public. We will not allow your company to engage in such manipulative tactics. Therefore, we do not issue press releases frequently, and we do not issue them unless we believe we have something significant to say.

Alternatively, we are sometimes criticized for responding slowly or poorly to direct inquiries by shareholders. Although we are a small company, many of you would be amazed at the number of communications we receive. As many of you know, Federal law generally prohibits us from disclosing material information about the Company or its operations on a selective basis. Therefore, we either must disclose information publicly, or not disclose it at all. In some circumstances, shareholder inquiries, particularly inquiries about ongoing research and development, would require us to announce publicly information that we do not believe is ripe for release. In these circumstances, we simply cannot release the information in response to a shareholder inquiry.

On the other hand, many shareholder inquiries we receive do not request material information. Sometimes they seek clarification of items we have previously reported, or they may pertain to what the investing public might consider an "immaterial" matter. Unfortunately, responding to these inquiries requires employee time and sometimes company money. We do not have an "investor relations" department staffed by personnel whose exclusive duty is to deal with investors. At this stage of the company`s development, we cannot afford to pay employees for exclusive investor relations’ duty. Therefore, we outsource this function, and we are obliged to pay for it.

As anyone who has followed the Company`s financial reports is aware, until the closing of the private placement in late 2003, your company suffered from an almost continuous cash flow crisis. Since the closing of the private placement, the crisis has abated, but we still do not have excess cash. Therefore, while we intend to use some proceeds of the private placement to improve our investor relations efforts, we ask you to bear with us in that area. When there are material items to report, we will either report them in an SEC filing or in a press release.

I have looked historically at the volume of trades that have occurred since March of 2001, and I was astonished to learn that nearly 2.1 trillion shares have traded during that time period. This volume indicates to me that we have a very active group of buyers and sellers of our stock, and that we are trading on average about 3.0 million shares per day. We believe that active buying and selling of our stock is good for the market and our shareholders. Personally, I believe our management team has made great strides in improving our company, and I have tremendous confidence in their abilities.

Finally, before closing, you will note that you have received a sheet of six numbered coupons for our service, ANCESTRYbyDNA, priced at $158.00 with the coupon. Feel free to pass them out to people that you know or perhaps use them for your own family. You can visit our website www.dnaprint.com and search for ANCESTRYbyDNA or go directly to www.ancestrybydna.com for more information. The normal price for the service is $219.00. We encourage you to take advantage of this special offer and try it out. You might be surprised at your results. I appreciate your consideration in this one time offer to our shareholders and their friends.

In the coming year, you can expect to see more advances in our technology and an increased effort to maximize shareholder value through the building of revenues and eventually, profits. I very much appreciate the support and dedication of our many shareholders, and I look forward to continuing to serve as the Chief Executive Officer and President of this company.

Respectfully and appreciatively,

Richard Gabriel

Chief Executive Officer and President

[ge4teilter]

Hvs....

Bin mit 31 Millionen PRIM`s in der ROTEN Zone.

Hihi.. das wird sich ändern.

oger


Hi "oger"!

Da mußt Du wohl das Bagua-Schemas Deines Gartens im Bereich "hinten links" nochmal überdenken, was?

Gruß ... g4

[cariocca]

G4

Die Lehre von Feng-Shui kennt keine Definition von "Zeit"
Ausserdem ist "Reichtum" ein dehnbarer Begriff. Für einen "Durchschnitts-Europäer" gehöre ich zum gehobenen Mittelstand.
Da kann ich doch wirklich zufrieden sein. Danke für Deine "unten rechts" Bemerkung.

Diese Antwort kannst Du übrigens im Feld "unten links" einordnen.



Fakt ist: Die ganze Börse ist im Moment (eben ein dehnbarer Begriff) am hinken...

Gruss

Roger

[ge4teilter]

Hi Rogi!

Habe zum Geburtstag zwei wunderbare Feng-Shui-Bücher geschenkt bekommen (eines zum Thema "draußen", eines für "drinnen") und bin seeehr begeistert! Habe letzte Woche ein Grundstück erstanden und sitze nun über der Planung für Haus & Garten.

Macht ja schon Spaß .....

Uns allen toi, toi, toi!

g4

[cariocca]

G4...

nachträglich herzlichen Glückwunsch zum Gebuddi.

Hier das TOP-Buch zum Thema:


JMHO

Roger

[ge4teilter]

Moin!

Kann jemand mal die neuesten Entwicklungen kommentieren? Ich blick da nicht mehr durch! Was läuft da mit Tony und Geroge und was ist das für eine neue Firma?

Gruß ... g4

[ge4teilter]

News out!

DNAPrint genomics and ReliaGene Enter Into Agreement
Tuesday July 13, 11:03 am ET

SARASOTA, Fla., July 13 /PRNewswire-FirstCall/ -- DNAPrint genomics (OTC Bulletin Board: DNAP - News) of Sarasota, FL (the "Company") announces today that it has entered into a distributorship agreement with ReliaGene Technologies Inc. The agreement enables ReliaGene to distribute DNAPrint`s flagship product, DNAWitness(TM) 2.5, to its extensive international client base of law enforcement agencies.
ADVERTISEMENT

The agreement is expected to significantly expand DNAPrint`s footprint in the forensics industry by providing access to a host of additional criminal investigation cases. Any case where no suspect has been identified will be eligible for DNAWitness(TM) 2.5, a ground-breaking genetic test which represents the first-ever DNA-based tool for the inference of physical characteristics from evidence samples. Through a molecular genetic appreciation of genetic ancestry, DNAWitness(TM) 2.5 provides physical information about suspects, victims and unidentified human remains, thereby furnishing invaluable assistance and direction to investigations. ReliaGene is a leading DNA laboratory and research facility with accreditation from the American Society of Crime Lab Directors (ASCLD), National Forensic Science Technology Center (NFSTC), Clinical Laboratory Improvement Amendments (CLIA), American Association of Blood Banks (AABB), and ISO/IEC 17025. ReliaGene regularly serves law enforcement agencies across the country and around the world, and has successfully analyzed over 400,000 biological samples.

"DNAWitness(TM) is a presumptive test that will enable investigators, prosecutors, medical examiners, forensic scientists and crime laboratories all over the world establish a `fuzzy photograph` of the DNA donor," said Richard Gabriel, CEO and President of DNAPrint genomics, Inc. "The single largest stumbling block to usage of this product on a much broader basis by the forensic community has been the lack of understanding as to how the product works within the current system of evidence control. We now have made arrangements with ReliaGene that ensures that our presumptive test can be used effectively in the early stages of the investigation in addition to when the trail grows cold over time. ReliaGene`s role is to control the evidence samples according to ASCLD standards, which it currently does for all its forensic clients, and perform standard DNA profiling when necessary. Select samples will be sent to DNAPrint, which will report the DNAWitness(TM) results back, and the outcome of our combined efforts will be a reduction in unsolved cases as well as the reactivation of many cold cases." He added, "We estimate that about 30% of criminal cases have no suspect (including CODIS suspectless cases) and all of the unidentified human remains stored in crime labs and medical examiner offices across the country are also excellent candidates for DNAWitness."

Dr. Sudhir Sinha, President of ReliaGene, stated, "We are very pleased and excited to have this unique opportunity to work with DNAPrint and accelerate the use of DNAWitness(TM) in the forensics market. ReliaGene has always prided itself on providing the utmost in cutting-edge forensic DNA capabilities. Now, through this partnership, we can offer unprecedented access to this revolutionary investigative tool, which has already assisted in the Louisiana Serial Killer Case, the Concord California Case, the Susannah Chase investigation and a number of other high-profile cases. There is no question that DNAWitness(TM) can greatly benefit our numerous customers in the forensic community. It will help them focus investigations in the crucial early stages, producing substantial time and cost-savings, and can assist in identification of human remains. It also bridges the gap for the countless no-suspect cases without a match on the national DNA database -- cases that might otherwise be shelved as dead-ends. We will focus our efforts on encouraging existing clients to take advantage of DNAWitness(TM), and we intend to secure future contracts by emphasizing this enhanced capability. DNAPrint is capable of processing over 500 samples per day using DNAWitness(TM), and there is no reason not to fully utilize this capability through this partnership," he concluded.

"There are over 70,000 DNA profiles from cases that are unsolved in the national U.S. DNA database. Almost all of them are good candidates for DNAWitness," said Zach Gaskin, Technical Director of Forensics at DNAPrint. "The DNA for those cases is sitting in freezers in crime labs across the country. We should get a portion of those as well as samples from future cases through this agreement with ReliaGene. We are working with ReliaGene to host seminars on the use of DNAWitness(TM) in the investigation process as well as workshops on how to write grants for federal funds available to local and state agencies for crime investigation," said Gaskin. "I would like to see more investigators using DNAWitness(TM) proactively in the early stages of an investigation when the trail is still hot, rather than waiting for the possibility that the person who left the DNA at the crime scene is one of the 1.6 million individuals in the national database known as CODIS. Most government crime labs have serious case backlogs, which do not allow them the luxury of processing cases without a suspect in custody. Many of these no- suspect cases are being sent to ReliaGene, and it seems to be a natural bundle with DNAWitness(TM)."

[ge4teilter]

Wenigstens kommt jetzt mal´n bisschen Bewegung rein:

Quote (del. 15 min.)
11:23 AM ET
0.0260
+0.0020 (+8.33 %)
Volume: 5,322,170
- - - - -
Full quote | LiveChart

[ge4teilter]

Sagt mal .... bin ich eigentlich hier der letzte Mohikaner?

[turbozertifikat]

Nein, ich bin auch noch drinn, weiss aber im Moment nicht wie`s weiter läuft.....

[Michiko]

g4,

falls es dich beruhigt: Gestern habe ich nachgelegt; zu 2,2 Cent.

Gruß

Michi

[ge4teilter]

Beruhigend zu wissen, daß man nicht der einzige Bekloppte ist!

[Michiko]

g4 speziell 4u:

Press Release Source: DNAPrint genomics, Inc.


DNAPrint Upgrades DNAWitness(TM) 2.5; New Information Technology for Better Physical Profiling
Thursday July 22, 11:29 am ET


SARASOTA, Fla., July 22 /PRNewswire-FirstCall/ -- DNAPrint genomics (OTC Bulletin Board: DNAP - News; the "Company") announces today that it has upgraded its DNAWitness(TM) 2.5 product for physical profiling from DNA with a proprietary database designed to help investigators learn what their results say, or don`t say, about physical appearance.
The DNAWitness(TM) 2.5 genome test allows forensics investigators to employ objective science, empiricism and statistical analysis in the reconstruction of a physical profile or "fuzzy photo" from DNA left at a crime scene. It employs the world`s first molecular genetics test for the inference of BioGeographical Ancestry (BGA) admixture. For example, DNA at a crime scene may indicate that a person is of 90% East Asian, 10% European mix. BGA is obviously related to physical appearance, and individuals with fewer admixtures tend to have more accentuated anthropometric characteristics (those that vary from race to race). Investigators who obtain a result such as 100% East Asian typically have little difficulty interpreting the result, but investigators who, for example, obtain a result such as 70% European, 30% East Asian usually ask whether the person`s physical appearance would reveal the East Asian admixture. Communicating how BGA relates to physical appearance is difficult to do with words in a scientific way, but the advance announced today is the first solution for this problem.

To project what a person may look like from knowledge of their DNA, DNAPrint has developed the DNAWitness(TM) 2.5 database of individual BGA admixture results. The database contains information on how individuals previously tested have self-defined in terms of ethnicity (called the "geopolitical" arm of the database) as well as their digital photographs. By querying the database using a specific BGA admixture result, investigators can see for themselves what the range of variability is corresponding to that result for various features, such as skin shade, hair texture, nose shape, epicanthal eye folding, etc. Whether or not, for example, individuals of 70% European, 30% East Asian admixture tend to show no East Asian features, would be apparent from the database query. Statistical tools soon to be added will allow investigators to use Analysis of Molecular Variance to determine whether there is a systematic difference in the expression of an anthropometric trait that can be measured from the photograph in one database sample set versus the international average, or versus another group. DNAPrint has already filed patent applications on the use of digital photograph databases and databases of biographical data with BioGeographical Ancestry admixture data.

Last week, the Company provided a mid-Atlantic customer access to this database for the first time; all DNAWitness(TM) 2.5 customers from today forward will enjoy its use.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company introduced AncestryByDNA in the consumer market and DNAWitness(TM) in the forensic market in 2003. DNAPrint is developing products in the pharmacogenomic market and has a disease gene discovery program. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit http://www.dnaprint.com.

All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Media and Press Contact
Richard Gabriel
DNAPrint genomics, Inc.
CEO/President
[phone]




--------------------------------------------------------------------------------
Source: DNAPrint genomics, Inc.

[Michiko]

und dann noch den:

Press Release Source: DNAPrint genomics, Inc.


DNAPrint Technology Featured in `Nature` Journal Review and Upcoming Textbook
Thursday July 22, 11:43 am ET


SARASOTA, Fla., July 22 /PRNewswire-FirstCall/ -- DNAPrint genomics (OTC Bulletin Board: "DNAP") (the "Company") announces today that its ANCESTRYbyDNA(TM) 2.5 product will be featured in a review article to be published next month in the journal "Nature Reviews." The article will focus on the growing interest in personal anthropology and will highlight the uniqueness of DNAPrint`s role in this growing market. The article represents the first discussion of the Company`s proprietary BioGeographical Ancestry (BGA) admixture test in the peer-reviewed literature.
In addition, at the invitation of Academic Press Publishers, DNAPrint`s Chief Scientific Officer has agreed to co-author a textbook on the history, molecular genetics, mathematics and practice of molecular photo fitting entitled "Molecular Photo Fitting: Predicting Ancestry and Phenotype Using DNA." Dr. Mark Shriver, a co-author of the Nature Review article, was invited by DNAPrint to join the project as a co-author. The Company expects the work, targeted for publication March 1, 2006, to serve as the interface between the Company`s unique pharmacogenomics/forensics platform and the scientific community.

About DNAPrint genomics, Inc.

DNAPrint genomics Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company introduced ANCESTRYbyDNA in the consumer market and DNAWitness in the forensic market in 2003. DNAPrint is developing products in the pharmacogenomic market and has a disease gene discovery program. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit http://www.dnaprint.com.

All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act, as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Media and Press Contacts:
Richard Gabriel
DNAPrint genomics, Inc. CEO/President
[phone]




--------------------------------------------------------------------------------
Source: DNAPrint genomics, Inc.

[hvs1]

Ich bin natürlich auch noch da.
650K sind nach wie vor in meinem Depot.Leider z.Zt. keine Kohle zum Nachlegen.

hvs1

[hvs1]

Michi,

was machen Deine Prim?
Sind ja ganz schön abgekackt.

hvs1

[Michiko]

hvs1,

von PRIM habe ich nur einige hunderttausend Stück, also lässt mich der Abfall relativ kalt.
Ich überlege allerdings, ob ich zukaufe.

Nur: Morgen geht´s ab in den Urlaub; dann passiert erstmal 2 Wochen lang garnix

Michi

[cariocca]

Abfall kann dein Leben verändern. 38 Mil. long.

[hvs1]

Michi,

ich wünsche Dir einen schönen Urlaub.Uns wünsche ich,
daß Dnap und Prim gen Norden marschieren.

hvs1

[Michiko]

hvs1,

Danke! Insbesondere bei DNAP wäre ein Rebound nichts Schlechtes!!

Und wenn Du schon am Daumendrücken bist: Vielleicht hast Du noch einen dritten Daumen für CMKX; da ist gerade einiges am Dampfen.

Michi

[hvs1]

G4,

leider wird es mit DNAP wohl auch in 2004 nichts werden.
Wenn die jeden Monat und das 1 1/2 Jahre lang 20 bis 30M
Shares auf den Markt schmeißen,dann kommen wir der 0.001
näher als der 0.1.


hvs1

[Dukkha]

@ hvs 1

woher hast du die Info???

gruß
Dukkha

[hvs1]

Dukkha,

aus dem RB.
Stockholder 101 hat derartiges gepostet.

Gruß hvs1

[cariocca]

Mit Verlaub... und um mich mal wieder zu melden:

Stocky ist ein egozentrischer und unglaubwürdiger Volltrottel!

Wie immer: meine persönliche Meinung.

[hvs1]

Roger,

ich traue seinen Prognosen auch nicht,aber Tatsache ist,
dass der Kurs ständig nach Süden geht.Und das hat er
schon seit längerer Zeit angekündigt.DNAP braucht Geld
und dazu müssen sie in der nächsten Zeit ständig Aktien
auf den Markt schmeissen und das treibt den Kurs unweiger-
lich gen Süden.

Gruß hvs1

[seriousguy]

hi all...

Habe mich schon seit längerer Zeit nicht mehr in den Boards gemeldet, da es mir zu dumm war irgendwelche blöden Antworten zu lesen (speziell RB)

ich bin schon seit längerer Zeit Investor von DNAP, und bin nachwievor von der Technologie überzeugt.
Vielleicht mehr überzeigt als ich es dazumals (vor 2 jahren) war

Man muß einige Tatsachen festhalten um die man nicht kommt.

* Outstanding Shares
* Management
* Agreements mit verschiedenen Firmen
* Technologie

zum ersten Punkt kann ich lediglich das sagen was ohnedies schon jeder weiß:
Die Firma brauch Kapital bzw. muß auf der anderen Seite auch das Management bezahlen.

Punkt 2:
Das Management ist soweit ich das betrachten kann OK, jedoch wäre der CFO nicht wirklich notwendig im moment
Mr. Gomez ist ein wertvoller Kerl der sich schon sehr viel reputation eingeholt hat.
Hatte lediglich einmal das Vergnügen ihn kennenzulernen.
(die Connections zu Bayer sind vorhanden)

Punkt 3:
als oberste Stelle steht meiner meinung die Vereinbarung mit Moffit.
Wenn man deren Histotry so ansieht dann bemerkt man das diese jungs wirklich ein Global Player in der Krebs Forschung sind. Das Budget haben sie ja *smile*

duie anderen Agreements sind Nice to have, aber nicht wirklich "Reißer".

Hatte vor einigen Wochen mit DAvid Moskowitz von Genomed einige e-mails ausgetauscht. DArin stellte ich auch die Frage was mit dem Agreement mit GMED und DNAP ist.
Er Antwortete mir, das das Agreement aufrecht sei, er jedoch mit Mr. Gabriel vereinbart hätte, nach dem 10Q (letzter März) mit ihm nähere Details zu besprechen.
Tja, bis dato hat Mr. Gabriel noch keinen Finger gerührt
...vielleicht hat ja DNAP was im hintertürl und sind nicht auf das Geld von GMEd angewiesen *g*

der letzte Punkt:
meiner meinung nach ist ABD 3.0 und Retinome fertig.
Es ist nur eine frage der zeit (innerhalb der nächsten 2 monate) bis es gelaunched wird.
Retinome wäre schon viel früher fertig gewesen, jedoch hatten die jungs probleme mit der genauigkeit.
Dies bedeutet also das wir vermutlich und wirklich nur rein theoreitsch DNA Witness 3.0 sehen könnten.
Aber vielleicht packen die Entwickler auch noch andere Features in das Forensic Tool.
Lassen wir uns überraschen.

Meiner meinung nach sind wir vom Aktienpreis niedergeprügelt worden.
abner alles hat einmal ein Ende.

Ich bleibe LONG
lg
seriousguy

[hvs1]

Hallo seriousguy,

schön mal wieder etwas von Dir zu hören.Am 28.08.04 habe
ich meine Shares 4 Jahre.Ich bleibe selbstverständlich long,wie Du ja auch.
Im Investors Hub-DNAP gibt es allerdings einige gute Infor-
mationen.-Leider ist mein Englisch nicht gut genug-
Es scheint Bewegung in die Aktie zu kommen.Auch könnten wir
in den nächsten 2 Monaten News von Tony erhalten.Warten
wir es einfach noch ein wenig ab.Wenn Du etwas neues hast,
stell es doch einfach kurz rein.

long hvs1

Zu diesen Kursen müßte man nachlegen,wenn man noch Geld frei hätte.

[marterpfahl]

Doch noch der Durchbruch ?
Warten wir mal die Verkaufszahlen ab !
Auf jeden Fall wird es heute noch weiter rauf gehen !

viel Glück,marterpfahl

Press Release Source: DNAPrint genomics, Inc.


DNAPrint Announces the Release of RETINOME(TM) for the Forensic Market: Eye Color Prediction From Crime Scene DNA!
Tuesday August 17, 10:02 am ET


SARASOTA, Fla., Aug. 17 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. announced today that it has finished validating an ultra-high throughput version of its proprietary RETINOME(TM) genetic test for predicting human (eye) iris color from DNA. The new test has been added to the Company`s proprietary DNAWitness(TM) 2.5 physical profiling package of genome tests sold to forensics and security investigators.
ADVERTISEMENT


The completion of the RETINOME(TM) project and the addition of the new RETINOME(TM) product to the Company`s DNAWitness(TM) package of genome tests constitute a dramatic advance in the newly developing science of molecular forensics profiling, where the goal is to paint a physical profile from crime scene DNA.

RETINOME(TM) provides an accurate inference of iris (eye) color from the measurement of proprietary single nucleotide polymorphisms (SNPs) distributed throughout the human genome. The genetic basis of this trait has vexed geneticists for decades. As detailed in an article published in a recent `Trends in Genetics` review article, RETINOME(TM) was developed from a genome screen of tens of thousands of genome SNPs in thousands of European subjects. A necessary but not sufficient component of the RETINOME(TM) technology was first published by DNAPrint(TM) scientists last spring in the peer-reviewed journal, "Genetics." Since the discovery of the genetic keys for predicting iris color from DNA 3 years ago, the Company has been augmenting, evaluating and optimizing the performance of its innovative RETINOME(TM) genome test. The most recent blind validation test for 65 individuals of predominant (>80%) European ancestry, between the ages of 10 and 60 years, showed greater than 97% accuracy. A "blind" test is one in which a model is used to classify a trait for samples that were not used to develop the model in any way, and provides an indication of the generality of the model for field application. DNAPrint`s computer scientists developed innovative and proprietary software that proved to be the key to unlocking the door to this difficult trait.

"As a presumptive test designed for investigative, rather than human identity applications which suggest culpability, a 97% accuracy rate corresponds to a solid `A` grade," said Zach Gaskin. "The test is appropriate for samples that have typed with the Company`s DNAWitness(TM) 2.5 test to be of predominant European continental ancestry, and was blindly validated strictly for individuals of both sexes between the ages of 10 and 60 years."

The validation and commercial implementation of RETINOME(TM) using this powerful approach is a historic event; RETINOME(TM) becomes the first test developed and validated for the inference of a complex genetics trait from DNA. Prior to the human genome era, complex genetics traits such as disease proclivity, drug response and particularly physical traits such as iris and hair color vexed geneticists for decades. The excitement generated by the completion of the human genome sequence draft in 2001 was based on the hope that common human traits would finally be understood from a genetics perspective. The ultimate expression of genetic understanding is demonstrated by showing an ability to predict or infer a trait from DNA sequences, but so far this hope has remained largely unfulfilled. Prior to RETINOME(TM), no predictive genome-based test had been developed, described in the peer- reviewed literature or, most importantly, launched commercially. DNAPrint`s ability to do so stems from its innovative approach for screening the human genome that feeds from the mathematical fuel provided by natural human population structure. "We are very proud to be the first to demonstrate how the promise of the human genome project can be fulfilled in a practical sense," said Tony Frudakis, DNAPrint`s Chief Scientific Officer.

"DNAPrint`s success with this difficult trait has profound implications for its goal of developing a pipeline of small molecule drugs that target specific human subpopulations," said Richard Gabriel, CEO and President. "More immediately, a grant is available from the National Institutes of Justice and can be found at: http://www.ojp.usdoj.gov/nij/funding.htm and is specific for `Solving Cold Cases with DNA.` Now not only can we tell the genetic profile of the crime scene DNA, but we can also describe the eye color if their DNA genetic results fall into the correct category. Each time we do this, we are reducing the "donor pool" of individuals and the number of suspects. Combining our DNAWitness(TM) technology with RETINOME(TM) and standard STR testing, as well as mitochondrial and y-Chromosome testing, this is a powerful combination of information for the investigators. Our photo database system of images, coupled with an eye color prediction, are just the beginning of our forensic products for the investigative community. We intend to aggressively roll out additional services over the next several years to enhance the predictive ability of our Company`s products and services from crime scene DNA."

RETINOME(TM) is available today along with DNAWitness(TM) and can be ordered directly from any of the following companies: DNAPrint genomics, Inc. http://www.dnaprint.com ; ReliaGene Technologies, Inc. http://www.reliagene.com and Lynn Peavey Company http://www.lynnpeavey.com .

About ReliaGene Technologies, Inc.

Founded in 1990 and based in the New Orleans, LA metro area, ReliaGene Technologies Inc. is a leading DNA laboratory facility specializing in human genetic identification and related bio-tech product development. With cutting-edge capabilities for forensic and paternity DNA testing, ReliaGene has now successfully detected human genetic profiles from over 400,000 biological samples, including cases from all 50 U.S. states and over 35 countries worldwide. ReliaGene`s Y-PLEX(TM) genotyping systems, first released in 2000, are now sold in over 40 countries with market demand increasing steadily. DNAWitness is available through ReliaGene and for more information, please visit: http://www.reliagene.com.

About Lynn Peavey Company

Lynn Peavey is the leader in providing law enforcement with forensic innovations for use at the crime scene and in the laboratory. Lynn Peavey reaches over 17,000 law enforcement agencies, medical examiners and crime laboratories across the country. The Lynn Peavey Company has an on-line catalog and bound catalog by request for all crime scene materials and including a DNAWitness testing kit. For more information, please visit: http://www.lynnpeavey.com

About DNAPrint genomics, Inc.

DNAPrint genomics Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company introduced Ancestrybydna in the consumer market and DNAWitness in the forensic market in 2003. DNAPrint is developing products in the pharmacogenomic market and has a disease gene discovery program. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit: http://www.dnaprint.com.

All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Media and Press Contacts
Richard Gabriel
DNAPrint genomics, Inc.
CEO/President
[phone]

[seriousguy]

DONE

[Michiko]

Die alte Börsenerfahrung Tuesday = Newsday hat mal wieder gestimmt.

Aber leider hat der Kurs nur zwischenzeitlich nen kleinen Hüpfer gemacht und das war´s bis jetzt.

Michi

[Michiko]

Nur mal so ne Idee:

Könnte es vielleicht sein, dass unsere shares geshortet werden auf Teufelkommraus?

Ganz egal, wie News und Nachfrage sind, die MMs verkaufen einfach leer?

Michi

[seriousguy]

good morning community!

Die News seitesn DNAP werden laufend mehr, auch wenn wir als Shareholder mehr wissen wollen als was tatsächlich berichtet wird.

Man muß einfach geduld haben!
Die letzten News bezüglich Euro-DNA bedeutet, das DNAP sein Produkt weiter und weiter ausbaut.
Es sit einfach eine Frage von Zeit und Geld bis sie dieses Tool noch präziser haben.

Klar ist es tatsache das durch das Investment von La Jolla die Aktie brutal gedrückt wird....
...wartet aber einfach ab was passiert wenn DNAP plötzlich nicht mehr auf solches Geld angewiesen ist.

Ich persönlich behaupte oder bin mir vielleicht ziemlich sicher das wir HEUER noch einen launch von OVANOME sehen werden !
Was dies dann bedeuten würde brauch ich glaube ich nicht erwähnen
---> Eintritt in ein MultiMillionen Dollar Business !

wartet einfach ab was passiert....
auch die tatsache das Retinome nun endlich gelaunched wurde bedeutet noch lange nicht das DnaWitness 3.0 auf dem markt kommt...obwohl ich das auch sehr bald auf uns zukommen sehe.

Die jenigen die LONG sind (so wie ich) werden es noch abwarten können (1-2 jahre) *smile*

glaubt mir, es passiert heuer noch einiges

lg
seriousguy

[Michiko]

seriousguy,

Was mich schon immer interessiert hat: Wann ist heuer ?

lg
Michi

[hvs1]

Michiko,

lt. Duden .... in diesem Jahr.Bezeichnung für Ösi`s,
Schweiz und Süddeutschland.

hvs1

[smiling]

http://www.drugresearcher.com/news/news-NG.asp?id=54499

DNAPrint launch ‘ethnicity’ test.


Related News & Analyses
Recently published on the site
All news : September 2004




03/09/2004 - The world’s first commercialised genetic test for determining intracontinental subpopulation (ethnic) admixture of individuals could lead to the development of more specific, better-tolerated and more effective drugs in the future.

Specifically developed for the drug development process, DNAPrint genomics has launched the Euro-DNA 1.0, a service that has never before been developed or provided with the specific intention of targeting the receptive population for a given drug, using objective, verifiable, repeatable, quantifiable measurements rather than questionnaire answers such as for `race`.
The new test is powered by 309 proprietary Ancestry Informative Markers (AIMs) distributed across all 23 human chromosomes. The AIMs were identified from a screen of approximately 12,000 candidate AIMs obtained from DNA chips and public genome database resources.

Tony Frudakis, Head of Research at DNAPrint Genomics told DrugResearcher.com: "Right now we sell to the general lay public based on a motivation to educate."

"However we reserve the application of the technology for drug development to our in-house R&D and for select partners as the opportunity arises."

Previously, the only genetic tests capable of tracing ethnic ancestry were Y-chromosome and mtDNA tests. Y-chromosome and mitochondrial DNA (mtDNA) tests only look at a specific portion of a person`s DNA heritage - the Y- chromosome, which is inherited paternally and the mtDNA, which is inherited maternally.

Because Y and mtDNA tests each look at only 1 of the 23 chromosomes, they ignore contribution from most of the individuals in a given family tree and for this reason, Y and mtDNA tests are not useful for the analysis of admixture within individuals. Euro-DNA 1.0 is the first test ever developed and commercialised capable of distinguishing ethnicity from each persons DNA.

Frudakis said: "One product that is comparable on the market is Y-chromosome and mtDNA testing, which look at only one of the 23 pairs of chromosomes in each person’s genome. Thus, they are useless for determining ancestry mix and the drug development process."

The concept of tailoring drug discovery and development, even drug programmes, according to ethnic make-up is seen as the next step in producing the next generation of increasingly effective drugs. Until the specific response pathway for each drug becomes possible and economically viable, biogeographical ancestry admixture will be used as a surrogate for predicting response.

"One could concievably use our AIM technology during phase I and II to plan phase III, but also develop a specific (gene variant based, not AIM based) pharmacogenomics test to accompany the drug during phase III or later," Frudakis added.

The new test is available now for $199 (€163) for former DNAPrint customers. New customers that are interested in the new service test can purchase the combined test for $399 (€328), which will include the AncesterybyDNA 2.5 test and the new Euro-DNA 1.0 test.

Copyright - Unless otherwise stated all contents of this web site are © 2000/2004– NOVIS. – All Rights Reserved.
For permission to reproduce any contents of this web site, please email our Syndication department: adminnovisgroup.com .
Full details for the use of materials on this site can be found in the Terms & Conditions.


still here still long

[hvs1]

Grüß Dich smiling,

habe die Nachricht heute morgen auch schon im RB gelesen.
Stabilisiert den Kurs vielleicht etwas.

Viel Glück uns longs.

hvs1

[ge4teilter]

Jo,

wünsch´ ich uns auch!

g4

[Neoe]

Morgen ist der letztmögliche Termin für die Einreichung von Förderungsanträgen. Die US-Behörden wollen 800 Millionen Dollar in die Aufarbeitung alter Kriminalfälle mit Hilfe neuer Technik investieren.
Da ihr es wahrscheinlich sowieso schon alle wisst, muß ich euch ja auch nicht sagen, daß bald News anstehen sollten. Darüber hinaus bringt Moffit 222 Medikamentenkanidaten in die klinische Forschung, da wird für DNAP einiges zu tun sein.

[Neoe]

Das heisst natürlich 22 Medikamentenkandidaten

[HenryR.Mandell]

up

Wird langsam Zeit wieder zu kaufen...

Oder doch noch warten ?

In Frankfurt hat einer ein Schnäppchen gemacht

Croko

[Michiko]

croko,

hab mich gestern in USA nochmal eingedeckt zu 1,5 US-Cent.
Viel billiger krieg ich sie wohl nicht mehr (hoffe ich doch!)

Michi

[hvs1]

Ich warte noch die kommende Woche ab.1,5 cent ist aber
schon ok.

Gruß hvs1

[HenryR.Mandell]

Moin,bin heftigst am rechnen - überlege meine PTSC einzutauschen...

Aber hat denn keiner den Kauf gestern in FRA gesehen ?

War der unlimitiert oder was ?

Muss doch zu 0,011€ auch gehen...

Fragen über Fragen...

Croko

[Michiko]

crocodito

Ein Dummi macht noch keinen Sommer!

Grießklöß

Michi

[HenryR.Mandell]

Hi Michi,wolln wir mal die Spazianer ärgern ?

[Michiko]

Croko

weißt Du schon, dass ich seit 2 Monaten SPD-Mit-Glied bin?

[HenryR.Mandell]

?

Grübel...

[Michiko]

Äi!

SPAZIANER ÄRGERN!!!

[cineman]

wieso passiert bei DNAP in den letzten Wochen gar nix??
Price ist mehr als DOWN , jetzt sollte doch mal ein UP move kommen.
Das Jahr 04 war es leider noch nicht. aber wir haben ja noch 3 Monate

cineman

[Michiko]

MIST!!

Auch mein Kauf bei 1,5 US-Cent war wieder mal falsch.

Jetzt würde ich sie für 1,35 kriegen!

Vielleicht irgendwann sogar für 0,01?

[Michiko]

DNAPrint investiert in Deutschland! Oha!!

Press Release Source: DNAPrint genomics, Inc.


DNAPrint(TM) genomics, Inc. Agrees to Acquire Majority Ownership in German Pharmaceutical Company Biofrontera AG; Secures $35 Million Equity Commitment from Dutchess Private Equities Fund, L.P.
Tuesday September 28, 2:40 pm ET


SARASOTA, Fla., Sept. 28 /PRNewswire-FirstCall/ -- DNAPrint(TM) genomics, Inc. (OTC Bulletin Board: DNAP - News) today announced that it has agreed to acquire a 51.77% stake in German pharmaceutical company Biofrontera AG. DNAPrint simultaneously announced that it has received a commitment from Dutchess Private Equities Fund, L.P. to purchase up to $35 million in DNAPrint common stock over the next two years.
ADVERTISEMENT


DNAPrint has agreed to invest 20 million euro (approximately $25.00 million) over 24 months in Biofrontera Series B preferred shares (68% of B shares) representing a 51.77% equity interest. Biofrontera will use the proceeds of the investment to advance its clinical and preclinical drug pipeline. DNAPrint is only obligated to close the transaction and to begin paying the purchase price for the Biofrontera shares after it begins making sales of common stock under its arrangement with Dutchess.

DNAPrint will participate in a clinical pipeline of novel drugs, as well as an extensive pre-clinical compound portfolio and a broad technology base. This strategic investment will form the basis of future joint ventures between the two companies, expanding DNAPrint`s presence in Europe and giving Biofrontera a presence in North America. DNAPrint and Biofrontera have signed a joint venture framework agreement designed to integrate the companies` technologies in a mutually beneficial way.

The acquisition will transform DNAPrint from a population genomics company into a genomics based pharmaceutical company devoted to the development of 21st century "Theranostics" products. "Theranostics" blend genomics-based tests with drugs as products to target segments of the patient population for enhanced efficacy and reduced side effects. Management expects the use of genome-based testing to facilitate the drug development process and accelerate selected drugs through the clinical trial process. Both DNAPrint and Biofrontera believe that Theranostics will form the foundation for post- genome, 21st century medical care.

Biofrontera`s lead product candidate, BF-Derm1, is currently in phase II clinical trials for the treatment of severe, antihistamine-refractory chronic Urticaria or chronic itching and scratching. The first interim report of a European adaptive phase II clinical trial recently indicated that the compound exhibited a 40% improvement above placebo in clinical symptoms. Biofrontera has also advanced a novel prophylactic migraine treatment to pre-clinical development, and has a series of other compounds at the pre-clinical stage. Professor Doctor Hermann Luebbert, CEO of Biofrontera AG, will join the DNAPrint board of directors.

DNAPrint also has entered into an Investment Agreement with Dutchess Private Equities Fund. Dutchess will purchase common stock from DNAPrint, at times and in amounts selected by DNAPrint, up to a total investment of $35 million over the next two years. The purchase price at which Dutchess will purchase DNAPrint`s stock is based on the trading price of the stock, and the funding will begin after DNAPrint registers the common stock that it will issue in the transaction. DNAPrint anticipates that the transaction will provide it with equity to build the business of the two companies. The commitment was arranged by Athena Capital Partners.

"We are extremely excited about the alliance between DNAPrint(TM) and Biofrontera, and we believe we have established a reliable and trustworthy source of capital for development of both companies," said Richard Gabriel, CEO and President of DNAPrint. "Our goal for this financing, once it is completed through the registration process, is to build shareholder value beyond the inherent investment value that Biofrontera brings to the relationship. The investment brings Biofrontera`s value to over $51 million, and we fully expect that value to increase for our shareholders if Biofrontera strikes its milestones. We hope to increase our revenues by combining the distinct businesses of the two companies and by offering services that address many of the problems in drug discovery and development. By paying for the Biofrontera shares over time we have a unique opportunity to achieve our mutual goals and objectives."

Professor Doctor Hermann Luebbert, CEO and founder of Biofrontera, commented: "This investment is a significant milestone for us that provides us with substantial resources we need to move our products ahead in clinical development, and to establish the key clinical milestones which will form the basis of the future value of Biofrontera. We are excited by the recent progress in developing our lead product BF-Derm1 for the treatment of severe chronic Urticaria, and the proceeds of this investment should enable us to bring this promising product to the market sooner. Including DNAPrint`s technology in our clinical studies for the selection of patients will reduce the cost of our studies and should allow more rapid development. We consider the ability to predict the individual patient`s response to our drugs an extremely valuable addition to our effort in serving the patients` needs. Capital from this investment will also fund the development of Biofrontera`s other clinical and preclinical projects and will us to move towards our goal of enhanced shareholder value."

Athena Capital Partners, Inc. in Tampa, Florida was the private merchant bank that brought Dutchess and DNAPrint together. "The chance to invest in a first rate European pharmaceutical company like Biofrontera and to share technologies and business operations makes this relationship one we had to forge. Dutchess was the obvious choice because it allows management to obtain the funding on its own timetable, dictated by the company`s needs," said Kevin Cimino, Managing Director and Principal at Athena.

"Biofrontera brings what DNAPrint has always wanted but few companies of its size and status have ever been able to obtain -- a viable drug discovery and development pipeline. I believe the value of population genomics lies in the sale of highly targeted drug/test combinations. The new DNAPrint/Biofrontera represents to me an example of the paradigm that most 21st century drug development firms should adhere to -- using population genomics to develop and obtain approval for `smart` drugs targeting specific patient subpopulations with highly predictable efficacy and minimal side effects," said Tony Frudakis, DNAPrint`s Founder and CSO. "As a scientist, I am delighted at the prospect of working with Biofrontera scientists. I believe this is the deal all DNAPrint shareholders have been waiting for - and we hope that it will put DNAPrint on the map."

Timo Hercegfi, partner at Biofrontera`s last lead-investor Heidelberg Innovation commented: "We are very pleased to welcome DNAPrint as a new investor on board. This agreement is mutually beneficial to both Biofrontera and DNAPrint and a great endorsement of Biofrontera`s development potential. It secures not only the funding needed to create further substantial value from Biofrontera`s clinical projects but also gives us great access to DNAPrint management`s highly relevant network in the US biotech and pharmaceutical industry."

About Biofrontera

Biofrontera is aiming to become a specialty pharma business with a profound internal research capacity to extend its drug pipeline. The company is located in Leverkusen and Heidelberg, Germany. Biofrontera`s existing major investor group participated in this financing round as well, including Heidelberg Innovation, 3i Group, TechnoMedia Kapitalbeteiligungsgesellschaft Kvln mbH, and Prof. Dr. Riesner, founder of Quiagen AG. Since its first financing round in 1998 Biofrontera has raised approximately 38 million euro in venture capital and strategic investments.

About DNAPrint genomics, Inc.

DNAPrint genomics Inc. was founded in 2000 by Dr. Tony Frukakis. Two products currently marketed by DNAPrint(TM), DNAWitness(TM) and the ANCESTRYbyDNA(TM), are a direct result of focused research by the DNAPrint(TM) research and development team. DNAPrint uses proprietary human genome research methods, to develop pharma-predictive tests for matching patients with drugs based on their genetic constitution, and to discover disease genes for the development of new drugs. DNAPrint will continue to develop new forensic genomics and consumer genomics testing products. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit http://www.dnaprint.com.

All statements in this press release that are not historical and are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint(TM)`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint(TM) genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint(TM)`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Media and Press Contacts
Richard Gabriel
DNAPrint(TM) genomics, Inc.
CEO/President
[phone]




--------------------------------------------------------------------------------
Source: DNAPrint genomics, Inc.

[Michiko]

. . . und schon geht´s a bisserl aufi mitm Kurs!

[Michiko]

. . . und auch mit dem Umsatz!!

Pennt Ihr denn alle?!?!?

Michi

[Michiko]

H A L L O O O O ! ! !

H I E R L Ä U F T G E R A D E W A S ! ! !

[Michiko]

S Ä U F F Z Z ! !

Wie sagte schon cariocca:

Diese Dame kann ihr Wasser nicht halten.

Oder auch: Sch**** MM!

[cariocca]

Jow.. im Moment gibts am OTC viele Damen mit diesem Problem.

Pinkies - oder ein...


Wird schon noch geben mit DNAP.

Das waren nun definitiv die Verzweifelten, welche sich schon länger von den Teilen trennen wollten. Denk ich mal.

Nu aber ab zur Arbeit.

[hvs1]

Hallo Roger,

Du lebst ja noch!
Was ist mit Prim los?
DNAP wird laufen.Michi Dein Deal zu 0,0135 war doch ok.

hvs1

[ge4teilter]

29 Sep 2004, 10:37am ET

Last price:0.024
0.009 or (60.00%)
DNAP detailed pricing and financial information. Metric Value
Day`s Low & High: 0.015 - 0.028
Open: 0.017
Previous Close: 0.015
Volume: 10,872,485
Avg. Volume: 3,483,276
52-week range: 0.0047 to 0.16

Okay, man weiß natürlich nicht, wie lange das hält, aber wenigstens hat man doch ab und zu noch mal Spaß mit seinem Investment (und das ist wichtig, auch wenn´s nur für Stunden ist)

Gruß ... g4

[wilfonx]

du sagst es.......einstand .13.--
mfg wf.

[ge4teilter]

Quote (del. 15 min.)
10:54 AM ET
0.0270
+0.0120 (+80.00 %)
Volume: 12,707,085



g4 (Einstand .11)

[ge4teilter]

Quote (del. 15 min.)
10:59 AM ET
0.0289
+0.0140 (+93.33 %)
Volume: 13,356,385

Holla!

g4

[Michiko]

hvs1

Du hast Recht. Mein Zukauf im low vor kurzer Zeit war wirklich eine glückliche Entscheidung.

Allerdings bin ich jetzt heftig am Überlegen, ob ich meine shares nicht lieber rauswerfe. Wir hatten schon öfter nen kurzzeitigen Hype und dann wieder Sense.

Andererseits: Der Einstieg in den Pharma-Markt könnte ein echter Wendepunkt werden.
Wenn ich mir vorstelle, ich steige jetzt aus und dann gehen die Dinger bis jenseits von 10 Cents . . .

Irgendwo . . .


..............................


. . . . . . . . . . . . . hatte ich doch ne Kristallkugel rumliegen

Bis danne

Michi

[hvs1]

Michi bist Du verrückt?

Bleib bloß drin,die Post muß doch irgendwann einmal abgehen
und dann bist Du nicht dabei.

hvs1

[Michiko]

hvs1

war doch nur ein

Habe doch nicht mühsam über eine Million shares zusammengeklaubt, um jetzt die Flatter zu machen.

mit iHub-Gruß

Tooodaaamooooooooooooooooooooooon

[wsperber]

Hallo Leute,

hab auch noch keine Aktie verkauft, da ich auch nur
derbe Minus gemacht habe und keine Lust hatte mit Verlust
zu verkaufen. Die Idee fände ich auch immer noch toll,
wenn langsam mal mehr Einnahmen als Ausgaben auf der Habenseite wären.

Aber, um die Euphorie etwas zu bremsen, frage ich mich
wie will DNAP Aktien einer Firma mit Aktienverkäufen
bezahlen die ihren eigenen Börsenwert überschreitet?

Fragend

Wolfgang

[Michiko]

Hallo Wolfgang,

hier mal ne finanzielle Theorie:

Der PR zufolge wird Biofrontera eine AG im Wert von gut 40 Millionen Euro, von denen "wir" dann knapp 52% besitzen.
In der Bilanz können wir also weitere ca. 20 Mill. Euro ausweisen (52% von 40 Mill.)
Diese 20 Millionen haben wir also praktisch von einer Tasche in die andere gesteckt.

Abgesehen davon ist der Kaufpreis nicht sofort fällig, sondern erst, wenn Erträge aus diesem Geschäft fließen (falls ich das richtig verstanden habe).

Zum dritten steckt doch in der PR auch noch die Nachricht, dass Dutchess Private Equities Fund sich verpflichtet hat, innerhalb der nächsten 2 Jahre 35 Millionen Dollar in DNAP zu investieren.

Sieht doch alles garnicht so unübel aus

Gruß an alle longs

Michi

[Michiko]

Hier die Presse-Mitteilung von Biofrontera:

Pressemitteilung
Seite 1
Für weitere Informationen:
Anke zur Mühlen
Corporate Communication
+ 49 (0) 214 87632 22
+ 49 (0) 214 87632 90
[e-mail]
Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen
29. September 2004
Biofrontera erhält strategisches Investment von DNAPrint in
Höhe von 20 Millionen Euro
Leverkusen, Deutschland − Biofrontera AG gab heute bekannt, dass auf
der Basis eines strategischen Investments von DNAPrint™ genomics, Inc.,
Sarasota, FL, USA eine Joint Venture Rahmenvereinbarung zwischen
beiden Unternehmen geschlossen wurde. DNAPrint erwirbt von Biofrontera
neu ausgegebene Vorzugsaktien der Serie B für 20 Mio Euro. Heidelberg
Innovation, 3i Group, TechnoMedia Kapitalbeteiligungsgesellschaft Köln
mbH sowie Herr Prof. Dr. Riesner erhöhen das Gesamtinvestitionsvolumen
auf 21,2 Mio Euro.
Biofrontera wird das aufgenommene Kapital zur Weiterentwicklung der
klinischen und präklinischen Produktpipeline nutzen. DNAPrint werden zwei
der sechs Aufsichtsratssitze der Biofrontera zugesprochen, und Prof. Dr.
Hermann Lübbert, Vorstandsvorsitzender der Biofrontera AG, wird dem
Board von DNAPrint beitreten.
Durch die unterzeichnete Rahmenvereinbarung sollen beide
Technologieplattformen zum gegenseitigem Nutzen der Unternehmen
kombiniert werden. Biofronteras Forschungs- und Entwicklungsprojekte für
neue Arzneimittel sollen durch DNAPrints einzigartigen Ansatz zur
Entwicklung von Diagnostika ergänzt werden, der auf
populationsgenetischen Analysen beruht. Patientengruppen können
hierdurch besser ausgewählt werden, damit Wirksamkeit und
Nebenwirkungen von potenziellen Medikamenten leichter nachweisbar
werden. Das Management erwartet, dass die frühzeitige Einbindung
geeigneter diagnostischer Tests den Prozess der Arzneimittelentwicklung
vereinfachen und beschleunigen wird.
Das Investment von DNAPrint ist gesichert durch die Zusage des Dutchess
Private Equity Fonds, der auf Anforderung von DNAPrint neu ausgegebene
DNAPrint Aktien für bis zu 35 Mio US$ innerhalb der kommenden beiden
Jahre erwerben wird. Die Transaktion wird mit der Registrierung der
neugeschaffenen Aktien am Aktienmarkt wirksam.
Pressemitteilung
Seite 2
„Der Abschluss einer derartigen Partnerschaft mit einem US Unternehmen
ist ein bedeutender Meilenstein für unser Unternehmen. Die
eingeworbenen Kapitalressourcen ermöglichen es uns unsere
Produktkandidaten in der klinischen Entwicklung voranzutreiben und
hierdurch den Wert der Firma drastisch zu steigern,“ kommentierte Prof.
Hermann Lübbert. „Mit Hilfe des Investments wollen wir unser führendes
Produkt BF-Derm1 zur Behandlung von chronischer Urtikaria und weitere
Produktkandidaten in den nächsten drei Jahren zur Marktreife führen.
Durch den Einsatz der DNAPrint Technologie wird die Entwicklung unserer
Arzneimittel beschleunigt und weniger kostenintensiv. Die Möglichkeit, die
Wirkung eines Medikaments in einem bestimmten Patienten vorherzusagen
wird zur optimalen Versorgung der Patienten beitragen. Schnellere
Entwicklungserfolge werden die Biofrontera einem angestrebten
Börsengang näher bringen.“
Richard Garbriel, Vorstandsvorsitzender und Präsident von DNAPrint
genomics Inc, sagte: „Wir freuen uns, dass wir der erfolgsversprechenden
Verbindung zwischen Biofrontera und DNAPrint eine zuverlässige
Kapitalbasis bieten können. Wir sind überzeugt, dass diese Finanzierung
nach der Registrierung der Aktien durch die SEC unseren Aktionären eine
Wertsteigerung bringt, die deutlich über den eigentlichen Wert der
Biofrontera Aktien hinausgeht. Durch die Kombination der
Technologieplattformen hoffen wir die derzeitigen Umsatzchancen beider
Unternehmen zu verbessern und dem Markt Lösungen für viele Probleme
der Pharmaforschung und -entwicklung anzubieten.“
Biofrontera AG
Biofrontera’s strategisches Ziel ist der Aufbau eines Specialty-
Pharmaunternehmens im Bereich Dermatologie bei Nutzung interner
Forschungskapazitäten zur Erweiterung der bestehenden Produktpipeline.
www.biofrontera.com
DNAPrint genomics Inc.
DNAPrint genomics Inc. nutzt patentierte DNA-basierende Forschungsmethoden
um daraus ihre Produkte und Services zu entwickeln. Die Firma hat 2003 die
Produkte ANCESTRYbyDNA™ in den Verbrauchermarkt und DNAWitness™ in
den forensischen Markt eingeführt und entwickelt derzeit Produkte im
Pharmacogenomics-Markt. Die Firma ist am NASDAQ OTC Bulletin Board (DNAP)
und der Berliner Börse (WKN-Nummer 940906) gelistet.
www.dnaprint.com

[Circle_Jerk]

Hier mal ein paar Erläuterungen / Schlußfolgerungen in Bezug auf diese Transaktion (die man in den USA bei OTC-Werten zu Dutzenden jedes Jahr finden kann):

1.
Der Kaufpreis wird durch die sukzessive Ausgabe neuer DNAP-Aktien finanziert, die sofort registriert und nicht gelockt werden.

2.
Der Ausgabekurs der neuen Aktien "orientiert sich am Börsenkurs", sprich wird mit einem margenträchtigen Abschlag zugunsten von Dutchess festgelegt werden

3.
Dutchess wird diese Aktien dann sofort an der Börse versilbern jeweils und druckt quasi Geld

4.
Die Kombination mit einem unbedeutenden oder sogar fragwürdigen Player wie DNAP ist sicher nicht der Herzenswunsch von Biofrontera, sondern vielmehr das geringere Übel vor einer eventuellen Insolvenz gewesen und spricht dementsprechend nicht für die Qualität des Produktportfolios.

5.
In der jüngeren Vergangenheit waren selbst für potentiell sehr viel höher zu bewertende deutsche Biotech-Unternehmen keine zusätzlichen Gelder mehr einzuwerben, wie die unerwartete Insolvenz von Munich Biotech (MBT) vor einiger Zeit deutlich zeigte. Medigene hat schliesslich für etwas Kleingeld die Konkursmasse übernommen.

6.
Zwar machen die Altinvestoren bei dieser jetzt mit DNAP vereinbarten Kapitalerhöhung mit, aber die drei Altaktionärsgruppen bringen es zusammen nur auf eine magere Zuzahlung von 1,2 Mio. Euro, die eher symbolische Bedeutung haben und bei 55 Angestellten und zwei Standorten sowie laufenden Forschungsausgaben ca. für zwei Monate Geschäftsbetrieb reichen würden.


7.
Zusammenfassend positioniert sich DNAP mit dieser Transaktion zwar neu, erwirbt aber mit Biofrontera eine Black Box, deren Potential vor dem aufgezeigten Hintergrund kaum als erstklassig beurteilt werden kann (sonst hätten sich prominentere Investoren gefunden). Dennoch könnte die Neuausrichtung und die vergleichsweise große Transaktion, die in dem Erwerb eines echten Assets resultiert für etwas Kursphantasie sorgen in naher Zukunft. Das ist auch sehr wünschenswert, denn je niedriger der Aktienkurs, desto höher die Verwässerung durch das Abkommen mit Dutchess. Rechnerisch bedeutet das bei aktuellen Kursen, dass für 20 Mill. Euro Mittelzufluss EINE MILLIARDE NEUE AKTIEN an Dutchess ausgegeben werden - Abschläge und Kursrückgänge nicht einmal mitgerechnet. Die daraus resultierende Verwässerung ist natürlich brutal.

8.
Für den Kurs bedeutet dies in naher Zukunft vielleicht einen weiteren Anstieg, der insbesondere von Aktionären, die ihren Einstand konsequent verbilligt hatten im Zeitablauf zum Ausstieg genutzt werden sollte, für Leute mit 95% Verlust ist es nicht mehr relevant, ob der Wert bei 2 oder 3 Cents steht. Mit dem Nachlassen der neuen Begeisterung, verstärkt aber insbesondere mit der Zulassung der ersten Tranchen der an Dutchess ausgegebenen Aktien zur Finanzierung der Transaktion wird wieder ein sehr hoher Verkaufsdruck auf der Aktie lasten, die eine positive Kursentwicklung fast unmöglich machen (andererseits könnten Erfolgsmeldungen der neuen Tochter Biofrontera immer mal wieder für kurze Hypes sorgen) - aber im Ergebnis müssen mindestens eine Milliarde neuer Aktien absorbiert werden, was nicht ohne Auswirkungen bleiben wird auf den Kurs. Das Fatale an dieser Art von Finanzierung ist, dass bei einem Kursverfall immer MEHR Aktien an Dutchess ausgegeben werden müssen, um an neue Gelder zu kommen. Sollte sich jetzt der Kurs von diesem Niveau wieder halbieren, werden z.B. schon ZWEI MILLIARDEN Aktien an Dutchess fällig usw.
Die Amerikaner nennen diese Art von Finanzierung "Death-Spiral-Financing", da die Gestaltung der Transaktion automatisch den Kurs im Zeitablauf spiralförmig in den Abgrund schickt. Diese Automatik lässt sich noch beschleunigen, wenn der Finanzierer (hier also Dutchess) die Aktien des finanzierten Unternehmens (hier DNAP) shortet. So entsteht schon vor der Ausgabe der neuen Aktien Kursdruck und der Finanzierer kann die Hypewirkung der Meldung für teure Leerverkäufe nutzen und dann die leer verkauften Stücke bequem wieder eindecken durch die aus der Finanzierung erhaltenen neuen Aktien - durch den von ihm mit dem Short verursachten Kursverfall bekommt er sogar deutlich mehr Stücke zugeteilt, als wenn der Aktienkurs nicht von ihm gedeckelt wäre.

9.
Für DNAP-Aktionäre mit akzeptablem Durchschnittskurs ist also Timing gefragt jetzt, sprich die eigene Position möglichst gut in einen Hype zu entsorgen. Prinzipiell sollten dann die freigewordenen Mittel in qualitativ bessere Anlagen investiert werden, aber mit etwas Restgeld kann man dann ja versuchen die Hypes und Lows der Aktie zu traden in den kommenden Monaten und Jahren.

10.
Merke:
OTC-Werte stellen zu 99% keine Langfristanlagen dar, sondern sind meist qualitativ bestenfalls fragwürdige Unternehmen, die in diesem Börsensegment nur geringen Reglementierungen unterliegen und viel Gestaltungsfreiheit beim Formulieren ihrer PRs in Anspruch nehmen. Des weiteren stehen meist die Geschäftsidee sowie die Kapitalstruktur auf wackligen Beinen, alles keine optimalen Voraussetzungen für einen Investor. Daher erscheint es geraten, OTC-Werte entsprechend ihrer von Zeit zu Zeit aufgrund von News stattfindenden Hypes zu traden - wenn überhaupt.
Eine 2-Jahres-Studie von OTC-Werten der amerikanischen Investorsite "Motley Fool" erbrachte ähnliche Ergebnisse: Von 20 betrachteten Werten, waren nach 2 Jahren 18 Werte um 50% und mehr gefallen, ein Wert in etwa gleich geblieben und ein weiterer mit 10% im Plus.

Viel Erfolg allen DNAP-Aktionären.

[Michiko]

@ Circle_Jerk

Du scheinst ne Menge Ahnung über die finanziellen Hintergründe solcher Joint-Ventures zu haben; mir fehlt diese.
Ich finde Deine systematische Darstellung sehr gelungen; ob die Gedanken für mich nachvollziehbar sind, muss ich erst noch genauer überdenken. Auf jeden Fall vielen Dank.
Manchmal ist es wichtig, Dinge von verschiedenen Aspekten aus zu sehen bzw. gezeigt zu bekommen.

Was mich ein wenig wundert: Du postest sehr selten! In letzter Zeit ein einziges Posting bzgl. TA und jetzt dieses.
Was hat Dich dazu bewogen, hier diesen Beitrag zu posten?

- Kennst Du Dich in dieser Materie besonders gut aus?
- Hast Du ein besonderes Interesse an DNAP
- sonstiger Grund?

Danke für Deine evtl. Antwort

Michi

[Circle_Jerk]

Hallo Michiko,

hab neulich meine alte Wallstreet-Online-ID wiedergefunden und dann gleich 2 Postings abgesetzt. TA interessieren mich als Investmentidee (vor dem Hintergrund einer Übernahme durch Kyocera), bin aber regelmässig entsetzt von der Unternehmenskommunikation und dem hiesigen Management.

Bei DNAP hatte ich gestern den Hype gesehen und die für ein Unternehmen wie DNAP ungewöhnliche Transaktion gefunden und dazu ein paar Anmerkungen gemacht.

[Michiko]

Circle_Jerk

ich habe Dein Einverständnis vorausgesetzt, Deinen Beitrag (mehr schlecht als recht) übersetzt und in ein amerikanisches Bord gesetzt.

Hoffentlich war ich nicht zu voreilig, aber Dein Beitrag sollte m.E.weitläufiger bekannt sein.

Gruß Michi

[hvs1]

Michi,

das eine Vewässerung durch den Verkauf von großen Mengen
von Aktien eintrifft,war doch schon länger bekannt.
Das OTC-Werte keine gesunde Kapitalanlage sind ebenso.
Wir spielen Risiko und träumen ein wenig.Die Theorien
von CJ sind sofort über den Haufen geworfen,wenn die ein
brauchbares Medikament auf den Markt werfen oder eines der anderen Patente greift.
Immer schön ruhig bleiben.

hvs1

[Michiko]

hvs1,

immer schön ruhig bleiben!?!?

Das sagt sich so schön.

Wenn der Hund nicht geschissen hätte, hätte er den Hasen gekriegt. Er hat aber geschissen!

Wenn ich 6 Richtige . . .

Du weißt, was ich ausdrücken will. Wie ist die Relation zwischen Risiko und Chance?

Komme ich mit Traden auf kleinen Wellen nicht viel weiter als mit Hoffen auf den BigBang?

Ich habe heute einige 100k abgeworfen zu 0,021.
Vielleicht kaufe ich sie wieder zurück, vielleicht werfe ich aber auch die nächste Runde.
Das mit dem Hoffen und Harren und den Narren macht mich wirklich allmählich nervös. Klar, kannst mir jetzt sagen: Genau das wollen die MMs ja erreichen.

Weiß momentan wirklich nicht, was ich von der Firma halten soll.

Zum Glück ist bald Wochenende.

Dann sehen wir weiter.

Gruß

Michi

[Pushi2]

Endlich mal ein vernünftiger Beitrag.
Danke, Cirkle_Jerk ...
Die Verwässerung wird vermutlich noch wesentlich deutlicher ausfallen.
Der Ausgabekurs der neuen Aktien wird durch die üblichen Abschläge zu bis zu 3.000.000.000 neuen Aktien führen.
Schaut Euch mal die jetzige Börsenkapitalisierung von DNAP an ...
Kurstreibende Gerüchte und Meldungen sollten bei OTC-Werten möglichst zu Gewinnmitnahmen genutzt werden.
Die Jungs die hier immer von "long" reden, sollten besser zum Roulette gehen, da sind die Quoten besser ...
Viel Glück weiterhin und den Zockern ein gutes Timing bei den Ein- und Ausstiegen in den nächsten 2 Jahren.

[wsperber]

Hallo Pushi2,

danke für die Glückwünsche.

Wünsche dir einen schönen Sonntag

Wolfgang

[cariocca]

Heute per Google News erhalten:

Pressemitteilung übermittelt von directnews. Für den Inhalt dieser Pressemitteilung ist allein das berichtende Unternehmen oder die berichtende Institution verantwortlich.

Biofrontera erwirbt Phase II-Produkt zur Erweiterung des Dermatologie-Produktportfolio

Leverkusen, Deutschland - Biofrontera AG gab heute bekannt, dass sie von der ASAT AG, Zug, Schweiz alle Eigentumsrechte, Patente und Material eines klinischen Phase II-Produktes zur Behandlung krebsartiger und präkanzeröser Hautläsionen sowie gynäkologischer Indikationen erworben hat. Das Produkt enthält Aminolävulinsäure (ALA) in einer patentierten Nanocolloid-Formulierung, ideal geeignet für die Photodynamische Therapie (PDT). PDT ist ein neuer und effektiver Ansatz zur Behandlung von Basalzellkarzinomen und aktinischer Keratose.

Mit zwei dermatologischen Produkten in fortgeschrittener klinischer Erprobung, beide mit einer erwarteten Markteinführung 2007 oder 2008, positioniert sich Biofrontera ideal als ein Specialty-Pharmaunternehmen im Bereich Dermatologie. Die neuartige Nanocolloid-Formulierung von ALA dringt überaus effizient und spezifisch in entartete Zellen ein und führt zu einer Anreicherung von Protoporphyrinen, die unter Lichtemission die Degeneration des entarteten Gewebes bewirken. Wirksamkeit und Arzneimittelsicherheit der neuen Formulierung konnten bereits durch positive Ergebnisse von Pilotstudien der Phasen II und III bestätigt werden.

Biofrontera ist überzeugt, dass die innovative Formulierung, bei der eine erheblich geringere Menge der aktiven Substanz auf das zu behandelnde Gewebe aufgebracht wird, deutliche Vorteile gegenüber bereits vermarkteten Therapien hat. Bei erfolgreichem Verlauf der klinischen Erprobung kann die Marktzulassung bereits 2007 erfolgen. Der Vertragsabschluss wurde von der InterPharmaLink AG, Basel, Schweiz vermittelt und koordiniert.

Prof. Dr. Hermann Lübbert, Vorstandsvorsitzender der Biofrontera AG, kommentierte: "Wir sind hoch erfreut über den Erwerb dieses überaus erfolgsversprechenden Produktes für die photodynamische Therapie, einem neuen und vielversprechenden Behandlungsansatz. Die Nanocolloid-Formulierung von ALA ergänzt in idealer Weise den Dermatologiefokus unserer klinischen Entwicklungssubstanz für chronische Urtikaria. Sie kombiniert die Vorteile einer bereits erprobten Therapie mit einem innovativen Formulierungsansatz. Das Entwicklungsrisiko dieses Präparates schätzen wir, wie auch das unseres anderen Dermatologieproduktes, als extrem gering ein. Diese Tatsache bestärkt uns in unserer Überzeugung, dass wir dieses Arzneimittel zügig in den Markt einführen können."


Biofrontera AG Biofrontera positioniert sich als Specialty-Pharmaunternehmen im Bereich Dermatologie bei Nutzung interner Forschungskapazitäten zur Erweiterung der bestehenden Produktpipeline. Hauptaktionäre der Biofrontera sind Heidelberg Innovation und die 3i Gruppe. DNAPrint genomics Inc., spezialisiert auf DNA-basierenden Forschungsmethoden, mit Sitz in Sarasota, FL, USA beteiligte sich kürzlich mit einen signifikanten Investment an Biofrontera. www.biofrontera.com

InterPharmaLink InterPharmaLink ist ein Consulting-Unternehmen im Bereich Gesundheitswesen. Der Schwerpunkt des Unternehmens liegt in der Anbahnung und Abwicklung von Geschäftsbeziehungen im Bereich von späten Entwicklungsprojekten, bereits vermarkteten Produkten und von Business Development Aktivitäten für die pharmazeutische Industrie.

Kontakt Biofrontera AG Anke zur Mühlen Corporate Communication Hemmelrather Weg 201 D-51377 Leverkusen E-mail: [e-mail] Phone: +49 - (0)214-87632 22 Fax: +49 - (0)214-87632 90

07.10.2004, 12:10

[Biotekky]

Moin,

ich habe mich schlau gemacht bezüglich des DNAP Deals mit Biofrontera. Wie man mir sagte, seien im Vertrag Leerverkäufe seitens Dutchess ausgeschlossen worden. Die Sorge hatte Prof Lübbert laut eigener Aussage ebenfalls. Insofern fällt ein Mißbrauch wie z.B. eine Todesspirale aus. Zudem bezeichneten die Investmentbanker den Deal als "sehr geschickt". Ich schreibe einen Bericht über den Deal in einer Zeitschrift. Wer möchte kann unter meiner eMail unverbindlich ein Exemplar anfordern.

[hvs1]

Biotekky,

stell doch Deinen Bericht hier rein.Oder kostet der was?

Gruß hvs1

[seriousguy]

hallo DNAP Longs...

ich verfolge nachwievor sehr intensiv diese firma und bin auch wirklich sehr damit beschäftigt mir verschiedene meinungen von Bankern, Investment Häusern , etc einzuholen.

Fakt ist das wir es nachwievor mit einem Pennystock zutun haben der unberechenbar ist. Für alle Longs hat sich nicht viel verändert...wir verfolgen nachwievor das gleiche ziel wie vor 2-3 jahre.

Der Deal mit Biofrontera ist sehr interessant obwohl er von manchen belächelt wird.
Millionen an eigenen aktien ausgeben für einen Haupt Aktionärsanteil an einer firma ? ...und das auch noch von einem Pennystock der selbst einen Überlebenskampf hat.

Meiner Meinung nach ist das ein perfekter Deal.
Dutchess weiß ganz genau was DNAP und biofontera in der Pipeline haben...auch wenn dies noch einige jahre dauern wird.

Tony verfolgt genau seine Strategie die er im TWST Interview von sich gab.
---> Drup Company !...etc
Mit Hr. Gabriel und konsorten hat er gute Partner im boot.

Eine Meinung die ich von jemanden bekommen habe klingt sehr vielversprechend und interessant zugleich.
Biofrontera erwähnte, das dies einer der ersten Schritte sei für deren IPO.
....Also würde es ganz normal klingen wenn DNAP mit Biofrontera "merged" wobei aber biofrontera hauptgelistet bleibt...aber dies dann sofort an der NASDAQ macht.

Na wie klingt das ? Ist alles theoretisch und existiert von einigen nur auf Papier....aber das wäre eine sinnvolle sache wie das Nasdaq Listing und in späterer folge fortune 500 machbar wäre.

Seien wir uns ehrlich. auf dem momentanen Level des PPS ist es höchstunwahrscheinlich ein Nasdaq listing herbeizuführen, oder ?

die Pipeline von DNA Print Genomics ist gefüllt und wird in naher zukunft für einige Interessante News sorgen.

ich bleib long

seriousguy

[Michiko]

Hi seriousguy,

schön, mal wieder was von einem Gleichgesinnten zu hören/lesen.

Auch ich bin inzwischen der Meinung, dass es bis zu einem eventuellen Erfolg von DNAP/Biofrontera vielleicht noch Jahre dauern kann.

Ich habe meinen Bestand bei einem Kurs von gut 2 Cents reduziert auf gut eine Million shares, weil ich
a) Cash für ein anderes Invest benötigt habe (CMKX)
b) befürchtet habe, dass der Kurs in gewohnter Weise weiter abbröckeln wird (was ja auch eingetreten ist).

Meine weitere Strategie:
- Diesen "Restbestand" werde ich auf alle Fälle halten (wenn es sein muss auch jahrelang)
- Wenn wieder "Cash in the Tash" ist und der Kurs so um einen Cent rumkrebst, bin ich auch wieder stärker dabei.

Frage an die anderen Longs: Wie haltet Ihr es mit Eurem Invest in DNAP?

Gruß Michi

[CCCesar]

halte meine noch, auch wenn ich die Hoffnung auf
baldige Umsätze bei DNAP (fast) aufgegeben habe.

Grüße, Cesar

[hvs1]

Michi,

weiterhin long mit 650K.
Werde Tiefkurse abwarten und zukaufen.

hvs1

[ge4teilter]

Hi zusammen!

Es gibt mal wieder was:



Riding the spiral of life
DNAPrint plans a big future as a drug developer, if its finances hold up
By MARGARET ANN MIILLE
[e-mail]

SARASOTA -- Tony Frudakis returned from Germany much more excited than when he had left.

The founder and chief science officer of DNAPrint Genomics Inc. already knew that Biofrontera AG, a German pharmaceutical company in which DNAPrint is acquiring majority ownership, had a handful of promising drugs being tested in clinical trials.

Until last month, he had not known about 30 chemical compounds Biofrontera had in earlier stages of development.

"I didn`t know that there was that rich of a pipeline of pre-clinical candidates," Frudakis said. "I knew about their later-stage compounds. I didn`t know the details of their earlier-stage projects, which illustrate the power of that company."

The recent deal with Biofrontera allows DNAPrint, a research and development company that makes genetics tests, to evolve into a pharmaceutical house. The 30 compounds have the potential to yield a healthy revenue stream, something that DNAPrint now lacks, a decade or so down the road.

The front-runner of drugs already in clinical trials is a treatment for chronic itching and scratching. "BF-Derm1," as it is called, is scheduled for release in the United States and Europe, where it has a combined $200 million potential market, in early 2007.

Because of a payment schedule -- DNAPrint has agreed to invest about $25 million over two years in Biofrontera shares to acquire a 51.77 percent equity interest -- the trick for DNAPrint will be to survive during the next few years with its over-the-counter stock trading at a little more than a penny per share.

That is because a $35 million commitment over the next two years from a private equity fund will be based on the trading price of DNAPrint`s stock. If the price continues to stay low, the company won`t have enough shares to raise the $35 million.

"As long as we survive as a company, the deal will be done," Frudakis said. "What would kill the deal are the same things that would kill DNAPrint, like if our stock price goes to zero, and we can`t raise money anymore and we can`t find any investors."

A research report released in June by independent investment research firm J.M. Dutton & Associates says that DNAPrint faces financial challenges typical of small-capitalization companies.

DNAPrint, with a market value of $18.6 million, has limited financial resources and operates at a loss, issuing stock instead of paying cash for a variety of business services and loans.
In a deal unrelated to Biofrontera, DNAPrint is getting up to $8 million over two years from a California investment group. While that should ease some of DNAPrint`s immediate financial pressure, the company most likely will need additional funding if it doesn`t turn a profit in two years, the Dutton report said. It deemed DNAPrint stock a speculative buy.

"We are horribly undervalued," Frudakis insists. "There is a point beyond which you really cannot drop much further, because you become so ridiculously undervalued that you become an attractive investment even though you have no money in the bank. So the question is, if the stock price stays the way it is right now, will we be able to finish the deal? We have tools in our belt to help us finish this deal."

If DNAPrint needs to create more shares, Frudakis said, the company could ask its shareholders to approve an increase in authorized shares, do a "reverse-split" or even seek a listing on a major stock exchange.

Drug developer Biofrontera, which bills itself as a specialty pharmaceutical business, focuses on developing treatments for inflammation and central nervous system diseases.

One of its drugs in the early development stages would prevent migraines.

Unlike most major drug manufacturers, the company uses what are called naturally-occurring chemical compounds, meaning those found in nature, rather than compounds made synthetically using a "combinatorial chemistry" approach, Frudakis said.

Naturally-occurring compounds constitute a more intelligently assembled collection of molecules that can target specific ailments, he said.

For example, Biofrontera is working on a drug for pancreatic cancer that would kill all pancreatic cancer cell lines without killing other cancer cells found in normal tissue.

"Those chemicals have more inherent natural biological relevance. They were designed by nature to be so," Frudakis said. "Obviously, evolution has been taking place for millions of years. Well, it turns out that evolution is much more clever and efficient at designing chemicals that modify the function of animal cells than a synthetic chemist in a pharmaceutical laboratory is."

The less precise combinatorial approach is the reason why the pharmaceutical industry has fewer blockbuster drug candidates these days undergoing clinical trials, Frudakis said.

Naturally-occurring compounds have fallen out of favor with pharmaceutical companies because scientists can produce synthetic compounds much faster than they can isolate and extract chemical compounds from plants and micro-organisms, said Richard Gabriel, DNAPrint`s chief executive.

"It`s trading complexity and natural activity for speed, and that hasn`t really worked as well as they would like it to," said Gabriel, who was hired by DNAPrint in April 2003 and was the man who put the Biofrontera deal together.

Gabriel`s relationship with the German company goes back a ways. He was previously chief executive of Calix Corp., which owned California-based Pharm-Eco Laboratories, a supplier of active pharmaceutical ingredients for clinical trial development. Before Pharm-Eco was sold to a Boston-based company, it helped Biofrontera manufacture its compounds.

Pharm-Eco also was part of Biofrontera`s original shareholder group, and helped kick off its initial round of financing.

Gabriel considered DNAPrint and Biofrontera a good match because they have different technologies that will allow them to focus on theranostics, a science that blends genomics testing with drugs to yield the best results in specific groups of people.

Biofrontera uses in-depth genetic analysis called "deferential expression pattern display," or DEPD. Gabriel said the technique allows scientists to see which genes are producing proteins and which are not in people with a particular disease and during treatment.

What DNAPrint brings to the table is its expertise in ancestry research, including its genetics tests. They are called DNAWitness when marketed to the forensics market and ANCESTRYbyDNA2.5 when sold to the public.

The tests determine the proportions of a person`s ancestral mix among four major population groups worldwide, and further distinguish between four European groups.

Delving into genetic studies involving race, however, is a controversial practice.

"Race is a really coarse indicator of how people are going to respond to a particular medication," said Dr. Fred Paola, an internist who teaches medical ethics at the University at South Florida.

The "racial slant" of DNAPrints technology concerns Paola.

"When you start using race as a surrogate for other things, you run into all kinds of problems," he said. "People may determine genetic differences between the races as meaning more than they do. In the end, you may end up with something that proves more divisive Frudakis has heard that argument before, and counters by saying that evidence is emerging in clinical trials in which people of one race fare better than another on a particular medication. In one example, a heart disease drug called BiDil being developed by Nitromed Inc. worked much better for blacks, so much so that it was eventually given to other blacks who were taking placebos.

"This is what pharmacologists have always known, this dirty little secret that they`ve never been able to talk about," Frudakis said. "Some of the ethicists are wringing their hands over this because it`s the first ethnic drug. This is really going to open up a watershed."

In DNAPrint`s case, the issue for now is academic. The company needs to stay afloat at least until 2007, when BF-Derm1 starts making money.

The company has never made a profit. In the six months ending June 30, it had a $1.94 million loss, compared with a $3.85 million loss in the same 2003 period.

"If the share price goes up, obviously we will be able to finish the deal easily," Frudakis said. "If the share price stays the same, we have to entertain strategies for finishing the deal. So we would have to create more shares somehow."

That might not go over easy with shareholders.

"We have negative shareholder equity," Frudakis said. "We are like a 3-year-old child that is eating more than he is producing. He is not producing in the workplace yet, he is still dependent on Mom, and he is still eating more than he is making.

"This deal kind of ratchets us up to maybe a 7- or 8-year-old. And we`ll be a teenager as soon as these drugs start to mature in the pipeline. Hopefully, we will live to adulthood, where we will be very productive."


Uns allen alles Gute!

g4

[hvs1]

Es kommt ein wenig Bewegung in unsere DNAP.

Uns allen noch viel Freude mit dieser Aktie.

hvs1

[ge4teilter]

Bewegung woher und in welche Richtung?

[seriousguy]

schönen Sonntag!

es kommt einiges auf DNAP zu in den nächsten Wochen bzw. Monaten.
Erst heute erschien ein interessanter amerik. Zeitungsartikel in dem geschrieben wurde das DNAP in 65! "Crime-Cases" involviert ist.

Vermutlich haben einige von euch vom Kansas Fall gehört, ...denkt ihr nicht das DNAP involviert ist ?
egal...diese dinge werden sich rasch herausstellen.

Interessant wird es demnächst, wenn der FDA Guidance "freigegeben" wird. Den dann denke ich das Frudakis einiges aus seinem Munde sprechen wird
....gerichtet an die Drug Firmen.

Bei Ovanome ist es reif für ein Update, was auch heuer kommen wird (Moffit wird seinen betrag dazuleisten)

hmm, über all die anderen themen kann und will ich nicht reden da man einfach geduld haben muß.
Wenn man an die Phantasie dieser firma glaubt, dann hat man schon fast gewonnen.

stay cool
seriousguy

[seriousguy]

nur so nebenbei erwähnt,
.. DNAP ist nun noch günstiger für uns
schließlich steht der euro/dollar bei 1,346
--> DNAP Kurs: ca. 0.0083 Euro

Für all jene die doppelt verdienen wollen, schnappt euch diesen wert.
Der dollar wird wieder stärker da die EZB was unternehmen wird....man wird sehn

lg
seriousguy

[Michiko]

seriousguy

damit stellt sich automatisch eine Frage:

Was wird dominieren?

a) Der Anstieg des Doller gegenüber dem Euro oder

b) Der weitere anscheinend unaufhaltsame Abfall des Kurses von DNAP

Punkt a) erscheint mir etwas an den Haaren herbeigezogen, wohingegen Punkt b) aller Erfahrung nach eine hohe Wahrscheinlichkeit hat.

Meine Meinung: Abwarten kann nicht schaden. Vermutlich werden wir DNAP noch wesentlich günstiger einkaufen können trotz eines eventuellen(!?!) Anstiegs des Dollar gegenüber dem Euro.

Nur meine Meinung natürlich!

Michi

[hvs1]

Michiko,

auch ich halte mein Pulver noch trocken,steh allerdings
Gewehr bei Fuß.
Da ich meine 650K immer noch halte, warte ich einen weiteren Einstieg ruhig noch ab.
Auch ich glaube,daß sie noch etwas günstiger werden.Mein
Ziel sind 2M.

Also bis denne.

hvs1

[marterpfahl]

Wassnlos ?

+60% !

marterpfahl

[Michiko]

Hier bitte:

Press Release Source: Orchid BioSciences, Inc.


Orchid Cellmark to Distribute Innovative DNA-Based Law Enforcement Tool
Tuesday December 14, 7:00 am ET
-- DNAWitness(TM) Uses Crime Scene DNA to Help Identify the Physical Characteristics of Suspects --


PRINCETON, N.J., Dec. 14 /PRNewswire-FirstCall/ -- Orchid BioSciences, Inc. (Nasdaq: ORCH - News), a leading worldwide supplier of identity DNA testing services, today announced an agreement to distribute DNAWitness(TM), a forensic service product developed and commercialized by DNAPrint genomics. DNAWitness enables criminal investigators to develop a profile of a suspect`s likely general physical attributes using DNA recovered from the crime scene. Insight into these physical attributes is generated by proprietary algorithms in DNAWitness that make it possible to determine the proportions of European, East Asian, Native American and sub-Saharan African ancestry indicated by the suspect`s DNA. DNAWitness has already demonstrated its utility as a crime- fighting tool in a number of high profile cases. Financial terms of the one- year, non-exclusive distribution agreement with DNAPrint genomics were not disclosed.
"With Orchid`s long-established role as a leading provider of DNA testing services to criminal justice agencies in the U.S. and Europe, DNAWitness is a logical addition to the forensic services toolbox we offer our clients," said Mark Stolorow, executive director of Orchid Cellmark. "Our commitment to scientific innovation in the application of DNA to solving crimes made us among the first to realize the potential of SNPs, or single nucleotide polymorphisms, to address unmet needs in identity testing. We are now pleased to offer our police department customers this unique SNP-based product to help them identify the likely physical characteristics of the perpetrators of the many serious unsolved crimes where the suspect`s DNA does not match any of the convicted offender DNA profiles already on file in state and federal databases."

DNAWitness has been used successfully in a number of investigations, including a recent case involving the now-convicted Louisiana serial killer Derrick Todd Lee. Information on Lee`s ancestry helped change the focus of the investigation of a spate of serial murders in the region, leading to his arrest and subsequent conviction. Law enforcement agencies using the DNAWitness service receive the ancestry profile generated by the suspect`s DNA and a photographic database of volunteers that provides examples of people with similar ancestry profiles, as well as identifying information for the case.

Under the Cellmark brand, Orchid has been a leader in private forensic DNA analysis since 1987 and is now one of the largest private DNA forensic testing providers in the world. Orchid has an international network of forensic testing laboratories in the U.S. and U.K., where it works with the famed "Scotland Yard" and others. The company provides a full range of high quality, customized forensic DNA testing and consultative services for both prosecutors and defendants. Its services include DNA testing for criminal casework analysis and expert testimony, as well as identification of victims of accidents and disasters. Last year the company launched DNA Express(TM), a premium service to help U.S. local law enforcement agencies analyze backlogs of DNA evidence from unsolved crimes in five business days, as compared to the standard one-to-two months. More information on DNAWitness and Orchid`s U.S. forensic DNA testing services can be found at http://www.orchidcellmark.com.

About Orchid BioSciences

Orchid BioSciences is a leading provider of identity genetics services for the forensic and paternity DNA testing markets and for public health and animal DNA testing for food safety. Orchid`s strong market positions in these segments leverage the company`s accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the world- renowned Cellmark and GeneScreen brands that have been associated with exceptional quality, reliability, innovation and customer service for nearly two decades. More information on Orchid can be found at http://www.orchid.com.

DNAWitness is a trademark of DNAPrint genomics.

DNAExpress is a trademark of Orchid BioSciences.


All statements in this press release that are not historical are forward- looking statements within the meaning of Private Securities Litigation Reform Act of 1995, including statements regarding: the expected ability of DNAWitness to help criminal investigators and police departments identify physical attributes and characteristics of suspects and perpetrators. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid products and services, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, patent protection, litigation and Orchid`s ability to obtain additional financing. These risks and other additional factors affecting Orchid`s business are discussed under the headings "Risks Related to Our Business," "Risks Related to the Biotechnology Industry" and "Risks Associated with Our Common Stock" in Orchid`s Annual Report on Form 10-K for the year ended December 31, 2003, as filed with the Securities and Exchange Commission, and in other filings made by Orchid with the Securities and Exchange Commission from time to time. Orchid expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.




--------------------------------------------------------------------------------
Source: Orchid BioSciences, Inc.

[marterpfahl]

Danke, michiko,

habs auch gerade gefunden.

marterpfahl

[cineman]

sehr interessant warum DNAP keine Meldung rausbringt!!
Vielleicht warten sie noch 1 Tag ab um vielleicht eine
2te NEWS ( z.B. über OVANOME ) zu bringen??

die zeit läuft für uns
cineman

[Michiko]

Die Umsätze sind gar nicht mal so unflott!

Bisher schon gut 39 Millionen shares über die Theke geschoben.

Michi

[Michiko]

War vielleicht keine schlechte Idee, dass ich mir gestern noch mal "so eben" 191.000 Stück zu 0,011 geleistet habe?!?

[McFlying]

Wird DNAP heute explodieren

Das raging Bull wird vollgeschrieben

[olivetty]

Wenn die SEC die entgültige Genehmigung zur Übernahme von Biofrontera gibt könnte es einen Schub geben. Noch ist nix durch. Nur Ankündigung unter SEC Filings unter Yahoo.com.
Dutchess ist ein sehr geschickter Geldgeber aus dem Private Equity-Bereich, der Shares von DNAP dafür bekommt immer wenn eine der Raten an Biofrontera fliesst.
Dutchess will Geld verdienen, also werden die Shares nach deutlicheren Kursanstiegen teilrealisiert. Der Rest verbleibt im Portfolio von Dutchess und man hofft auf weitere Steigerungsraten. So findet durch die immense Anzahl neuer Aktien natürlich ein Verwässerungseffekt statt im Gewinn/Umsatz pro Aktie. Allerdings könnte durch Roadshows des Unternehmens und schliesslich von Dutchess selbst DNAP wesentlich bekannter werden.
Da ja bekanntlich Angebot und Nachfrage den Kurs bestimmen bin ich mal gespannt.....

Olivetty

[McFlying]

es wird im Raging Bull heiss diskutiert

Es wird für Montag eine PR erwartet

[tonimontana]

hallo leute,
weiss einer mehr als wir?
der kurs gibt auf 0,012$ nach!

[WOchmann]

So, bin jetzt auch eingestiegen
Hoffentlich ist es eine positive PR, falls überhaupt eine kommen sollte.
Was ich noch fragen wollte: wieviele Stellen hinterm Komma könnt Ihr eingeben ? Bei meiner Comdirect kann ich höchstens 2 Stellen eingeben, mußte also unlimitiert ordern hat aber gut geklappt mit dem Kurs
Gruß
WOchmann

[McFlying]

das mit Comdirekt das stimmt

Es soll etwas großes anstehen. ich denke das wir in kürze über die 0,04 fahren

[babe_in_the_woods]

@McFlying

halt, halt, halt

vorher muss ich nochmals nachkaufen !



hat jemand rt ?

[Michiko]

zu #195 und 196:

Ihr könnt bei comdirect auch auf 3 Stellen hinter dem Komma limitieren. Geht allerdings nur, wenn Ihr dort anruft.
Bei Hinweis, dass das online nicht möglich ist, bezahlt Ihr auch nur die normale Ordergebühr.

[Michiko]

rt: bid 0,012
ask 0,0125

[babe_in_the_woods]

@Michiko

Danke

ich probiers mal mit 0.012

[hvs1]

Hatte drei Tage eine 1M Order zu 0,0115 drin und wurde nicht bedient.
Habe heute auf 0.0125 erhöht,hoffe Sie ist durch.

hvs1

[Michiko]

hvs1

Und? Ist sie durch??

[V51]

Nein, er kauft nun in D kräftig.



Geile Coop.

[babe_in_the_woods]

@all

ich hab sie zu 0.0121 und zu 0.013 USD bekommen.

bin gut eingedeckt

[babe_in_the_woods]

@all

wieso kaufen die in Deutschland ein,
ist ja viel zu teuer!

Sachen gibts

[hvs1]

Michi,

1,0 M sind zu 0,012 durch.

im Depot liegen jetzt 1,65 M.Bis 2,0 M fehlen nur noch 35K.

V51,was sollte denn der Spruch?

Gruß hvs1

[babe_in_the_woods]

@hvs1

du meinst wohl 350k

[babe_in_the_woods]

@all

kennt jemand eine Link, wo RT oder einen Live-Ticker vorhanden ist ?

Danke im voraus

für MCLD hatte ich einen

[WOchmann]

RT in Fra 0,012€
Warum dieser Aufschlag ?
Kommt der Aufschlag vielleicht von den Leuten, die nicht in USA ordern können, aber um jeden Preis rein wollen ?
Weil sie vielleicht auch vom Kuchen was abhaben wollen, und es spielt absolut keine Rolle, ob man dafür 0,012 US Cent oder 0,012 EuroCent zahlt ?
Weil diese Kurse einfach nur lächerlich sind und wir nächstes Jahr jenseits unserer Vorstellungen stehen werden ?
Fragen über Fragen. Die Antworten muß sich aber jeder selber geben
Gruß
WOchmann

[McFlying]

Vielleicht kommt heute etwas

ich rechne kurzfristig mit den 5 Cent

[babe_in_the_woods]

@all

ja ich hab auch das Gefühl, dass es bald losgeht.

siehe Frankfurt, vor 6 Monaten fast kein Umsatz und jetzt !



bitw

[babe_in_the_woods]

@all

und hier der US-Chart
der 50M Umsatz gefällt mir sehr gut



bitw

[tonimontana]

hi McFlying ,
wie kommst du auf 5 cent kurzfristig??
einfach im gefühl oder hast du infos?
mfg toni

[McFlying]

Toni

Bauchgefühl

Vielleicht ein wenig.

Bin eingestiegen weil USER BIOM mir den Tipp gegeben hat.

Bisher waren es nur 100 bis 500% die kurzfristig explodiert sind nach seinen Empfehlungen und dies alles innerhalb einer Woche.

Ich lese regelmäßig das RB und dort wird heiss gepostet.

Das riecht danach das etwas großes bevorsteht.

Bisher war es immer so, und deshalb gehe ich avon aus, das wir diese Woche explodieren werden.

Erstes KZ 5 cent

Viel Glück an allen Investierten

[babe_in_the_woods]

@all

BIOM rechnet mit 200% kurzfristig !
9 von 10 Empfehlungen gingen 40% bis sogar über 200% in die Höhe !

siehe z.B. MCLD
empfohlen bei 0.26 USD, Gewinnmitnahme bei 0.64 USD
(akt. Kurs bei 0.72 USD)

ich war dabei

Klasse Performance

[hvs1]

babe,

ja 350K fehlen noch zu 2M.Ich kaufe nur in USA.Gestern wie
schon genannt 1M zu 0,012 USD.

Gruß hvs1

Ich bin seit 2000 drin und mir ist es fast egal ob heute
oder morgen die News kommt.In 2005 kommen viele News.Wer
noch warten kann,der muß bei diesen Kursen einsteigen.
Es kann durchaus noch weiter nach unten gehen,es kann aber
auch mit dem Fahrstuhl ganz kurzfristig nach oben gehen.Das
ist nun einmal bei OTC-Werten so.

[babe_in_the_woods]

@hvs1

du legst mit 2M mächtig ins Zeug.

ich gönne es dir !

[olivetty]

Ich hatte bei 0,014 im Ask eine Order drinnen zu 0,01 glatt vor einer guten Woche. Und siehe da sie ging mittags durch.
Der Kursaufschlag kommt bestimmt nicht dadurch, dass alle hier in D rein wollen. Die Makler kassieren kräftig ab. Meistens werden einigermaßen faire Geld-Brief-Kurse erst ab 15.30 Uhr gestellt, wenn der Makler direkt in USA eindecken kann. Aber es gibt immer ein Paar Chaoten, die billigst reingehen. Die werden dann abgezockt.
Bei grösseren Orders ab 2500 Euro Gegenwert sowieso in USA kaufen.

Olivetty

[hvs1]

So Jungs,

meine 350K Order zu 0,012 USD ist gestern durchgegangen.
Mein Soll 2M ist erfüllt.

Jetzt kann es losgehen.

hvs1

[babe_in_the_woods]

@hvs1

ja dann, viel Spass damit.

die Party kann steigen !

[OTCNeuling]

Und ich bin seit gestern auch mit von der Partie. Geschrieben so von mir gestern schon im Shelron Thread.
Umsatz zieht in Deutschland schön an. Kommt vielleicht schon diese Woche die Mega-News ??

[McFlying]

[ge4teilter]

Das ist ja schön, dass wir ein paar neue Mit-Träumer haben! In der Gruppe sind die Gewinne doppelt und die Verluste nur halb so hoch!

Frohes Fest und viel Asche wünscht sich und Euch .... g4

[hvs1]

babe,

eine geile Truppe,die da tanzt.

G4,

habe damit meinen Einstiegspreis halbiert 0.038

Gruß und frohe Weihnachten

hvs1

[babe_in_the_woods]

@hvs1

ich wusste gar nicht, dass du schon früher eingestiegen bist.
wie lange bist du schon investiert?

falls ich fragen darf

ich bin erst vor etwa 4 Tagen eingestiegen mit der Empfehlung vom BIOM

bitw

[Michiko]

hvs1

habe mich von Deinen Träumen anstecken lassen und soeben auf 1,5 Millionen shares erhöht.
Mein durchschnittlicher Einkaufspreis liegt jetzt unter 3 US-Cent.

Auch von mir aus kann´s jetzt losgehen!

Gruß Michi

[McFlying]

OK


Dann schnall ich mich auch schon an

Wer fährt den Zug

[McFlying]

BID zieht an

[hvs1]

babe,

ich bin seit September 2000 dabei und habe meine ersten
50.000 Stck zu 0,16 USD gekauft.Die zweiten 50.000,- zu
0.43 ,die haben mich seinerzeit DM 47.3562,33 gekostet.
Wahnsinn,wenn ich heute darüber nachdenke.
Danach habe ich ständig verbilligt und bin heute bei 0,038 Euro.
Glaube absolut langfristig an diesen Laden.

Michi,

das wird schon.

hvs1

[McFlying]

Sehr ruhiger Handel heute

[McFlying]

Massive Käufe aus dem Ask

[McFlying]

DNAP bricht unter hohen Umsätzen aus

[McFlying]

Ask 0,00134

Go Baby Go

[McFlying]

BID ,013

[OTCNeuling]

Der Startschuß für unsere Party ist erfolgt
OTCN

[McFlying]

[babe_in_the_woods]

gefällt mir

Wer organisiert die Party überhaupt ?
Ja, wenn sich niemand meldet, mach ich das

1. die Live-Band kommt heute Abend noch

2. Alkohol darf nicht fehlen

3. ...auch nicht zum Knabbern

4. uuups die Deko


5. ...

...fehlt nur noch die 0.10 USD (langfristig)

[hvs1]

babe,

das machst Du klasse,Du bist der Teamchef.
Die 0,10 werden langfristig nicht reichen.

Gruß hvs1

[McFlying]

Orchid Cellmark to Distribute Innovative DNA-Based Law Enforcement Tool
Tuesday December 14, 7:00 am ET
-- DNAWitness(TM) Uses Crime Scene DNA to Help Identify the Physical Characteristics of Suspects --


PRINCETON, N.J., Dec. 14 /PRNewswire-FirstCall/ -- Orchid BioSciences, Inc. (Nasdaq: ORCH - News), a leading worldwide supplier of identity DNA testing services, today announced an agreement to distribute DNAWitness(TM), a forensic service product developed and commercialized by DNAPrint genomics. DNAWitness enables criminal investigators to develop a profile of a suspect`s likely general physical attributes using DNA recovered from the crime scene. Insight into these physical attributes is generated by proprietary algorithms in DNAWitness that make it possible to determine the proportions of European, East Asian, Native American and sub-Saharan African ancestry indicated by the suspect`s DNA. DNAWitness has already demonstrated its utility as a crime- fighting tool in a number of high profile cases. Financial terms of the one- year, non-exclusive distribution agreement with DNAPrint genomics were not disclosed.
"With Orchid`s long-established role as a leading provider of DNA testing services to criminal justice agencies in the U.S. and Europe, DNAWitness is a logical addition to the forensic services toolbox we offer our clients," said Mark Stolorow, executive director of Orchid Cellmark. "Our commitment to scientific innovation in the application of DNA to solving crimes made us among the first to realize the potential of SNPs, or single nucleotide polymorphisms, to address unmet needs in identity testing. We are now pleased to offer our police department customers this unique SNP-based product to help them identify the likely physical characteristics of the perpetrators of the many serious unsolved crimes where the suspect`s DNA does not match any of the convicted offender DNA profiles already on file in state and federal databases."

DNAWitness has been used successfully in a number of investigations, including a recent case involving the now-convicted Louisiana serial killer Derrick Todd Lee. Information on Lee`s ancestry helped change the focus of the investigation of a spate of serial murders in the region, leading to his arrest and subsequent conviction. Law enforcement agencies using the DNAWitness service receive the ancestry profile generated by the suspect`s DNA and a photographic database of volunteers that provides examples of people with similar ancestry profiles, as well as identifying information for the case.

Under the Cellmark brand, Orchid has been a leader in private forensic DNA analysis since 1987 and is now one of the largest private DNA forensic testing providers in the world. Orchid has an international network of forensic testing laboratories in the U.S. and U.K., where it works with the famed "Scotland Yard" and others. The company provides a full range of high quality, customized forensic DNA testing and consultative services for both prosecutors and defendants. Its services include DNA testing for criminal casework analysis and expert testimony, as well as identification of victims of accidents and disasters. Last year the company launched DNA Express(TM), a premium service to help U.S. local law enforcement agencies analyze backlogs of DNA evidence from unsolved crimes in five business days, as compared to the standard one-to-two months. More information on DNAWitness and Orchid`s U.S. forensic DNA testing services can be found at http://www.orchidcellmark.com.

About Orchid BioSciences

Orchid BioSciences is a leading provider of identity genetics services for the forensic and paternity DNA testing markets and for public health and animal DNA testing for food safety. Orchid`s strong market positions in these segments leverage the company`s accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the world- renowned Cellmark and GeneScreen brands that have been associated with exceptional quality, reliability, innovation and customer service for nearly two decades. More information on Orchid can be found at http://www.orchid.com.

DNAWitness is a trademark of DNAPrint genomics.

DNAExpress is a trademark of Orchid BioSciences.


All statements in this press release that are not historical are forward- looking statements within the meaning of Private Securities Litigation Reform Act of 1995, including statements regarding: the expected ability of DNAWitness to help criminal investigators and police departments identify physical attributes and characteristics of suspects and perpetrators. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid products and services, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, patent protection, litigation and Orchid`s ability to obtain additional financing. These risks and other additional factors affecting Orchid`s business are discussed under the headings "Risks Related to Our Business," "Risks Related to the Biotechnology Industry" and "Risks Associated with Our Common Stock" in Orchid`s Annual Report on Form 10-K for the year ended December 31, 2003, as filed with the Securities and Exchange Commission, and in other filings made by Orchid with the Securities and Exchange Commission from time to time. Orchid expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.




--------------------------------------------------------------------------------
Source: Orchid BioSciences, Inc.

[McFlying]

Orchidee Cellmark, um Innovative DNS-Basierte Gesetzes-Durchsetzung Werkzeug den Dienstag den 14. Dezember Zu Verteilen, 7:00 bin ET -- DNAWitness(TM) Verwendungs-Verbrechens-Szenen-DNS Zu Helfen daß man die Körperlichen Merkmale von Verdächtigen Identifiziert --


PRINCETON, N.J., der Dez. 14 /PRNewswire-FirstCall/ -- Orchideen-Biowissenschaften, Inc. (Nasdaq: ORCH - Nachrichten), ein führender weltweiter Lieferant von Identitäts-DNS, die Dienstleistungen prüft, heute eine Übereinstimmung bekanntgegeben, DNAWitness(TM zu verteilen), ein gerichtsmedizinisches entwickeltes und von DNAPrint-genomics ein Geschäft gemachtes Dienstleistungserzeugnis. DNAWitness ermöglicht kriminelle Untersuchungsbeamte, eine Seitenansicht der wahrscheinlichen allgemeinen körperlichen von der Verbrechensszene wiedergewonnenen Merkmalsbenützungs-DNS eines Verdächtigen zu entwickeln. Verständnis für diese körperlichen Merkmale wird von eigenen Algorithmen in DNAWitness erstellt, das es ermöglicht, die Teile von Europäer, zeigte ostasiatische, Einheimische amerikanische und untersaharan afrikanische Abstammung von der DNS des Verdächtigen an zu bestimmen. DNAWitness hat schon seine Nützlichkeit wie ein Verbrechen bewiesen- Kampfwerkzeug in einer Anzahl hoher Seitenansichtenfälle. Finanzielle Begriffe von der eins- Jahr, wurde nichtausschließliche Verteilungsübereinstimmung mit DNAPrint-genomics nicht aufgedeckt.
"Mit der sehn-bestanden werdend Rolle der Orchidee als ein Vorlaufanbieter von DNS, die Dienstleistungen zu kriminellen Gerechtigkeitsagenturen in den U.S.A. und Europa prüft, ist DNAWitness ein logischer Zusatz zu dem gerichtsmedizinischen Dienstleistungs-toolbox, dem wir unsere Kunden anbieten", Mark Stolorow sagte, Vorstandsmitglied von Orchid Cellmark. "Unsere Verpflichtung zu wissenschaftlicher Neuerung in der Anwendung von DNS zu Lösungsverbrechen, zu uns unter dem ersten gemacht um das Potential von SNPs, oder einzelne Nukleoflut-polymorphisms zu erkennen, um unentsprochenen Bedarf in prüfender Identität anzusprechen. Wir freuen uns jetzt unsere Polizeiabteilungskunden dieses einmalige SNP-gestandene Erzeugnis der vieler ernsten unaufgeklärten Verbrechen, wo die DNS des Verdächtigen zu keiner der überführten Missetäter-DNS-Seitenansichten paßt, anzubieten, um ihnen zu helfen die wahrscheinlichen körperlichen Merkmale der Täter identifizieren, schon auf Ordner in Staat und föderative Datenbanken.

DNAWitness ist benutzt worden erfolgreich in einer Anzahl von Untersuchungen, einschließlich eines jüngsten Falles, der den jetzt-überführten Louisiana-Seriellmörder Derrick Todd Lee betrifft. Auskunft über die Abstammung der Lee half, den Brennpunkt der Untersuchung einer Serie von seriellen Morden in der Region verändern, zu seiner Verhaftung und nachfolgender Überzeugung führend. Die DNAWitness-Dienstleistung benutzende Gesetzes-Durchsetzungsagenturen bekommen die von der DNS des Verdächtigen und einer fotografischen Datenbank erstellte Abstammungsseitenansicht von Freiwilligen, die Beispiele von Leuten mit ähnlichen Abstammungsseitenansichten, und auch Identifizierungsauskunft für den Fall besorgt.

Unter der Cellmark-Marke ist Orchidee ein Führer in privater gerichtsmedizinischer DNS-Analyse seit 1987 gewesen und ist jetzt eine der größten privaten DNS gerichtsmedizinische Prüfungsanbieter in der Welt. Orchidee hat ein internationales Netz aus gerichtsmedizinischen Prüflaboren in den U.S.A. und U.K., wo es mit dem berühmten "Schottlands-Garten" und anderen arbeitet. Die Gesellschaft beschafft eine volle Reihe von hoher Qualität, gerichtsmedizinische prüfende DNS und beratende Dienstleistungen sowohl für Kläger als auch für Angeklagte für spezielle Bedürfnisse angepaßt. Seine Dienstleistungen schließen ein, daß DNS auf kriminelle Sozialarbeitsanalyse und fachmännische Zeugenaussage, und auch Identifizierung von Opfern Unfälle und Katastrophen prüft. Letztes Jahr begann die Gesellschaft DNS Express(TM), eine Prämiendienstleistung, um U.S.A.-Lokalgesetzes durchsetzungsagenturen zu helfen Rückstaue analysieren, von DNS-Beweis von unaufgeklärten Verbrechen in fünf Geschäft die Tage, im Vergleich zu den standardmäßigen eins-zu-zwei Monaten. Mehr Auskunft über DNAWitness und die U.S.A.-gerichtsmedizinisch-DNS-prüfungs-Dienstleistungen der Orchidee kann bei http://www.orchidcellmark.com gefunden werden.

Über Orchideen-Biowissenschaften

Orchideen-Biowissenschaften ist ein Vorlaufanbieter von Identitätsgenetikdienstleistungen für das gerichtsmedizinische und Vaterschafts-DNS, die Märkte prüfend und für Gesundheitswesen und tierische DNS auf Nahrungssicherheit prüft. Der starke Markt der Orchidee positioniert in diesen Segmenten leverage die akkreditierten Labore der Gesellschaft in den U.S.A. und U.K., seinen innovativen genetischen Analysetechnologien und Sachkenntnissen, und der Welt- berühmtes Cellmark und GeneScreen-Marken, die sich mit außerordentlicher Qualität, Zuverlässigkeit, Neuerung und Kundendienst für beinah zwei Jahrzehnte verbunden haben. Mehr Auskunft über Orchidee kann bei http://www.orchid.com gefunden werden.

DNAWitness ist ein Warenzeichen von DNAPrint-genomics.

DNAExpress ist ein Warenzeichen von Orchideen-Biowissenschaften.


Alle Aussagen in dieser Pressemitteilung, die nicht historisch sind, sind schicke- Aussehaussagen innerhalb der Bedeutung Private Securities Litigation Reform Acts von 1995, einschließlich Aussagen unter Berücksichtigung: die erwartete Fähigkeit von DNAWitness, kriminellen Untersuchungsbeamten und Polizeiabteilungen zu helfen, körperliche Merkmale und Merkmale von Verdächtigen und Tätern identifizieren. Solche Aussagen sind abhängig von den Risiken und Ungewißheiten, die eigentliche Ergebnisse verursachen könnten um sich materiell von jenen zu unterscheiden, übertrugen, einschließlich, aber beschränkt nicht zu, Ungewißheiten, bezüglich daß Technologien, Erzeugnisentwicklung, herstellen, Marktannahme, Kosten und Preisbestimmung von Orchideen-Erzeugnissen und Dienstleistungen, Abhängigkeit von collaborations und Partnern, regulative Zustimmungen, Wettbewerb, geistiges Eigentum von anderen, Patentschutz, Prozeß und der Fähigkeit der Orchidee, zusätzliche Finanzierung zu erhalten. Diese Risiken und anders zusätzliche Faktoren das Geschäft der Orchidee beeinflussend werden diskutiert unter den Überschriften ""Auf Unser Geschäft Bezogene Risiken", "Auf die Biotechnik-Industrie Bezogene Risiken" und Risiken Verbanden sich mit Unserem Üblichen Vorrat" im Jahresbericht der Orchidee auf Form-10-K da das Jahr den Dezember 31, 2003, wie eingeordnet, mit den Sicherheiten und Austausch-Kommission beendete, und in anderem von Orchidee mit den Sicherheiten gemachten Einordnen und Austausch-Kommission von Zeit zu Zeit. Orchidee verleugnet ausdrücklich Verpflichtung oder Unternehmung, um öffentlich Updates oder Überarbeitungen freizugeben, zu schick-aussehenden Aussagen, enthalten um hierin Änderung von den Erwartungen der Orchidee mit Hinsicht dazu widerzuspiegeln, oder Änderung von Ereignissen, Zuständen, oder Umständen, auf die ein solche Aussagen basieren, außer wie erfordert werden kann von Gesetz.




---------------------------------------------------------------------------------Quelle: Orchideen-Biowissenschaften, Inc.

[McFlying]

#1 von ge4teilter

Steigst du nun aus

Jetzt gehts es doch erst richtig los


#1 von ge4teilter 05.03.04 11:40:01 Beitrag Nr.: 12.342.190
Dieses Posting: versenden | melden | drucken | Antwort schreiben DNA PRINT GENOMICS DL-,01

Moin!

Auf Wunsch unseres verdienten Alt- aber seit 3. März 2004 leider auch Ex-Aktionärskollegen cariocca aus der Schweiz möchte ich nun einen neuen DNAP-Thread für 2004 eröffnen.

Obwohl ich ein sehr positives und optimistisches Kerlchen bin, will ich gleich vorausschicken, daß auch ich nicht mehr länger als bis 31.12.2004 Geduld haben werde.

Denn, wie der Threadtitel schon sagt: Wann, wenn nicht 2004?!

Ich wünsch´ Euch was!

ge4teilter

[babe_in_the_woods]

@ge4teilter

drin bleiben sonst gibts Popoklatsch

Frankfurt machts vor, immerhin 100k

[ge4teilter]

Moin zusammen!

Was kümmert mich denn mein Geschwätz von gestern?

Klar bleib´ ich drin! Alles oder nichts!

g4

[McFlying]

Bid und Ask ziehen kräftig an

[carlo49]

mich würden mal genaue fakten zu diesem wert interessieren.
warum ist der kurs so tief?
warum soll dieser wert so stark anziehen?
gibts ne story oder eine fantasie, die dnap interessant macht?
oder ist das alles nur bauchgefühl hier?
über fundierte informationen wäre ich ( und nicht nur ich!)sehr dankbar.

[McFlying]

3 Filings sind da

http://yahoo.brand.edgar-online.com/default.aspx?cik=1127354

[Michiko]

Weiß nicht, ob Ihr diesen Ausschnitt aus den Filings schon gelesen habt:

We intend to file a proxy statement with the Securities and Exchange Commission and hold an annual meeting of our shareholders in order to obtain shareholder approval to increase our number of authorized shares of common stock to 3,000,000,000.

Das heißt: Die Firma will sich zu den schon vorhandenen 1,5 Millarden shares noch einmal die gleiche Anzahl genehmigen lassen, um daraus ihre finaziellen Verpflichtungen Biofrontera gegenüber bezahlen zu können

[Menglovator]

+22,22 %

Weis jemand mehr ?

[Michiko]

Menglovator,

ich weiß nicht, woher Du diese Zahl hast.
Bei mir auf dem Monitor sind es momentan -3,5% bei hohem Volume (fast 14 Millionen shares bisher gehandelt).

Meine Vermutung: Die Amis haben die Filings inzwischen gelesen und festgestellt, dass die Anzahl der A/S verdoppelt werden soll. Auf deutsch: dilution!
Ist für viele momentan wohl ein Grund, rauszugehen.

Meinungen dazu?

Michi

[WOchmann]

Er meint den Anstieg von 22% in Frankfurt.

Gruß
WOchmann

[Michiko]

WOchmann

da hat aber einer arg teuer gekauft!

Gruß

Michiko

[McFlying]

Michiko

abwarten wie USA schliest

Es werden noch News für heute erwartet

[Michiko]

McFlying

Es werden noch News für heute erwartet

Sorry! Mit dieser vernebelnden Ausdrucksweise kann ich nix anfangen.
Wer erwartet News und woraufhin?

Nur so aus dem Bauch heraus?

Sollte mich natürlich freuen, wenn das mit den News stimmen würde, denn ich habe in letzter Zeit auch noch mal nachgekauft und bin jetzt kräftigst drin.
Aber so einfach ins Blaue hinein eine Hoffnung projezieren liegt mir nicht.
Mein Bauchgefühl hat mich schon zu oft betrogen!

[Michiko]

Schlusskurs in USA 0,0117 (im ask). bid 0,011.

Volumen gut 16 millionen shares.

Michiko

[hvs1]

Michiko,

geht mir genauso.Habe auch noch 1M nachgelegt.Im RB hatte einer gepostet,dass heute noch News kommen sollen.
Ich glaube heute passiert nichts mehr.Der kommende Ver-
wässerungseffekt war vorauszusehen.Aber ohne News und ohne
Kurserhöhung erreichen sie die 35M für Biofrontera und
eigene Liquidität nicht.
Ich bin trotzdem guten Mutes.

hvs1

[hvs1]

Ups,

war ja schon nach 22.00 Uhr

hvs1

[Michiko]

hvs1

Wir longs stehen halt mal wieder vor einer Entscheidung:
Vertrauen wir unserer Firma so sehr, dass wir sagen: Okay, es muss halt sein! Ohne neue shares lässt sich der Masterplan nicht verwirklichen. Beißen wir halt in den sauren Apfel in der Hoffnung, dass wir irgendwann für unsere ausdauernde Treue belohnt werden (dann aber gründlich!).

Oder entscheiden wir uns anders: Seit vier Jahren hoffen und harren wir. Die treuesten Longs sind teuer eingestiegen, konnten vielleicht verbilligen, aber niemals bis zum jetzigen Level. Und wieder gibt´s eine neue Dilution. Und wer sagt denn, dass dies die letzte war!
Haben wir vielleicht in einem Jahr 10 Milliarden O/S?

Sollten wir nicht lieber jetzt verkaufen und dann, wenn es in dieser Tendenz auf 0,001 runtergegangen ist, und wir evtl. dabei sind, neue Hoffnung zu schöpfen, mit dem jetzt erlösten Geld auf die 10-fache Zahl an shares zu erhöhen, mit denen wir dann vielleicht wirklich einen sauberen Gewinn machen könnten?

Fragen über Fragen! Und DNAP macht uns die Antwort wirklich nicht leichter!

Gruß

Michi

[hvs1]

Michiko,

ich hoffe einfach mal,dass wir nicht unter 0,01 fallen.
Einige News stehen an,ohne Zweifel in diesem Monat.

hvs1

[Michiko]

Off topic: Kennt jemand von Euch ein französisches Börsen-Board ähnlich unserem W: O?

Wäre für einen link dankbar!

Michiko

[carlo49]

ich beobachte dnap seit einiger zeit. die heutige meldung, das 3 mrd neuer shares genehmigt werden sollen, zur finanzierung eines deals, ist für mich negativ hoch drei.
die verdoppelung der anzahl der handelbaren aktien wird den kurs weiter sehr stark drücken, denn die suppe kommt auf den markt, mit sicherheit, wie soll da ein kurs steigen?
die krebsen doch schon jetzt am bankrott rum.
also ich rate, finger weg!
ich werde dnap von meiner watchlist streichen.
viel glück

[Michiko]

carlo49

An diese Firma muss man "glauben", oder man lässt besser die Finger davon!

Ebenfalls viel Glück anderswo.

[Pushi2]

Hier nochmal mein Posting #169 vom 02.10.04

Endlich mal ein vernünftiger Beitrag.
Danke, Cirkle_Jerk ...
Die Verwässerung wird vermutlich noch wesentlich deutlicher ausfallen.
Der Ausgabekurs der neuen Aktien wird durch die üblichen Abschläge zu bis zu 3.000.000.000 neuen Aktien führen.
Schaut Euch mal die jetzige Börsenkapitalisierung von DNAP an ...
Kurstreibende Gerüchte und Meldungen sollten bei OTC-Werten möglichst zu Gewinnmitnahmen genutzt werden.
Die Jungs die hier immer von " long" reden, sollten besser zum Roulette gehen, da sind die Quoten besser ...
Viel Glück weiterhin und den Zockern ein gutes Timing bei den Ein- und Ausstiegen in den nächsten 2 Jahren.


und Posting #10 vom 25.12.04 (anderer Thread)

Auf welche Nachrichten wartet Ihr denn alle???
Bald wird sich zeigen, ob der Taschenspielertrick mit DUTCHESS gelingt.
Leider war der Kursverlauf seit Oktober nicht so, wie sich das die Verantwortlichen vorgestellt haben.
Und die große Verwässerung der Aktie steht im Falle einer SEC-Genehmigung erst noch bevor. (Wenn es soweit kommt ...)
Insoweit weiß ich auch noch nicht, wie ich die hohen Umsätze der vergangenen Woche deuten soll.
Viel Glück weiterhin.
Aber wundert Euch nicht über einen Totalverlust in 2005!?

" We do not expect our revenue stream to be sufficient to cover costs of operations in the immediate future. We anticipate that the funding we expect to receive from the minimum conversions of the outstanding debenture into common stock and the related exercise of the non-detachable warrants will fund our operating activities through 2004. The Dutchess agreement that we recently negotiated will provide up to $35 million in additional cash over a 24-month period. It is anticipated that approximately $25 million will be used in the Biofrontera investment and the remaining $10 million will be used to fund our operations through 2006. If our share price continues to remain weak; if our shareholders` do not approve an increase in capitalization when required; if the SEC S-2 registration is not completed by February 7, 2005, and if any number of adverse factors or events occur, we will not have enough equity to complete either the Biofrontera or the Dutchess transaction or possibly to continue operations beyond 2004. Management is adequately confident that equity financing or debt will be available to fund our operations until revenue streams are sufficient to fund operations; however, the terms and timing of such equity or debt cannot be predicted."


und Posting #12 vom 25.12.04 (anderer Thread)

Erläuterungen zum vorgestellten Quartalsbericht-Auszug:

Sollte das " Spiel" funktionieren, müssen in den nächsten 24 Monaten ca. 3.000.000.000 frische Aktien plaziert werden. (Ob die SEC dies zuläßt, sehen wir frühestens im Februar.)
Vergleicht den Gegenwert (beim aktuellen Kurs von 0.0117 USD) mal kurz mit der aktuellen Marktkapitalisierung.
Wer weiter mitspielen möchte, muss dann zum verwässerten Kurs nachlegen und hoffen, dass Biofrontera die 25 Mio. USD wenigstens z.T. wert ist. (Hier wird aber auf absehbare Zeit auch kein Geld verdient ...)
Die restlichen 10 Mio. USD sollen dann für ca. weitere 12 - 18 Monate Hoffnung reichen. Ansonsten müssen dann erneut Anleger gefunden werden, die frisches Geld in DNAP pumpen.
Hier wird viel Geld verbrannt, was für diese Branche auch normal ist ;-))))
Was natürlich nicht heissen soll, dass man mit gutem Timing und viel Glück auch Geld verdienen kann.
Mich wundert immer nur das Gerede über " long" ...
Die Risiken eines Totalverlusts sind wesentlich höher als die hier propagierten Gewinnchancen. (So ist es das halt mit OTC-Werten.)
Den Zockern weiterhin viel Erfolg - Anfänger bitte Finger weg.

[carlo49]

@pushi
ich bin ganz deiner meinung, dem ist nichts hinzuzufügen.
es ist alles gesagt

[hvs1]

In Frankfurt hat wohl einer auf Grund der beiden letzten
Postings die Panik gekriegt.

hvs1

[Pushi2]

Solche engen Werte sollte man ohnehin nicht in D traden ...

[hvs1]

Pushi2,das ist wohl wahr.

hvs1

[hvs1]

Michiko,

bist Du noch drin?

hvs1

[Michiko]

hvs1

yep! Bin aber dabei, meine Strategie zu überdenken.

[hvs1]

Michiko,

was heißt das?

hvs1

[Michiko]

hvs1

Es gibt im Moment für mich fünf Varianten:

a) Ich bleibe long mit allem was ich habe evtl. über Jahre hinweg.

b) Ich bleibe long mit ca. 50% meines Invests. Mit der anderen Hälfte werde ich traden, d.h. ich werde versuchen, die Spikes zum Verkauf zu nutzen und beim anschließenden (unausweichlichen!) Return wieder billiger nachzukaufen.

c) Wie b) aber mit 100% meines Invests.

d) Beim nächsten Up verkaufe ich alles und schaue nie wieder zurück.

e) Sobald wieder Cash in the Tash ist, kaufe ich nach.

Momentan tendiere ich zu b)

Deine momentane Taktik/Strategie?

Michi

[hvs1]

Michiko,

3M sind im Depot davon trade ich mit 1M,ansonsten wie b)

hvs1

[hvs1]

Was ist da los,das sind ja mini Umsätze?

hvs1

[hvs1]

DNAP`ler,

hat keiner mehr etwas zu sagen.
Es ist sehr ruhig hier.

Schlaft gut.
hvs1

[Pushi2]

@hvs1
Es passiert ja auch nichts ...
Wenn die SEC S-2 Registrierung bis zum 07. Februar nicht vollständig ist und nicht zugleich auch positive Unternehmensnachrichten den Kurs stärken, dann wird es wirklich eng
Dennoch viel Erfolg allen Trader.
Ansonsten kann man dann auf Basis 0,001 USD noch mal spekulieren, um sich dann bei Gerüchten der totgesagten DNAP über eine Kursverzehnfachung zu freuen (vgl. aktuell HTDS und manche anderen Pennystocks. Leider ist bei der Mehrzahl der OTC-Werte jedoch irgendwann das Licht aus.
Willkommen bei den hochspekulativen Werten ...

[hvs1]

Pushi2,

wie sagte Michiko schon so schön,man muss an diese Firma glauben.

Beide Firmen DNAP und Biofrontera haben derart viele
Sachen gleichzeitig in der Pipelnine,da muß kurzfristig
eine gute Nachricht kommen.
Das weiß DNAP auch,dass da was kommen muss.

hvs1

[OTCNeuling]

275: Da sollte schon längst was gekommen sein, laut biom aber bis jetzt immer noch TOTE HOSE

[Pushi2]

Haben beide "Ideen" in der Pipeline, aber leider kein Geld zum Überleben ...
Hoffe, dass bis zum 07.02. ein Lebenszeichen erfolgt.
Ggf. sollte man dann bei positiven Gerüchten realisieren und beim zu erwartenden Rückschlag wg. der Kursverwässerung durch die evtl. neuen Aktien wieder mit Spielgeld einsteigen.
Dies hat im Sommer 2003 auch schon grossen Spass gemacht und geht vielleicht bald wieder.

[Michiko]

Pushi2

der Juni 2003 ist auch mir noch in sehr angenehmer Erinnerung.
Habe damals ne Menge Cash einsammeln können.

Eigentlich schade, dass die "Longs" nicht belohnt werden, sondern die Trader!
Aber: That´s life.

Aber mit der emotionalen Hälfte meines Herzens bleibe ich long.

Gruß Michi

[hvs1]

Michiko,

das ist eine Abwägungssache.
DNAP wird kurzfristig steigen,möglicherweise 4-6 cent
Mit 30 bis 50% raus und wieder rein ist ok,aber alles raus-
schmeissen und zum richtigen Zeitpunkt verbilligt wieder
rein,ist mir zu unsicher.
Pushi geht davon aus,dass DNAP nicht überlebt.Ich gehe
davon aus,das DNAP eine enorme Zukunft hat.Deshalb werde
ich max. mit 1M traden und nicht mit der gesamten Anzahl.
Kurzfristig ist bis Ende Januar.

hvs1

[McFlying]

Unter 0,02 gebe ich keine her

[Menglovator]

+ 25%
Weis jemand mehr?

[Michiko]

Menglovator

der Frankfurter Kurs ist völlig ohne Bedeutung!

[Pushi2]

Hohe Umsätze - 20% Verlust - keine Postings

[McFlying]

DNAPrint Teams With Senecio Software To Win NIH-SBIR Grant
E-mail or Print this story

2 February 2005, 12:26pm ET

SARASOTA, Fla., Feb. 2 /PRNewswire-FirstCall/ -- DNAPrint genomics (BBNAP) of Sarasota, FL (the "Company") announces today that the Company and Senecio Software Inc. have been awarded a highly competitive Small Business Initiative Research (SBIR) grant by the National Institutes of Health (NIH).

The principle objective of the co-authored grant application is to create software systems that will expand DNAPrint`s technology reach to institutional, government and academic markets.

Recent federal directives require the use of multiracial classification on official forms and surveys and call for the Government to do a better job of recognizing diversity in ancestral origins. However, demographic research on race is becoming increasingly difficult given its multiple measures and the growing complexity in defining race.

As the first to enable an objective and quantitative measurement of continental and/or ethnogeographic ancestry admixture, DNAPrint`s innovative genetic testing technology (ANCESTRYbyDNA(TM) 2.5, DNAWitness(TM) 2.5, EURO-DNA(TM) 1.0, EURO-Witness(TM) 1.0) represents a logical, scientific and convenient proxy measure for institutional, government and academic researchers.

Target markets for the software system to be developed in this grant project include government and academic demographers, social scientists and policy makers.

Customers can learn more about DNAPrint`s tests for the inference of ancestry admixture at http://www.ancestrybydna.com .

About DNAPrint genomics, Inc.

DNAPrint genomics Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company introduced ANCESTRYbyDNA(TM) in the consumer market and DNAWitness(TM) in the forensic market in 2003. DNAPrint is developing products in the pharmacogenomic market and has a disease gene discovery program. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit http://www.dnaprint.com .

About Senecio Software

[Michiko]

Die Kooperation mit BIOFRONTERA ist gestorben; ohne eine Erhöhung der A/S auf 3 Milliarden wird`s nicht mehr lange laufen.

Hier das 10K-filing:

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=3328…

[Bombenleger]

@ Michiko,

wo steht das das Verhältnis gestorben ist?

As part of our development strategy, we have entered into a relationship with Biofrontera AG, a cutting edge genomics/pharmaceutical company based in Europe. Our technology allows us to determine a patient`s response to a drug treatment thereby allowing us to isolate those patients that are non-responders to the drug treatment. Biofrontera, using their differential expression pattern display (DEPD) technology can compare those patients who have not responded to treatment with patients who have responded and they are then able to identify unique inherited cellular pathways that may help us develop better medications for non-responders. The combination of unique technologies held by Biofrontera and us provides the innovative edge we believe will be needed to meet the challenges of the emerging market of personalized medicine. We believe that our approach to drug discovery and development offers our shareholders and the shareholders of Biofrontera a unique opportunity. The combination of Biofrontera`s and DNAPrint`s technologies provides a library of novel compounds (1,500,000 isolates), screening technologies, cloning capabilities, animal testing, receptor pathway development, clinical trials experience and novel patient screening to help accelerate drug discovery, development and approval. Additionally, Biofrontera has two phase two drugs, one for chronic itching and another for pre-cancerous skin lesions with a pre-clinical migraine product to treat re-occurring migraine headaches which in the U.S. alone effects nearly 14 . . .

[Michiko]

Bombenleger,

guckst Du auf Seite 6 unter Recent Developments:

RECENT DEVELOPMENTS

Biofrontera Agreement


Effective September 28, 2004, we entered into an Investment Agreement with
Biofrontera AG, a German corporation, and the shareholders of Biofrontera.
Pursuant to the Biofrontera Agreement, we agreed to purchase certain Series B
preferred shares of Biofrontera. The purchase of the shares would have given us
an equity interest of approximately 51% in Biofrontera. The purchase price of
the shares was 20 million Euro, or approximately $24,648,755 pursuant to a .8114
exchange rate on October 13, 2004, payable in monthly installments of 833,333
Euro, or approximately $US 1,086,856, over a period of 24 months. Our investment
in Biofrontera and the monthly installments which we would have been required to
pay was to be secured by a commitment by Dutchess Private Equities Fund, II,
L.P. to invest up to $35,000,000 in our common stock over a period of two years
from the date of the Biofrontera Agreement. We intended to fund the monthly
payments payable to Biofrontera with the $35,000,000 equity line facility which
we have with Dutchess.

The transaction would not close, and our payment obligation would not begin,
until after the effectiveness of this registration statement in order to permit
sales of our common stock by Dutchess under the aforementioned equity line
arrangement. In the event that such registration statement did not become
effective on or before February 7, 2005, the Biofrontera Agreement will
terminate without liability to either party. This registration statement was not
declared effective by the Securities and Exchange Commission on or before
February 7, 2005. Accordingly, we filed a current report on Form 8-K filed on
February 25, 2005 in which we disclosed that after discussions with Biofrontera,
on February 18, 2005, we exercised our right to terminate the Biofrontera Agreement.

Gruß

Michi

[ge4teilter]

Tach zusammen!

0,006 $! Das ist schon ein Hammer, wenn man einen durchschnittlichen Einstandspreis von fast 0,11 $ bezahlt wie ich! Wenn ich heute nochmal 2000€ in die Hand nehmen würde könnte ich die Menge verdoppeln und den Durchschnittspreis halbieren!

Aber habe ich noch so viel Vetrauen? Hmmmm ..... ich weiß es wirklich nicht.

Wißt Ihr es?

Gruß ... g4

[babe_in_the_woods]

Ja Ja die MMs NITE und SCHB, die machen den Kurs.

RT 0.006

irgendwann muss doch der Rebound kommen!?
Aber es kann eingige Monate dauern!

[hvs1]

Der Verfall ist schon grausam,

damit habe ich nicht gerechnet.0,01 war eigentlich mein
Tiefstwert.

Grausam,grausam,grausam.
Hatte echt nicht geglaubt,daß die die Shareholder derart
bestrafen.
Halte 3M bis zum Schluß.

hvs1

[Michiko]

. . . und was mich auch noch stört:

Ich habe kürzlich ne Mail an DNAPrint geschickt mit der Bitte um Infos, ob es eine Hoffnung für uns shareholder gibt, oder ob wir uns darauf einstellen müssen, dass der pps nach und nach auf 0,001 runtergeht.

Reaktion: NULL!

[hvs1]

Michiko,

wir wollen nicht klagen.
Wir wussten,dass es ein OTCBB-Wert ist und alles passieren
kann.
Aber ,dass Tony das Spiel mitmacht und seine Geldgeber
der ersten Stunden derart verprügeln lässt,verwundert mich
schon sehr.
Die Basher im RB werden wahrscheinlich recht behalten.Sie
sind schon sehr nah an 0.001 dran.
Allerdings,meine Hoffnung
ist noch nicht gestorben,dass das Ding noch dreht.

hvs1

[Bombenleger]

@Michiko,

glaubst du man gibt dir eine Antwort auf so eine Frage?

[Michiko]

Bombenleger,

natürlich erwarte ich keine Antwort nach dem Muster "Lieber shareholder, wir würden Ihnen raten, jetzt zu verkaufen, da nicht auszuschließen ist, dass der pps demnächst 0,001 beträgt!"

Aber IRGENDEINE Raktion hätte ich schon erwartet. Zumindest um nicht den Eindruck zu erwecken, dass die Aktionäre für TF & Co sch....egal sind!

[Bombenleger]

FEATURE-American Indians look to DNA tests to prove heritage
Fri Mar 25, 2005 08:00 AM ET
By Adam Tanner
SAN FRANCISCO, March 25 (Reuters) - The United States has treated its indigenous people poorly for much of its history, yet today thousands of people are anxious to show their Native American heritage and are turning to DNA testing for help.


FACT BOX
DNAP.OB (DNAPRINT GENOME)
Last: 0.01
Change: -0.00
Up/Down: -1.47%

Quote
Full Chart
Company Profile
Research Reports

News for DNAP.OB
FEATURE-American Indians look to DNA tests to prove heritage


Some white Americans have long claimed distant ties to Cherokee princesses or other legendary figures among those explorer Christopher Columbus mistakenly called Indians when he thought he had arrived in South Asia.
Now Indian heritage -- which can make a person eligible for federal assistance programs or a share of tribal casino profits or just satisfy curiosity -- can be determined through genetic testing. Advances in DNA screening have provided new tools to document Native American ancestry, although some say such data is open to be interpretation.

"If you are interested in determining your eligibility for Native American rights or just want to satisfy your curiosity, our ancestry DNA test is the only method available for this purpose today," one firm, Genelex, advertises.

Although U.S. citizens typically know the broad outlines of their ancestry, for Native Americans the exact fractions of their heritage can take on heightened importance.

Nineteenth-century treaties obligate the U.S. government to provide education, health care and other services to many tribes. Indian sovereignty also means tribes can set up casinos on reservations, and Indian casinos now generate $18 billion annually and the numbers are growing.

Many tribes set as a membership standard that a person must have at least one Indian grandparent or one great grandparent. Others among the 562 federally recognized tribes require links to members on a tribal membership roll in past generations.

With individuals seeking to affirm membership in recognized tribes and dozens of unrecognized tribes seeking federal acknowledgment, commercial firms have in the last two years stepped up marketing of genetic ancestry tests. A positive test result is not sufficient to enable someone to claim Indian benefits because they must prove a link to a specific tribe.

"Nobody else in this nation has to prove their ancestry except for American Indians," said Ken Adams, chief of the Upper Mattaponni Tribe in Virginia which is not recognized by the U.S. government. "It`s so ironic because we were the original ones."

Since Genelex started offering the test more than a year ago, 600 people have paid $395 to learn the degree of their Native American heritage, said Kristine Ashcraft, director of client relations.

Firms such as Genelex offer three types of tests: on male ancestors, on female ancestors, and a third to determine a percentage of Native American, East Asian, Indo-European and African heritage.

A Sarasota, Florida company DNAPrint (DNAP.OB: Quote, Profile, Research) processes that third test, and has done it for 12,000 to 13,000 people since 2000, said firm director Richard Gabriel. DNAPrint uses data from South American Indians as a genetic reference point, he said.

LIMITS OF DNA TESTING

Mark Shriver, an anthropologist at Pennsylvania State University who helped develop the DNAPrint ancestry test, cautions its results without family history prove little.

"Just simple belief in a test without considering all the other data is, you know, foolish," he said. "The science is not simply true and objective...It is one clue in the picture."

He cited one of his graduate students from France whose test found a 14 percent Native American heritage. He said that number was likely the result of intermixing following the 13th century invasion of Europe by Mongols, who hailed from the same region of Asia as the forefathers of Native Americans.

The DNA tests are also unable to differentiate between Indian tribes.

The issue of who is an Indian also hangs over future generations. For members whose tribes share revenues from casino operations, marrying outside the tribe could have major financial implications.

As in many cultures, some parents encourage children to marry within the tribe, but some, especially in smaller tribes, see the request as very limiting.

"Everyone in the tribe is a distant cousin," complained one 18-year-old Indian woman who works at a casino in the Pueblo of Acoma, New Mexico. She hoped to marry outside the tribe.

As important as identity is in Native American culture, for some the motivation for a DNA test is just curiosity.

"It`s growing in popularity much faster than any of our expectations," said Terry Carmichael, vice president for sales and marketing at GeneTree, whose advertising asks "Do you have Native American DNA?".

"A lot of people out there primarily want to find out if they have Native American ancestry, not for purposes of claiming rights to a casino but more for their own understanding," he said. "They want to be able to understand their ancestry a little bit more."


© Reuters 2005. All Rights Reserved.

[Bombenleger]

Form 10KSB for DNAPRINT GENOMICS INC


--------------------------------------------------------------------------------

31-Mar-2005

Annual Report



ITEM 6. MANAGEMENT`S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.
The following discussion and analysis should be read in conjunction with the balance sheet as of December 31, 2004 and the financial statements as of and for the years ended December 31, 2004 and 2003 included with this Form 10-KSB.


SUMMARY
Although we have been in existence for a number of years, management`s efforts to develop our business have not yet resulted in the generation of significant revenues. Initially, management`s efforts focused on developing licensing relationships from our research and development. More recently, management has chosen to focus on increasing sales volume in the consumer market and building sales in the forensic market while continuing to develop products for introduction to the pharmacogenomics market. We continue to devote substantially all of our efforts in initiating and developing our planned principal operations. While sales of our forensic product DNAWitness(TM) , paternity service and genotyping services have increased compared to the prior year, sales of our ancestry product, ANCESTRYbyDNA(TM) decreased. Our new consumer product EURO-DNA(TM) 1.0 was introduced in the marketplace in late 2004 with a few sales during December 2004. Our DNAWitness(TM) product was introduced in late 2003 and in 2004; therefore during 2004 we had the opportunity to increase our customer base thereby increasing our sales of this product. Our pharmacogenomics products are still in development. Because our products are relatively new to the market, we believe that sales will continue to fluctuate from period to period until we can better determine through continued market research and experience how and where to best market and sell the products.

In late 2003, we successfully secured funding of a convertible debenture of $500,000 with non-detachable warrants. During 2004, some of the warrants were exercised as well as some of the debenture converted to our common stock. The exercise of the warrants provided $4.6 million ($4.2 million, net of offering costs) of funding during 2004 and we received $255,000 prepayment for the exercise of warrants during early 2005. We also sold preferred stock during 2004 which provided $255,000 of proceeds. Management continues to implement and refine operational procedures and controls to support future growth and development. We intend to support research and development as a vital component of our overall growth strategy. Until potential customers are familiar with our technology and products, which will come from continued research and development and proven market use, it is unlikely that we will generate significant revenue. The following discussion of our historical financial results should be read against that background.

Management plans to continue to focus on increasing sales in the market areas of forensics and genealogy and to move towards the introduction of new and expanded products in these markets. We plan to continue market research within both segments to further expand our knowledge and understanding of the most efficient way to market and sell our products.

We will continue work on OVANOME(TM), a Taxol screening diagnostic test, and STATINOME(TM), a test for the cardiac drug market, which are both currently under development. We will also continue our efforts on other research and development projects that are underway. We will continue to explore joint venture opportunities, particularly within the pharmacogenomic segment, in order to potentially expand our position within the pharmaceutical market. A major goal of our joint venture program is to seek opportunities for drug pipeline acquisition.

Internally, management will continue to develop and implement organizational policies and procedures to increase operating efficiency and move us closer to our goal of attaining and maintaining our planned principal operations.

Our plan of operations for the ensuing twelve months includes efforts to: 1) increase sales of our existing products; 2) introduce new and expanded products in the genealogy and forensic markets; 3) continue promoting our genotyping and paternity services while continuing to concentrate on research and development for both our existing products and our anticipated pharmacogenomic products and services. We expect to add personnel in the laboratory and in administration, as growth warrants. Capital expenditures needed for the next twelve months are discussed in this 10-KSB below under the section entitled "Liquidity and Capital Resources".


RESULTS OF OPERATIONS
REVENUES AND COST OF SALES

For the years ended December 31, 2004 and 2003, revenues were $785,632 and $709,638, respectively. A $75,994 increase in revenues from the prior year is an 11% increase that was a result of our sales of DNAWitness(TM) increasing by approximately $44,000, paternity services increasing by approximately $24,000 and genotyping services increasing approximately $49,000 compared to the prior year. These increases are due to our increased promotion and marketing of these products. Also EURO-DNA(TM) 1.0 was introduced to the general public in the fourth quarter of 2004 and contributed $4,000 of revenue for 2004. This was offset by a decrease of approximately $45,000 from our ANCESTRYbyDNA(TM) sales.

Our sales of DNAWitness(TM) increased due to our increased marketing efforts to promote awareness of this product during 2004. Our forensic sales are generated through marketing to various agencies, our attendance at trade shows and through our relationship with Lynn Peavey catalog. During 2004, we entered into a contract with the Lynn Peavey Company. Lynn Peavey Company is a well-recognized and highly respected supplier of crime scene support materials to over 17,000 police and crime laboratories around the world. Our product, DNAWitness(TM) 2.0, is now featured in the Lynn Peavey Company catalog. We also plan to work with Lynn Peavey Company personnel to establish and conduct seminars and training programs for detectives, crime laboratory personnel and crime scene personnel on DNAWitness(TM). Because this is a new product and there are no similar products being marketed, we believe that forensic revenues will continue to fluctuate as we continue to research the markets and refine our sales and marketing strategy for the products.

Paternity sales are generated primarily through our various distributors and from our website www.ancestrybydna.com. The majority of the increase in sales during 2004 compared to 2003 is because paternity testing was not offered prior to the second quarter of 2003. Paternity testing is an add-on service, and we expect revenues to continue to fluctuate in this market. While we have not yet implemented a formal marketing and sales plan for this service, we continue to perform market research and gather information in order to define and implement a formal marketing strategy.

Genotyping sales were generated primarily through work with universities with one university being our major client of this service. To date, our genotyping service customers have come to us either through client referrals or our general website. In the future, we plan to concentrate our genotyping services on specific diseases, including cancer, neurological disorders, and heart disease. By concentrating on specific diseases, we hope to develop an expertise that will attract customers in those areas requiring external assistance and additional research capacity.

During 2004, our sales of ANCESTRYbyDNA(TM) decreased from the prior year. Because this product is relatively new to the market we believe that sales will continue to fluctuate from period to period until we can better determine through continued market research and time how and where to best market and sell this product. We introduced another ancestry product, EURO-DNA(TM) 1.0, during late 2004. Sales of our ancestry products were generated through advertising in Family Tree, a genealogy periodical, and through public exposure that we received during the year in newspapers, magazines and television. In addition, sales were generated through our various distributors and from our website www.ancestrybydna.com. During early 2005, we have entered into agreements with five new distributors to sell our ancestry products.

Promotional efforts to date have been fruitful but sporadic. We have been featured on or in ABC`s Prime Time Thursday, the CBS Evening News with Dan Rather, The New York Times, Miami Channel 10 WPLG, UPI, US News and World Report, Popular Science Magazine, Tampa`s Fox Channel 13 News, Germany`s ZDF News Channel, The Australian Broadcasting Corporation and The Sarasota-Bradenton Herald Tribune KTTV Fox 11 in LA, ABC Tampa, Howard Stern`s radio show, PBS WEDU Sarasota, USA Today, and Dallas Morning News.

In order to build consistent sales, we have begun to implement formal sales and marketing plans, including advertising and promotional campaigns. Implementing these plans results in increased expenses for personnel, advertising, promotion, and the collateral materials associated with these programs. We plan to continue to add to our advertising and presentation campaign throughout 2005, as cash flow permits. Overall, our goal is to focus on increasing market awareness of all of our products, particularly within the consumer and forensic markets.

While we continue to improve and refine our accounting systems, we currently do not segregate product costs by product or service. At December 31, 2004, we began recording inventory since during the last half of 2004, we were increasing the amount of raw materials we have on hand. We have been and continue to be a development stage company as described in Financial Accounting Standards Board Statement No. 7. We continue to devote substantially all of our efforts to initiating and developing our planned principal operations. We expect that our pharmacogenomic products and services, once introduced, will be our major revenue generator.

Management does not manage on a product cost basis at this time. Further, management does not allocate resources based on product lines. For the most part, personnel are not solely devoted to a product or a specific task. As a development stage company, personnel are required to perform a multitude of tasks including production and research and development. Revenue generation to date has not been substantial or steady enough to warrant segregation of duties. As such, labor costs vary from period to period. Further, we have not reached a stage where economies of scale are available to us. Production costs vary from period to period due to the level of revenue produced and research performed. We anticipate, as stated previously, that as we move from a development stage company to an operating company, management will focus on product revenues, costs and the associated margins. As part of our effort to become an operating company, we continue to develop and refine our production processes for our introduced products; so that over time and as sales increase, an efficient process can be implemented and managed on an ongoing basis. In addition, we continue to work towards designing and establishing a cohesive marketing and sales effort for our introduced products. Although both the forensic and genealogy markets have been in existence for several years, our products are new and unique to their markets, and it requires market research and testing in order to arrive at the best way to present our products. We continue to test markets through primary market research and advertising. This effort is ongoing and will continue to develop as we gather information.

Cost of sales increased from $432,224 (61% of revenues) in 2003 to $507,927 (65% of revenues) in 2004. The increase in cost of sales as a percent of revenues is due to our refinement of our estimate and allocation of research and development costs. Because of our small sales volume, these results are not indicative of the margins that we expect to attain if our long-term goals are achieved. We anticipate that as we gain experience and can begin to take advantage of economies of scale benefits through increased revenues and our margins will stabilize and begin to track in line with other companies in similar industries. However, in the near term, while we continue to be a development stage enterprise, we expect that our margins will continue to fluctuate.

RESEARCH AND DEVELOPMENT EXPENSES

Our research and development costs consist of raw materials, laboratory supplies, equipment expense, facilities costs and employment-related costs. The expenses were incurred in support of our currently available consumer and forensics products and genotyping services and for our anticipated pharmacogenomics products.

In 2003 and 2004, we also conducted research for future enhancements to DNAWitness(TM). The research included much needed sample collection for our eye and hair color studies. As a result of our past research, in early June of 2004, we introduced a new tool to our forensic customers. We compiled a volunteer photo database that we can use to help investigators visualize the DNA donor. This new tool augments the effectiveness of our product, DNAWithness(TM). During the third quarter, we completed work on our eye color service, RETINOME(TM), and EURO-DNA(TM), a service that allows customers to determine their Northern European, Mediterranean, Middle Eastern and Indo European ancestry and introduced them to the market. In addition, we continued our research work on STATINOME(TM) and ace inhibitor projects. We also, in conjunction with researchers at the Moffitt Cancer Center, continued work on OVANOME(TM) and other identified cancer projects. Some of this research involved the acquisition and evaluation of new samples with corresponding medical histories. We continued to evaluate and analyze our preliminary results and to extend those results to other patients` samples for Taxol, Statins, and Ace inhibitor work.

We continue our work in forensics to expand the physical descriptors that can be derived from crime scene DNA samples. Our research also continued in hair color, skin shade, and we carried on work to improve our recently introduced eye color predictor model. Additionally, we have collected nearly 1,500 volunteer photo database samples and will incorporate those new samples into our forensic photo database array in the near future.

Research and development costs decreased from $2,654,259 in 2003 to $1,561,142 in 2004, a decrease of $1,093,117, or 41%. This decrease is primarily the result of the stock-based compensation and the associated tax bonus received by our Chief Scientific Officer during 2003 in return for his services to us. Some differences could also result from our refinement in estimates and allocation of research and development costs.

Because we are in the development stage of our long-term business, it is not possible to directly correlate our current research and development costs to our future costs. Currently we do not manage on a project cost basis with respect to research and development. We are implementing revenue recognition and project status measures which will in the future disclose such information. Our revenue generation to date has not been substantial or steady enough to warrant segregation of time, costs and revenue. We are a development stage enterprise with new products that are not available through competitors for forensics and genealogy. For example, many of our products and services are in the development stage, such as ANCESTRYbyDNA(TM) and DNAWitness(TM), and the segregation of each project by its particular cost, revenue and cash flow is currently not feasible.

We continue to support research and development to attain our long-term business strategy, and it will remain a high priority and a necessary resource to sustain future growth. We will continue to hire research and development personnel and invest in the infrastructure required to support future innovation, including equipment, supplies and other asset purchases. In order to advance our pharmacogenomic products, OVANOME(TM) and STATINOME(TM), to commercialization, our development costs for these products will increase in 2005. In addition, as we move other pharmacogenomic products forward, research and development costs will likely increase proportionately.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

Another significant component of our operating expenses is selling, general and administrative expenses. These expenses resulted from (i) accounting and other fees associated with being a public company and other regulatory compliance activities, (ii) legal fees associated with our patent filings and maintenance, a lawsuit against a former employee and preparation of our securities law filings, (iii) selling and marketing costs to promote our products and (iv) administrative and other salaries and expenses.

For the year ended December 31, 2004, selling, general and administrative expenses decreased $1,806,944, from $3,857,925 in 2003 to $2,050,981, in 2004. During 2003 compared to 2004, we incurred approximately $700,000 of higher compensation from the stock-based compensation paid to the three top executives that were recruited during 2003. We also incurred approximately $1.5 million higher consulting expense during 2003 compared to 2004 for consulting services principally from our consulting agreements with a former director and a marketing consultant. These decreases were offset by an increase in selling, general and administrative expenses, including our costs associated with being a public company.

As discussed in Research and Development expenses, we are not able to extrapolate current general and administrative costs to our future costs. As our long-term business develops, we believe our general and administrative costs will increase with revenue growth. For example, to increase sales, an increase in marketing and sales expenditures will be required to broaden and expand our market awareness and penetration. We expect all costs associated with normal marketing and sales activities to increase including trade shows, advertising, promotion, and marketing and sales tools such as brochures and sales pamphlets. In addition, our current facility of approximately 4,000 square feet, will not meet our growth plans, and we will need to expand our facilities to accommodate new personnel, increased production and future research and development. Our general and administrative cost will rise accordingly, along with the associated costs such as utilities, taxes and maintenance. Over the long-term, as we become an established business, we anticipate that our costs will be comparable to other similar businesses of our size and type.

STOCK-BASED SETTLEMENT EXPENSE

During 2003, Tampa Bay Financial, Inc. exercised a right to purchase 4,763,662 shares of our common stock at a price of $0.05 per share. Because the fair market value of our stock was $0.082 at the date they exercised their right, we have recognized $152,437 of expense, the difference between the fair market value and the exercise price. This amount has been reflected as a settlement expense as this right was granted to Tampa Bay Financial in connection with the termination of their funding agreement. This expense did not recur in 2004.

INTEREST EXPENSE

For the year ended December 31, 2004, interest expense decreased significantly from $902,698 in 2003, to $81,429 in 2004. During 2004, we recorded interest expense of approximately $29,000 on related party notes and certain capital leases and $52,000 on the convertible debenture and related deferred financing fee. During 2003, we recorded interest expense of approximately $26,000 on related party notes and certain capital leases, $5,000 on the convertible debenture and related deferred financing fee and $872,000 for the issuance of our common stock for the payment of related party notes payable, at an agreed upon per share price which was less than the market price of our stock. We accounted for the difference between the stock issue price and the market price as interest expense.

During 2004, we will continue to incur interest on the related party note and the convertible debenture. We may elect to pay the remaining notes outstanding to Tony Frudakis with common stock. If we elect to do so, these payments will result in additional interest expense for the difference between the stock issue price and the market price at the date the common stock is issued. Our interest expense will decrease on our convertible debenture as the principal has been reduced during 2004.

INTRINSIC VALUE OF CONVERTIBLE DEBT AND NON-DETACHABLE WARRANTS

During 2003, we recorded $500,000 of expense to record the intrinsic value of the conversion feature of the convertible debt and non-detachable warrant. There was no such expense during 2004.

OTHER EXPENSES

Effective September 28, 2004, we entered into an Investment Agreement (the "Biofrontera Agreement") with Biofrontera AG, a German corporation ("Biofrontera") and the shareholders of Biofrontera to purchase certain Series B preferred shares of Biofrontera. This transaction was conditioned upon the effectiveness of a registration statement to be filed under the Securities Act of 1933 by us with respect to a financing agreement with Dutchess Private Equities Fund, II, L.P. The Biofrontera Agreement provided that if the registration statement did not become effective on or before February 7, 2005, either party had the ability to terminate the Biofrontera Agreement without liability. The registration statement had not become effective as of such date. After discussions with Biofrontera, on February 18, 2005, we exercised our right to terminate the Biofrontera Agreement. We expensed $293,007 of costs that related to this transaction.

During 2004, the Company paid $75,000 to George Frudakis (father of our Chief Scientific Officer and a shareholder of the Company) to pay the principal of approximately $45,000, accrued interest of approximately $4,000 and approximately $26,000 was recorded as other expense on our Consolidated Statements of Operations to satisfy in full any other claims related to his note and funding agreement.


LIQUIDITY AND CAPITAL RESOURCES
During 2004, our operating requirements generated negative cash flow from operations as we continue to engage in testing and development of our products. Our cash used by operating activities for the year ended December 31, 2004 was $3,764,425. We also invested in equipment, software and computers of approximately $57,000, had principal payments on capital lease obligations of approximately $66,000 and made principal note payments of approximately $83,000. The resulting cash shortfall was financed primarily through the exercise of non-detachable warrants, prepayment for future warrant exercises and proceeds from the issuance of Series A preferred stock.

Based upon our current plans, we will continue to focus on increasing market awareness of our products and developing sales for our currently available consumer and forensic products and to begin introductory marketing for our new products, EUROWitness(TM), RETINOME(TM) and EURO- DNA(TM). Our efforts are ongoing; however, it is difficult to predict what revenue stream, if any, they will generate.

Although consumer products and forensics are cornerstones of our technology, our single largest opportunity remains applying our technology for the benefit of patients. Management has developed and has begun to implement a global strategy for our growth and development in the pharmaceutical market. Our strategy is to partner certain specialized tasks rather than create them internally. Developing a pharmaceutical product is a long, complex and diverse mission. It requires a multitude of diverse scientific expertise and technologies. This is complicated further by recent FDA promulgations that we believe will compel the pharmaceutical industry to develop genetic specific drugs that are more efficacious.

As part of our development strategy during late 2004, we entered into a relationship with Biofrontera AG, a cutting edge genomics/pharmaceutical company based in Europe. This transaction was conditioned upon the effectiveness of a registration statement to be filed under the Securities Act of 1933 by us with respect to a financing agreement with Dutchess Private Equities Fund, II, L.P. The Biofrontera Agreement provided that if the registration statement did not become effective on or before February 7, 2005, either party had the ability to terminate the Biofrontera Agreement without liability. The registration statement had not become effective as of such date. After discussions with Biofrontera, on February 18, 2005, we exercised our right to terminate the Biofrontera Agreement and expensed $293,007 of costs associated with this deal.

Although the Biofrontera acquisition was terminated, the Company expects to use its $35 million dollar funding facility with Dutchess Equity Partners because of its previously stated goals and objectives to grow the business. The Company is currently seeking acquisition candidates that will meet criteria set out by the Board of Directors of the Company that include but are not limited to:

1. Positive Cash Flow
2. Profitable Operations
3. Market Recognition
4. Talented and Dedicated Staff
5. Complimentary Certifications that can include: American Society of Forensic Laboratory Directors, American Blood Bank Certification or Clinical Laboratory Certification or other complementary certifications that will help the Company expand its products, services and research and development into consumer, forensics and pharmaceutical applications.

In order to complete future acquisitions and to provide working capital for us, on September 28, 2004, we entered into an Investment Agreement and a Registration Rights Agreement with Dutchess Private Equities Fund, II, L.P., ("Dutchess", or the "Investor") a Delaware limited partnership. The agreement will require us to register a sufficient number of shares that we will then issue to Dutchess in return for up to $35 million in cash over a two-year period. The Company will be required to seek additional shareholder approval for a restructuring of the capital stock of the Company in order to use fully the Dutchess facility in order to continue operations and complete acquisitions.

We evaluated a number of other investment vehicles, including private placement through venture capital sources and concluded that not only were the terms and conditions prohibitive to our Company but they also brought high equity dilution. The Dutchess Agreement provided the lowest dilution (dependent upon our share price) with the fewest restrictions.

The Dutchess Agreement provides that we from time to time may deliver a notice to the Investor that will state the dollar amount of common stock that we desire the Investor to purchase. The maximum amount permitted pursuant to any such notice is $600,000, and we can give approximately three such notices per month. Upon receipt of the notice, the Investor is obliged to purchase the dollar amount of common stock set forth in the notice at a purchase price equal to 96% of the average of the two lowest closing bid prices of the common stock during the five trading days after the notice.

The obligation of the Investor to purchase under the Dutchess Agreement is contingent upon our filing and having declared effective a registration statement registering the resale of the shares by the Investor. Simultaneously, the parties entered into a Registration Rights Agreement requiring us to file such a registration statement. In addition, we are not permitted to provide a notice, and the Investor is not obliged to purchase any shares, in the event that we do not have sufficient authorized shares available for purchase to fulfill such commitment.

We do not expect our revenue stream to be sufficient to cover costs of operations in the immediate future. We anticipate that the funding we expect to receive from the minimum conversions of the outstanding debenture into common stock, the related exercise of the non-detachable warrants and the Dutchess agreement will fund our operating activities through 2005. The Dutchess agreement that we recently negotiated will provide up to $35 million in additional cash over a 24-month period to fund future acquisitions, if any, and provide operating cash flow. If our share price continues to remain weak; if our shareholders` do not approve an increase in capitalization when required; if the SEC S-2 registration is not completed, and if any number of adverse factors or . . .

[Pushi2]

Es ist so still hier ...

Kaufen!!!
Bei 0.001 USD
Alles oder nichts ;-)))

[Michiko]

Ich bin gerade ein wenig am "Stänkern" drüben in USA!

Es ist schon echt eine Unverschämtheit, wie DNAPrint rein informativ mit seinen Aktionären umgeht!

Aber vielleicht haben sie wirklich nichts zu sagen?!?

Zero content?

[Michiko]

Endlich mal etwas Bewegung, zumindest einige News:

DNAPrint genomics Obtains Exclusive License From Beth Israel Deaconess Medical Center, Harvard Affiliate, to Develop New Anemia Drug
4/5/2005 8:30:47 AM
Major Step Toward Transformation Into Genomics-Based Pharmaceutical Company

SARASOTA, Fla., April 5, 2005 /PRNewswire-FirstCall via COMTEX/ -- DNAPrint genomics, Inc. ( DNAP ) today announced that it has acquired an exclusive worldwide license from Harvard Medical School`s Beth Israel Deaconess Medical Center (BIDMC) to develop a new, more potent and longer-acting form of the anemia drug Erythropoietin (EPO).

The licensing agreement is part of an overarching strategy to utilize recent genomics and chemistry advances made by researchers at DNAPrint to develop next-generation drugs that maximize efficacy and minimize side effects by tailoring medication for specific individuals and well-defined population sectors.

The royalty bearing licensing agreement creates an opportunity for DNAPrint genomics to develop and market an improved "Super"- EPO. EPO is currently commercialized by several pharmaceutical companies for a worldwide market that exceeds $10 billion, and the EPO market is growing at an average annual rate of 21%. Leading participants in the existing monomer EPO market include Amgen, Johnson & Johnson and Roche.

EPO is a glycoprotein naturally made by the body to stimulate red blood cell production; the marketed forms are manufactured by recombinant DNA technology and are used to treat anemia or low blood cell count that results from a variety of illnesses and conditions. PT-401, the improved version of EPO licensed by DNAPrint, is an Erythropoietin dimer, or a double form of the natural protein.

"With the first pharmaceutical in our nascent drug pipeline, our Company is evolving into a genomics-based pharmaceutical company that develops innovative `theranostic` products, which blend genomics-based tests with drugs as products to target segments of the patient population for enhanced efficacy and reduced side effects," stated DNAPrint genomics Chief Executive Officer Richard Gabriel. "Everything we have done as a company up until this point -- aggressively introducing new tests, forging new markets, expanding the envelope of genomics expectations in the fields of forensics, consumer genomics and pharmacogenomics -- has made today`s announcement possible."

"DNAPrint genomics has taken a major step forward in establishing a drug pipeline that has the potential to provide the Company a significant opportunity for growth," stated Tony Frudakis, Ph.D., Founder and Chief Scientific Officer. "We are pleased that a prestigious organization such as Beth Israel Deaconess is embracing our innovative technology in the development of our first drug candidate."

"Starting immediately, we intend to devote a very significant proportion of our resources to fund and execute the PT-401 development program. EPO exhibits an element of variable response that DNAPrint management believes Company technology can help address. PT-401 will be coupled with a genetic test for predicting response and individualizing dosage, thereby providing personalized treatment," said Hector J. Gomez, MD, Ph.D., DNAPrint`s Chairman and Chief Medical Officer. "We believe we have made a wise choice in selecting PT-401 to apply our genomics expertise -- expertise which is not restricted to xenobiotic metabolism genetics but inclusive of far more complex gene-drug interactions."

"Our EPO technology has significant promise as a more powerful and commercially successful application of Erythropoietin," stated BIDMC`s Dr. Arthur J. Sytkowski, who holds patents related to the new "Super"-EPO. "We are pleased that DNAPrint has made a commitment to work with BIDMC in expanding the potential for this drug."

The human gene that produces EPO was cloned in 1985, and, in 1989, scientists at Amgen introduced to market a recombinant form under the trade name EPOGEN(R), a drug that many credit for the rise of Amgen in the 1990s as one of the world`s most successful biotechnology companies ever.

Patients undergoing certain therapies or with certain conditions are often rendered anemic, meaning their red blood cell count drops dramatically. Without adequate amounts of erythropoietin in the blood, red blood cells are not regenerated efficiently, and there are too few red blood cells to deliver oxygen sufficiently throughout the body. Erythropoietin has been approved by the U.S. Food and Drug Administration as a treatment for anemia associated with renal failure, cancer chemotherapy, zidovudine-treated HIV-infected patients and to reduce blood transfusion in surgery patients. Anemia leaves patients tired, often impairing their ability to work or perform even routine tasks and over the last decade, EPO has proven to improve quality of life and overall fitness of those patients.

In 1995, Dr. Sytkowski, Director for the Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology at Beth Israel Deaconess, was awarded the first in a string of eight patents covering methods of producing and using recombinant protein multimers with increased biological activity. In these patents, which are subject of the exclusive DNAPrint license announced today, Dr. Sytkowski described a new dimer (double) form of EPO -- "Super"-EPO, that elicited a heartier, more predictable hematocrit (red blood cell count) response, constituting a significant improvement over existing EPO technology.

About Harvard Medical School`s Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and ranks third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit http://www.bidmc.harvard.edu .

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company`s ANCESTRYby DNA(TM) is a consumer product for individuals interested in learning their family heritage. DNAWitness(TM) is a forensics market tool for analyzing DNA evidence recovered at a crime scene. DNAPrint is also developing products in the pharmacogenomic market including OVANOME(TM), a genomic-based diagnostic tool that matches ovarian cancer patients with the most suitable form and dose of chemotherapy, and STATINOME(TM), a test for the cardiac drug market to determine whether patients will be good or poor responders to statins, which are effective in cholesterol reduction. For more information about the company, please visit http://www.dnaprint.com .

Safe Harbor Provision

All statements in this press release that are not historical are forward- looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

[Michiko]

Vielleicht hat mein Gestänkere gestern Abend ja was bewirkt!

[babe_in_the_woods]

@Michiko

bitte weiter stänkern!

[babe_in_the_woods]

RT 0.0082 USD

+71%

[babe_in_the_woods]

RT 0.0074 / 14.6 Mio

[ge4teilter]

Kommt aber schon wieder runter:

Quote (del. 15 min.)
10:19 AM ET
0.0070
+0.0020 (+40.00 %)
Volume: 14,360,905

g4

[babe_in_the_woods]

RT 0.0076 / 27 Mio

[Michiko]

BTW

Achtet mal auf den Kursverlauf!

[Michiko]

Interessanter Kursverlauf heute bei DNAP!

[ge4teilter]

Quote (del. 15 min.)
9:53 AM ET
0.0109
+0.0020 (+22.22 %)
Volume: 7,814,848
- - - - -
Full quote | LiveChart

[Der Papst]

Hallo DNAP-ler,

seit Tagen steigt die Aktie nach den guten Meldungen. Darf man fragen wie weit der Kurs nach eurer Einschätzung noch laufen kann, denn er war auch in der letzten Zeit sehr verprügelt worden. Besitze eine kleine Positon und die schon sehr lange. Vielen Dank im voraus.

Amen

Der Papst

[Optimierer]

Hallo,

DNAP hat es nicht geschafft, seinen Schrott kapitalistisch zu verkaufen, da sind zu viele Unfähige am Werk.
Frukadis ist vielleicht ein guter Wissenschaftler, aber das wars dann auch schon, sonst ein geborener Loser.

Unfähig und geistig Insolvent, muß er jetzt seinen Schrott verscherbeln...!!

Gruß

Optimierer

[ge4teilter]

Optimierer,

vielleicht solltest Du erstmal Deine Umgangs- und Ausdrucksformen optimieren, bevor Du uns hier mit Deinen fundierten Informationen heimsuchst.

g4

[Optimierer]

Hi ge4teilter,

wer will schon gern die Wahrheit hören.....!!

Wenn Du "DNAP" die letzten Jahre verfolgt hast, dann mußt Du doch erkannt haben, dass Frukadis vielleicht ein guter Wissenschaftler aber ein schlechter Kaufmann war und ist.
Jetzt hat er ein Kaufmann eingestellt und trotzdem geht der Kurs den bach runter, man kann vieles schön reden und sich selbst belügen aber die Realität sieht halt doch anderst aus und kann man bei einer AG halt am Kurs ablesen !!!

Und schließlich ist das doch nicht der Stein der Weißen, was Frukadis entdeckt hat.....!!!

Das Geld, was Frukadis mit seinen Patenten verdient, reicht ja nicht einmal für sein Solär. Er muß ja immer wieder seine Aktiendruckmaschine anwerfen um an Kohle zu kommen.

Das ist wie bei Mark Hofmann dem Exträumer von Commerceone,
Realitätsfremd und Größenwahnsinnig, ein möchtegern Bill Gates.

Gruß Opti....

[ge4teilter]

@ Optimierer: Na siehste ... geht doch!

Ich stimme übr. mit Dir überein, dass Frudakis nicht den Stein der Weißen entdeckt hat. Wenn, dann wäre es der Stein der Weisen gewesen und wenn der Stein keine Eltern mehr gehabt hätte hätte es auch der Stein der Wisen gewesen sein können.

Während Du Dich als Optimierer siehst würde ich mich eher als Optimisten gesehen wollen und als solcher hoffe ich nach wie vor, irgendwann mit meinem DNAP-Investment Geld zu verdienen!

Gruß ... g4

[ge4teilter]

Ich meinte natürlich den Stein der Waisen - sorry!

[ge4teilter]

P.S.:

11:01 AM ET
0.0120
+0.0020 (+20.00 %)
Volume: 8,311,264
- - - - -
Full quote | LiveChart

[ge4teilter]

Und hey ..... noch 800% und ich bin wieder auf Null!!!

Wenn das kein Grund zur Freude ist!

g4

[Der Papst]

Hallo dnapler,

warum kann mir keiner antworten, war meine Frage zu dumm?

Amen

Der Papst

[ge4teilter]

Na, wenn Du es schon nicht weißt .....

[Der Papst]

Hallo ge-4-teilter,

heißt deine Antwort jetzt ich muss dich noch zweimal bitten mir zu antworten. Möchtest du das? Mir scheint das du hier die meiste Ahnung von DNAP hast, denn nach deinem Post ( noch 800 % dann auf Null ) vermute ich einmal ist die Aktie dir ans Herz gewachsen. Also, lass dich nicht zu sehr bitten!!

Amen

Der Papst

[ge4teilter]

Heiliger Vater,

ich bin hier schon seit 2000 oder so investiert, habe für meine ersten Shares sage und schreibe 58 Cent (!) bezahlt und mich über die Jahre auf einen Einstiegspreis von 10 bis 11 Cent runtergekauft. Jegliche Vermutung über die Entwicklung dieser Aktie ist bislang stets komplett in die Hose gegangen. Das hier ist Biotechnologie, da passiert entweder was oder nicht. Wenn Du einen Totalverlust verschmerzen kannst, dann kauf ruhig ein paar. Du kannst zwar 100% verlieren, aber viele hundert % gewinnen! Na,ist das kein Geschäft?

g4

[ge4teilter]

OTCBB / Pinks / hoch / runter / hüü / hott ......



Man kann ja sagen was man will, aber ein langweiliges Investment ist das nun wahrlich nicht!

Nerven behalten!

Gruß ... g4

[kaliho]

genau... erst hiess es pink, dann stellte sich raus das war ein fehler. mal sehen wie sich der kurs heute in den USA entwickelt.

[Michiko]

Pech, wenn gestern einer in Panik geschmissen hat.

Heute schon wieder gut 20% hoch bis jetzt!

Michi

[ge4teilter]

Michi,

wie gesagt: Langweilig ist es zumindest nicht ........... nur ein teurer Spaß!

g4

[Michiko]

g4

. . . und irgendwann auch mal ein lukrativer Spaß = doppelter Spaß!

[ge4teilter]

Wahrscheinlich glaubt mir jetzt keiner, aber bei 0.004 hatte ich doch tatsächlich an´s Nachkaufen gedacht

Man sollte doch öfters auf seine Intuition hören
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

(wenn´s nur nicht so oft schon so teuer gewesen wäre!)

Gruß ... g4

[Michiko]

g4,

das mit der Intuition ist so ne Sache.

Nachdem sie von 0,004 auf 0,008 gestiegen waren, habe ich einen Großteil meiner shares verkauft in der Gewissheit: Sehr bald kommen sie wieder runter; wie schon so oft.

P U S T E K U C H E N ! !

Ergo: Bei 0,12 habe ich wieder rückgekauft

[hvs1]

Hallo G4,
hallo Michi,

halte meine Shares (3M ) ohne wenn und aber!Einstandskurs
ca. 0,028

Gruß hvs1

[Michiko]

hvs1

nur die Harten . . .

. . . kommen in den Garten!

Werde ich mich auch abhärten müssen!

[ge4teilter]

@ Michiko:
Ergo: Bei 0,12 habe ich wieder rückgekauft

0,12? Glaub ich Dir nicht!


Gruß g4

[Michiko]

g4,

wenigstens einer, der aufpasst! Weiter so

Gruß

[Menglovator]

+37,50 % !

Was ist nun los ?

[Menglovator]

Heute 62% plus.

Da bin ich ja mal auf nächste Woche (News?) gespannt.

http://www.benecke.com/gendna.html

[Menglovator]

Letzte DNAPrint Press Releases April 05, 2005 siehe hier:

http://www.dnaprint.com/2003/pressreleases/pr_04_05_05.htm

[Menglovator]

DNAPrint genomics to Discuss Role of Biological Ancestry In Criminal Investigations at International Web Symposium
Wednesday April 13, 8:30 am ET


SARASOTA, Fla., April 13 /PRNewswire-FirstCall/ -- DNAPrint(TM) genomics, Inc. (OTC Bulletin Board: DNAP - News) announced today that the Company will make a presentation covering the role of biological ancestry in criminal investigations at the Human Identification E-Symposium International Web Conference (HumID) at 3:30 p.m. Eastern time on Thursday, April 14.
DNAPrint Forensics Technical Coordinator Zach Gaskin will specifically focus on applying the Company`s DNA technology to forensics investigations.

"The worldwide HumID symposium will be an excellent forum for raising awareness among law enforcement officials for our DNAWITNESS(TM) forensics technology," said Mr. Gaskin. "DNAWITNESS(TM) is the only testing method available with predictive capabilities for identifying the percentage of a person`s genetic makeup from DNA recovered at a crime scene. And because it narrows the search for potential DNA donors, it can reduce costs and the time needed to identify and question a person of interest."

Law enforcement and forensics professionals can participate in a live question-and-answer session with Mr. Gaskin and other leading industry experts by registering for the conference at http://www.humid.e-symposium.com/speaker-program.php . All presentations and roundtable discussions at the symposium will be archived on the web site for one year. The symposium is sponsored by the Forensic Institute, based in London.

DNAPrint genomics also announced that Mr. Gaskin will discuss the science behind DNAWITNESS(TM) and case studies involving the product`s application during a presentation to the Florida Homicide Investigators Association meeting in Cocoa Beach, Fla., on Friday, April 15.

The technology behind DNAWITNESS(TM) has proven useful in allowing forensics investigators to "paint" physical descriptions of a potential crime scene suspect. Using DNA samples lifted from a crime scene, DNAWITNESS(TM) can identify the percentage of a person`s genetic makeup among four possible groups -- Sub-Saharan Africa, Native American, East Asian and Indo-European. The recent addition of four additional sub-groups including Northern European, Middle Eastern, Mediterranean and Indo, plus the addition of a predictive test for eye color, make this combined technology unique for criminal detective work.

Mr. Gaskin will describe how DNAWITNESS(TM) assay and associated digital photograph databases constitute a unique forensics product that has been utilized over the past two years in high profile murder cases in the United States, including the Louisiana serial killer and two California slayings -- the Concord Trail Side murder and the Mammoth Lakes murder probe. DNAWITNESS(TM) currently is being utilized in 80 other investigations worldwide.

DNAPrint genomics is continuing to make advances with its technology and recently introduced a DNAWITNESS(TM) test kit, which simplifies the process by enabling forensics experts to conduct their own tests in their own facilities without sending recovered DNA back to the Company for analysis.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company`s ANCESTRYbyDNA(TM) is a consumer product for individuals interested in learning their family heritage. DNAWitness(TM) is a forensics market tool for analyzing DNA evidence recovered at a crime scene. DNAPrint is also developing products in the pharmacogenomic market including OVANOME(TM), a genomic-based diagnostic tool that matches ovarian cancer patients with the most suitable form and dose of chemotherapy, and STATINOME(TM), a test for the cardiac drug market to determine whether patients will be good or poor responders to statins, which are effective in cholesterol reduction. For more information about the company, please visit http://www.dnaprint.com .

Safe Harbor Provision

All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


Company Contact:
Richard Gabriel
President and CEO
941-366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848

[Menglovator]

Vielleicht ist der Anstieg hier zu suchen.

23.02.2005 16:23
DNAPrint genomics Introduces New Product for Law Enforcement
SARASOTA, Fla., Feb. 23 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (BULLETIN BOARD: DNAP) today announced the introduction of its new DNAWitness(TM) testing kit utilizing the Company``s proprietary DNAWitness(TM) forensics technology for the law enforcement market, the only testing method available with predictive capability that can identify the percentage of a person``s genetic makeup.

"The kit is a natural progression of the Company``s DNAWitness(TM) testing service, which previously was only performed at DNAPrint``s Sarasota laboratory, and will enable forensics experts to conduct their own tests in their own facilities," stated Richard Gabriel, the Company``s President and Chief Executive Officer. "We anticipate that by making DNAWitness(TM) directly available to law enforcement agencies, the kit will lead to more rapid integration of our technology into the global forensics market and we expect it to be a significant revenue source for the Company. At the same time, we will continue to build on our established DNAWitness(TM) custom services at our own facilities to clients who prefer to outsource their DNA laboratory work."

DNAWitness(TM) forensics technology analyzes DNA recovered at a crime scene and provides the percentage of Bio-Geographical Ancestry (BGA) makeup among four possible genetic groups -- Sub-Saharan Africa, Native American, East Asian and Indo-European, narrowing the list of potential suspects that investigators are seeking in connection with a crime.

"The kit puts the power of DNAPrint``s forensics technology directly into the hands of local crime scene investigators," stated Zach Gaskin, DNAPrint``s Technical Coordinator of Forensics. "It also is a valuable time- and cost- saving investigative tool because it reduces the number of false leads that detectives normally would have to chase. In addition, many forensics laboratories want to keep control of their crime scene samples in order to maintain a chain of custody for evidence in order to reduce challenges in court."

The kit, officially introduced on Tuesday at the American Academy of Forensic Science meeting in New Orleans, La., is the first of its kind developed for the consumable test kit market and contains all of the reagents and protocols required for forensics laboratories around the world to perform their own ancestry analysis. Proprietary on-line software systems provided by DNAPrint(TM) are expected to enable investigators to interpret their results and relate them to the likely anthropometric (physical) features of a would-be suspect by referencing DNA samples to DNAPrint``s proprietary ancestry databases.

The DNAWitness(TM) kit can be utilized on capillary electrophoresis (CE) instruments commonly found in forensic and university laboratories. Starting this week, the kit will be entering beta testing at select forensics laboratories. After the testing phase, which is expected to take three to four months, the Company intends to build an inventory of kits for its distributor network and its own sales force for sale to the forensics market. The Company``s testing services are available for the screening of a large number of samples or individual samples, until and even after the kit is available; investigators, forensic scientists and medical examiners need not wait until the kit is available to access this powerful new technology.

DNAPrint(TM) introduced DNAWitness(TM) technology to the law enforcement community in early 2003 and immediately gained national attention when it was credited with assisting in the apprehension of a suspected serial killer in Louisiana. It currently is aiding law enforcement agencies in more than 80 criminal investigations in the United States, United Kingdom, Australia and Canada.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company``s ANCESTRYby DNA(TM) is a consumer product for individuals interested in learning their family heritage. DNAWitness(TM) is a forensics market tool for analyzing DNA evidence recovered at a crime scene. DNAPrint is also developing products in the pharmacogenomic market including OVANOME(TM), a genomic-based diagnostic tool that matches ovarian cancer patients with the most suitable form and dose of chemotherapy, and STATINOME(TM), a test for the cardiac drug market to determine whether patients will be good or poor responders to statins, which are effective in cholesterol reduction. For more information about the company, please visit http://www.dnaprint.com/ .

Safe Harbor Provision

All statements in this press release that are not historical are forward- looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint``s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint``s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Company Contact: Richard Gabriel President and CEO 941-366-3400 -or- Ron Stabiner The Wall Street Group, Inc. 212-888-4848

DNAPrint genomics

[Menglovator]

SARASOTA -- DNAPrint genomics plans to pump a little iron into its financial future.


The company has a deal with Beth Israel Deaconess Medical Center in Boston, an affiliate of Harvard Medical School, to develop a longer-acting and more effective drug to treat people with anemia.

It`s a major step for Sarasota-based DNAPrint genomics (OTCBB: DNAP), a biotech firm focused on human genome sciences, which lost $3.3 million on revenue of $785,000 in 2004, most of that from sales of genetic testing products and services to law enforcement agencies.

The deal with Beth Israel puts DNAPrint squarely in the national pharmacogenomics market, developing drugs tailored to an individual`s genetic makeup.

The announcement of the deal caused the trading volume to swell and the stock price of DNAPrint to double, from about a half-penny a share on the day before the April 5 announcement to a close of 1.12 cents on April 11.

Richard Gabriel, president and CEO of DNAPrint, didn`t want to say how much potential revenue the company might get from the agreement, which calls for Beth Israel to license to DNAPrint patents for a newer form of the anemia drug erythropoietin (EPO). But there`s a $10-billion market for EPO, currently made by pharmaceutical giants Amgen, Johnson & Johnson and Roche, and sold under the brand names Epogen and Procrit in the United States, Gabriel said.

Terms of the deal
DNAPrint will develop, market and sell products derived from the patents licensed from Beth Israel.

DNAPrint paid Beth Israel a $25,000 signing fee and agreed to make payments tied to key benchmarks totaling $2.2 million, according to an April 8 Securities and Exchange Commission filing.

DNAPrint also agreed to pay an annual royalty of up to 4 percent of the new sales of all products developed from the licensed technology, with a minimum royalty payment of $100,000 a year.

"We`re a medical center. We discover and invent things," said Dr. Arthur Sytkowski, the Beth Israel physician behind the patents. "We look for a commercial enterprise to develop that into a therapeutic or diagnostic or procedural protocol to help patients. That has to be done by a company willing to invest the money."

Development costs for the advanced form of EPO are $15 million to $25 million, Gabriel estimated.

The company plans to tap into a $35 million investment commitment it received last fall from Dutchess Private Equities Fund L.P., as well as proceeds from a pending stock offering, which could raise up to $3.6 million. Gabriel said DNAPrint also would look for pharmaceutical partners for the project.

Enhancing the zing
The FDA has approved EPO to treat patients with anemia associated with renal or kidney failure, cancer chemotherapy and some cases of HIV, as well as those needing blood transfusions after surgery. The drug is effective, but has to be injected two or three times a week, Sytkowski said.

"Patients and physicians are looking for ways to prolong the action of the drugs so the injections can be given less frequently," he said. "It`s more convenient, and we believe we`ll get more compliance if they only have to get it once every two weeks."

Sytkowski began working on a longer-acting drug, one with "enhanced zing," several years ago.

DNAPrint will develop a drug based on those findings, while also using its genetic expertise to help the small group of people resistant to EPO treatment.

"We know from other drug studies that groups of people have certain small genetic differences that cause them to metabolize a drug differently," Sytkowski said. "DNAPrint thinks they may be able to derive a diagnostic test that would predict EPO resistance."

DNAPrint, with 12 employees, already is working on a different diagnostic test -- one to predict how cancer patients will respond to various chemotherapies -- with the H. Lee Moffitt Cancer Center & Research Institute in Tampa.

[e-mail] | 813.342.2473

[hvs1]

Es kommt ja wieder etwas Bewegung in die Aktie.
Meine 3M sind ja schon wieder etwas wert.
Mal sehen,was Montag kommt.

Gruß hvs1

[Timburg]

@hvs1

Wieviele Aktien sind denn insgesamt ausgegeben??

Thx TB

[hvs1]

Timburg

Restricted Shares 158.365.209,- am 21.04.05

Gruß hvs1

[Michiko]

hvs1

ich sehe einen Tunnel am Ende des Lichts (oder war das umgekehrt? )

Schönes WE

Michi

[Timburg]

@hvs1

Danke. Muss mir mal übers WE Eure Diskussionen hier durchlesen, hab mich noch nie mit der Aktie befasst.

Gruss TB

[Timburg]

Sorry dass ich nochmals störe, hvs, handle aber selten mit US-Pennystocks. Sind es nun 158 Mill. wie von Dir gespostet?? Hab nämlich zum 31.12.04 irgendwas von 707 Mill. gefunden ???


For the Year For the 1998 (date of
Ended Year Ended inception) to
December 31, December December 31,
2004 31, 2003 2004
------------- ------------- -------------
<S> <C> <C> <C>
SALES $ 785,632 $ 709,638 $ 1,766,208

COST OF SALES 507,927 432,224 1,113,027
------------- ------------- -------------

GROSS PROFIT 277,705 277,414 653,181
------------- ------------- -------------

OTHER OPERATING EXPENSES:
Research and development 1,561,142 2,654,259 8,645,667
Selling, general and administrative 2,050,981 3,857,925 7,899,936
------------- ------------- -------------
Total other operating expenses 3,612,123 6,512,184 16,545,603
------------- ------------- -------------

LOSS FROM OPERATIONS (3,334,418) (6,234,770) (15,892,422)
------------- ------------- -------------

OTHER INCOME (EXPENSE):
Sale of option to Orchid Biosciences -- -- 353,090
Loss on disposal of investments -- -- (349,006)
Stock-based settlement expense -- (152,437) (152,437)
Interest expense (81,429) (902,698) (1,467,857)
Intrinsic value of convertible debt and non-detachable
warrants -- (500,000) (500,000)
Other expenses (319,135) -- (365,905)
------------- ------------- -------------
Total other income (expense) - net (400,564) (1,555,135) (2,482,115)
------------- ------------- -------------

NET LOSS $ (3,734,982) $ (7,789,905) $ (18,374,537)
============= ============= =============

NET LOSS PER SHARE - Basic and Diluted $ (.01) $ (.02) $ (.04)
============= ============= =============

SHARES USED IN COMPUTING NET
LOSS PER SHARE - Basic and Diluted 707,474,628 499,603,483 445,343,852
============= ============= =============
</TABLE>
See notes to consolidated financial statements

<PAGE>

Wie gesagt, hab zwar schon häufig US-Werte gehandelt, aber noch nie OTCBB-Werte, darum will ich mich da erstmal etwas umhören. Und für die MK spielt es schon eine Rolle, ob nun tatsächlich 150 Mill. oder 707 Mill. Aktien ausgegeben sind.

PS: mit Deinen 3 Mill. müsstest ja bei den Top-Holders auftauchen. Da ist Frudakis mit 30 Mill. und als nächstes eine FCA Corporation mit 100k

TB

[Michiko]

Timburg

Ich weiß nicht, ob Dir meine Infos helfen, ich versuch es einfach mal. hvs1 hat Dir nur die Anzahl der restricted shares genannt. Warum? Das weiß ich auch nicht.

Folgendes habe ich aus der Homepage von DNAP entnommen:
Common stock, $.01 par value, 1,500,000,000 shares authorized; 7,839,046 5,238,986
783,904,632 and 523,898,635 shares issued and outstanding, respectively

Aber vielleicht schaust Du besser mal selbst nach.

Link: http://www.sec.gov/Archives/edgar/data/1127354/0001144204050…

Die Homepage von DNAP kennst Du vermutlich schon. Falls nicht: http://www.dnaprint.com/

Gruß Michi

[Blackjack2000]

Hi @all

vom RB Board

By: wishbone115
20 Apr 2005, 04:40 PM EDT
Msg. 329489 of 329848
Jump to msg. #
Outstanding Shares = 1,090,893,175 as of 4-20-2005
- - - - -
View Replies »


Gruß

Blackjack

[Timburg]

Danke, Michiko & Blackjack

Ich denke schon, dass es mit den 1 Mld. Shares einigermaßen hinkommt.

Hatte nämlich am Anfang des Threads etwas von 400Ml. Aktien gelesen, dies mal 0,01 wären ca. 4 Mill. MK gewesen und darum bin ich überhaupt auf die Aktie aufmerksam geworden. Aber da anscheinend von den 1,5MLD. genehmigten Aktien laufend neue ausgegeben werden, dürfte die aktuelle MK bei ca. 16 Mill. Dollar liegen. Ist zwar nicht zuviel, falls die Company die Wende schafft.

Aber wenn ich in einen solchen Wert investiere, dann nur in der Hoffnung auf einige 100% (für 30-50% bleib ich bei meinen dt. Nebenwerten) und dann sind wir bei DNA schon bei 50-70 Mill. MK und dafür muss die Firma entschieden mehr tun als bisher.

Ich werde das Ganze jetzt erstmal von der Seitenlinie verfolgen, wünsche allen Investierten aber trotzdem viel Glück

TB

[hvs1]

Timburg,

ich entschuldige mich,habe geglaubt Dir beide Werte
durchgegeben zu haben.Restricted and Outstandig Shares.

Michi und Blackjack haben ja schnell reagiert.

Michi, Licht am Ende des Tunnels wäre mir lieber!

hvs1

[calibra21]

Das randvolle Orderbuch(auf der Bidseite) stimmen mich äußerst positiv. Morgen dürfte die 0,17 Marke ebenfalls fallen.

Time MMID Size Bid
15:57 SCHB 50 0.015
15:56 NITE 50 0.015
14:43 PERT 50 0.015
15:01 SACM 50 0.014
12:54 ETRD 50 0.014
12:43 HDSN 50 0.014
12:56 WAXM 50 0.014
14:06 VFIN 50 0.014
14:35 JEFF 50 0.014
15:03 BMIC 50 0.014
15:04 TDCM 50 0.014
15:54 SEAB 50 0.014
18:01 BEST 50 0.014
13:19 PUGS 50 0.013
13:35 DOMS 50 0.012
11:46 AGIS 50 0.011
15:01 SBSH 50 0.011
07:30 FRAN 50 0.010
07:57 ABLE 50 0.010
12:50 VERT 50 0.010
11:03 VIEW 50 0.0091
13:20 HILL 50 0.009
07:30 TASL 50 0.005
07:30 MAXM 50 0.004
07:30 STCS 50 0.001
07:30 VNDM 50 0.001
12:51 FLCR 50 0.001
07:30 DATA 0 0.000
07:30 TRAC 0 0.000
16:01 GNET 0 0.000

Ask Size MMID Time
0.016 50 NITE 15:56
0.016 50 SBSH 15:01
0.017 50 JEFF 14:35
0.017 50 SCHB 15:57
0.018 50 MAXM 07:30
0.018 50 ABLE 07:57
0.018 50 ETRD 12:54
0.018 50 HILL 13:20
0.018 50 VFIN 14:06
0.019 50 TDCM 15:04
0.02 50 FRAN 07:30
0.02 50 VNDM 07:30
0.02 50 VIEW 11:03
0.02 50 AGIS 11:46
0.02 50 HDSN 12:43
0.02 50 VERT 12:50
0.02 50 WAXM 12:56

[Michiko]

Timburg

Danke für Deine guten Wünsche.

Dir wünsche ich, dass Du nicht beim Zuschauen an der Seitenlinie plötzlich nur noch die Auspuff-Gase schnupperst und der Rakete hinterherschauen musst.

Mir wünsche ich, dass genau dies passiert!

No risk - no fun

Michi

[Menglovator]

Schaumer mal, was der morgige Tag bringt.

[calibra21]

Bei 0,014 u. 0,015 finden sich soviele Käufer. Bei 0,016 sowie auch bei 0,017 nur wenige Verkäufer. Gut möglich das wir heute sogar die 0,02$ Marke sehen. Eines dürfte sicher sein. Unter 0,013 € (Frankfurt) oder 0,016$ (USA)kommt man heute nicht mehr rein.

[Menglovator]

Ich habe mir eben nochmal die Patente angesehen :

http://www.dnaprint.com/2003/technology/ip.html

Wenn eine News, dann innerhalb der nächsten 3 Tage - oder ?

[Michiko]

Wenn man illwill vom IHub-Board Glauben schenkt (und er hat schon des öfteren das Richtige prognostiziert), dann kommen in den nächsten drei oder vier Tagen News.

[Menglovator]

Michiko,

hoffen wir, dass es so kommen wird

http://www.dnaprint.com/index.html

[titin]

erste vorbörsliche kurse.....


PLUS!!!!!

0,016-0,017

[Menglovator]

Welcome [Sign In] To track stocks & more, Register
Financial News
Enter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup


Press Release Source: DNAPrint genomics, Inc.


DNAPrint genomics to Discuss Role of Biological Ancestry In Criminal Investigations at International Web Symposium
Wednesday April 13, 8:30 am ET


SARASOTA, Fla., April 13, 2005 /PRNewswire-FirstCall/ -- DNAPrint(TM) genomics, Inc. (OTC Bulletin Board: DNAP - News) announced today that the Company will make a presentation covering the role of biological ancestry in criminal investigations at the Human Identification E-Symposium International Web Conference (HumID) at 3:30 p.m. Eastern time on Thursday, April 14.
DNAPrint Forensics Technical Coordinator Zach Gaskin will specifically focus on applying the Company`s DNA technology to forensics investigations.

"The worldwide HumID symposium will be an excellent forum for raising awareness among law enforcement officials for our DNAWITNESS(TM) forensics technology," said Mr. Gaskin. "DNAWITNESS(TM) is the only testing method available with predictive capabilities for identifying the percentage of a person`s genetic makeup from DNA recovered at a crime scene. And because it narrows the search for potential DNA donors, it can reduce costs and the time needed to identify and question a person of interest."

Law enforcement and forensics professionals can participate in a live question-and-answer session with Mr. Gaskin and other leading industry experts by registering for the conference at http://www.humid.e-symposium.com/speaker-program.php . All presentations and roundtable discussions at the symposium will be archived on the web site for one year. The symposium is sponsored by the Forensic Institute, based in London.

DNAPrint genomics also announced that Mr. Gaskin will discuss the science behind DNAWITNESS(TM) and case studies involving the product`s application during a presentation to the Florida Homicide Investigators Association meeting in Cocoa Beach, Fla., on Friday, April 15.

The technology behind DNAWITNESS(TM) has proven useful in allowing forensics investigators to "paint" physical descriptions of a potential crime scene suspect. Using DNA samples lifted from a crime scene, DNAWITNESS(TM) can identify the percentage of a person`s genetic makeup among four possible groups -- Sub-Saharan Africa, Native American, East Asian and Indo-European. The recent addition of four additional sub-groups including Northern European, Middle Eastern, Mediterranean and Indo, plus the addition of a predictive test for eye color, make this combined technology unique for criminal detective work.

Mr. Gaskin will describe how DNAWITNESS(TM) assay and associated digital photograph databases constitute a unique forensics product that has been utilized over the past two years in high profile murder cases in the United States, including the Louisiana serial killer and two California slayings -- the Concord Trail Side murder and the Mammoth Lakes murder probe. DNAWITNESS(TM) currently is being utilized in 80 other investigations worldwide.

DNAPrint genomics is continuing to make advances with its technology and recently introduced a DNAWITNESS(TM) test kit, which simplifies the process by enabling forensics experts to conduct their own tests in their own facilities without sending recovered DNA back to the Company for analysis.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company`s ANCESTRYbyDNA(TM) is a consumer product for individuals interested in learning their family heritage. DNAWitness(TM) is a forensics market tool for analyzing DNA evidence recovered at a crime scene. DNAPrint is also developing products in the pharmacogenomic market including OVANOME(TM), a genomic-based diagnostic tool that matches ovarian cancer patients with the most suitable form and dose of chemotherapy, and STATINOME(TM), a test for the cardiac drug market to determine whether patients will be good or poor responders to statins, which are effective in cholesterol reduction. For more information about the company, please visit http://www.dnaprint.com .

Safe Harbor Provision

All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

[titin]

nun schon 0,017-0,018!!!!

WAHNSINN!!!!!

[titin]

WOW!!!

0,0185....+23,33!!!!

[ge4teilter]

Geht gut ab - bin mal gespannt!

Quote (del. 15 min.)
9:32 AM ET
0.0189
+0.0030 (+20.00 %)
Volume: 1,104,431

[Michiko]

Klasse!

Nach ner halben Stunde sind schon 6 Millionen shares über die Theke gegangen.

Der zweite Cent ist nahe!

[ge4teilter]

Joooooo .... und dann nur nochmal 500% und ich bin wieder in den schwarzen Zahlen!

[Menglovator]

#361 von ge4teilter ,

die 500 % plus X gönne ich Dir.

[ge4teilter]

Menglovator,

das ist sehr nett von Dir! Aber wenn´s denn nicht klappt ist´s auch nicht schlimm, denn wir wissen doch: Geben ist seliger denn nehmen!

Ich habe das Geld seit einiger Zeit ohnehin so gut wie abgeschrieben und freue mich daher über jeden upmove!

g4

[Michiko]

g4,

jetzt mal langsam mit dem Abschreiben.

Wir haben jetzt eine Vervierfachung!!! des Kurses innerhalb von nur drei Wochen!

Da ist noch so manche Überraschung drin.
Hoffentlich nach oben.

[ge4teilter]

25 Apr 2005, 10:06am ET

Last price:0.0197
0.0047 or (31.33%)

[Michiko]

Press Release Source: DNAPrint genomics, Inc.


DNAPrint genomics CEO Richard Gabriel Interviewed by Wall Street Transcript
Monday April 25, 10:21 am ET


SARASOTA, Fla.--(BUSINESS WIRE)--April 25, 2005--The Wall Street Transcript has published an in-depth interview with Richard Gabriel, President and Chief Executive Officer of DNAPrint(TM) genomics, Inc. (OTCBBNAP - News), in which he discusses how the Company is applying its proprietary DNA technology to the development of new drugs, as well as the law enforcement and consumer markets.
The interview is available free on line at the Transcript`s Web site (www.twst.com/ceos.htm).

Mr. Gabriel provides examples of how DNAPrint genomics` DNAWITNESS(TM) forensics technology for the law enforcement market is utilized in crime scene investigations. He also went into detail about the Company`s ANCESTRYbyDNA(TM) product for the consumer market, which targets individuals who want to trace their family heritage.

Mr. Gabriel also discussed the Company`s recently announced exclusive worldwide license from Harvard Medical School`s Beth Israel Deaconess Medical Center (BIDMC) for a project to develop a new, more potent and longer acting form of the anemia drug Erythropoietin (EPO), which currently has a worldwide market that exceeds $10 billion.

"Our goal is to develop and market a `Super`-EPO, a more powerful form of the drug," Mr. Gabriel said. "This is a perfect fit within the Company`s overarching strategy to utilize recent genomics and chemistry advances made by our researchers to develop next-generation drugs that maximize efficacy and minimize side effects by tailoring medication for specific individuals and well-defined population sectors."

The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800-246-7673.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company`s ANCESTRYby DNA(TM) is a consumer product for individuals interested in learning their family heritage. DNAWitness(TM) is a forensics market tool for analyzing DNA evidence recovered at a crime scene. DNAPrint is also developing products in the pharmacogenomic market including OVANOME(TM), a genomic-based diagnostic tool that matches ovarian cancer patients with the most suitable form and dose of chemotherapy, and STATINOME(TM), a test for the cardiac drug market to determine whether patients will be good or poor responders to statins, which are effective in cholesterol reduction. For more information about the company, please visit www.dnaprint.com.

Forward Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

[Michiko]

. . . und schaut Euch auch DAS mal an, von Gabriel:

http://www.twst.com/ceos/ABN618.htm

[Michiko]

Zitat Gabriel:

"the goal is to boost shareholder value. I myself am a shareholder. "

[Menglovator]

RICHARD GABRIEL - DNAPRINT GENOMICS INC (DNAP)
CEO Interview - published 04/25/2005

DOCUMENT ABN618

RICHARD GABRIEL is President and Chief Executive Officer of DNAPrint_
genomics, Inc. Mr. Gabriel served as President and Chief Executive
Officer of Calix Corp., parent company to Pharm-Eco Laboratories, Inc.,
from 1998 to 2001. He was instrumental in closing and managing more than
$135 million in contract revenue for Pharm-Eco Laboratories and
successfully completed the formation of numerous joint ventures, limited
liability companies and spin-offs that resulted in several public and
private companies in the genetics/chemistry/pharmaceutical field. From
2001 until joining DNAPrint, Mr. Gabriel consulted for several startup
companies while working as a Partner at Genbiomics, LLC, and as head of
Life Sciences Practice at Semaphore, Inc. Prior to the formation of his
own consulting practice in 1985, he was a Product Manager for W.R.
Grace. Mr. Gabriel obtained his MBA from Suffolk University`s Executive
MBA Program, Boston, Massachusetts, in 1985, and a BS in Chemistry from
Ohio Dominican College, Columbus, Ohio, in 1978.

Sector: BIOTECHNOLOGY

TWST: Would you give us an overview of DNAPrint_ genomics and how you
conceptualize the company at this point?


Mr. Gabriel: Dr. Tony Frudakis founded the company in 1999. Tony is a
geneticist who has worked in the field all his life, and it was while
working for another company that he had some different ideas about how
genetics could be applied, especially in the pharmaceutical area. So he
decided to start his own company. I came on in 2003 with the goal of
staying focused on Tony`s vision. At the time Tony formed the company,
the pharmaceutical industry was trying to determine how genetics could
be applied in developing drugs. A lot of companies were gathering
information on what they consider to be isolated populations that were
relatively `pure.` Tony sensed that there was a problem with this. The
so-called `pure` populations, based on his analysis, showed admixtures
of populations that had different origins, and came from different
regions of the world. For instance, Icelanders have anywhere from 5%-20%
East Asian in them. Now, when you look at an Icelander, you wouldn`t
automatically think that person is from East Asia. As a matter of fact,
those genes are probably inherited from the Mongol invasion, which
occurred in the 12th century. So once the genes are inherited through
some political/social event, unless there is a dilution of those genes,
they stay within that community as long as the community continues to
remain isolated, or relatively intact. Tony came to the conclusion that,
since there are no truly `pure` populations, why not study admixtures,
and that`s exactly what the company did. Rather than go directly after
the pharmacogenomics area (that`s the buzzword everyone is using now for
pharmaceuticals developed through an understanding of genetics) we
actually used the genealogy market to validate our technology. In
September 2002, we introduced ANCESTRYbyDNA_, a consumer product that
provides individuals insight as to their family heritage. We provide a
kit containing a mouth swab, which is sent back to DNAPrint`s
laboratory. Following analysis, the complete results, including
genealogical history, are returned on a CD-ROM disc. The kit retails for
$219.

TWST: What are the genetic parameters for ancestry?


Mr. Gabriel: We originally launched our ancestry program based on four
population founder groups. ANCESTRYbyDNA can determine to which of the
four major bio-geographical ancestry groups a person belongs ` Sub-
Saharan African, Indo European, East Asian or Native American ` as well
as the relative percentages. Those founder groups have all been
established and accepted by the anthropological and archeological
community as being the migratory patterns of mankind. That`s been well
documented. In August 2004, we took it a step further and developed
EuroDNA_. If you`re 50% or more Indo-European we can determine your
genetic ancestry ` Northern European, Mediterranean, Middle Eastern or
Indo, which includes Pakistan and India. So now we can separate eight
groups. Why is this important? It goes back to not what your social and
your geopolitical affiliations are, but what are your inherited genes.
From the medical side, this is an important component in diagnosing and
treating patients. Because our technology is highly versatile, we turned
our attention to the commercial markets in 2003. At that time, we
launched DNAWITNESS_, an investigative tool for the law enforcement
forensics market. DNAWITNESS already has played a key role in the
apprehension of a serial killer and currently is being utilized in more
than 80 criminal investigations worldwide.

TWST: Can you tell us more about it?


Mr. Gabriel: DNAWITNESS is an investigative tool that analyzes DNA
recovered at a crime scene and can narrow the search for potential
suspects, reducing cost and time in making an apprehension. One of the
best examples that I can give you is the role that DNAWITNESS played in
identifying a serial killer in Louisiana. A police investigation into
eight murders over an 18-month period had come to a standstill.
Authorities were looking for a white male based on eyewitness accounts
of a suspicious man spotted near one of the crime scenes. Police rounded
up a number of individuals but DNA lifted at the crime scene did not
match. Then in March 2003, the authorities sent the DNA sample to us.
Now here`s what makes the case interesting. We determined that the
authorities were looking for a killer of the wrong race. We were able to
call back and tell them, `What you`re looking for is an individual who`s
85% Sub-Saharan and 15% Native American; clearly, he`s not a Caucasian.`
About six weeks later an African American male who was previously
discounted as a suspect was arrested after his DNA matched the sample.
As I noted, we`re involved in approximately 80 cases now, most of which
we can`t discuss, for obvious reasons. Another one that we can talk
about, however, was in Concord, California. This is a case that had
exactly the opposite results: the targeted groups in a murder, based on
eyewitness reports, were Hispanics and Asian gang members. However, it
turned out that the individual who committed that murder was Caucasian.
DNAWITNESS is a technology that we continue to enhance. We recently
streamlined the analysis process by introducing a DNAWITNESS test kit.
The kit enables forensics experts to conduct their own tests in their
own facilities without sending recovered DNA back to us for analysis.
With most forensics work done by state and federal labs, the kits will
enable them to utilize DNAWITNESS technology while running DNA under
their own control. We`ve also signed a number of distributors ` Orchid
Biosciences is one of them, as well as ReliaGene and Lynn Peavey `
companies which are well known in the forensics and investigative
communities as suppliers of crime scene products. Our kit actually will
go out through our distributors as well as directly to forensics
laboratories. We`re in the beta testing stage right now, and we`ve
selected a number of sites that will be running their analyses with our
kits. We also have a database with 2,500 photos that includes eye color,
skin shade, hair color and a number of other features ` which brings me
to the next point. We recently added another product in DNAPrint`s
forensics arsenal called RETINOME_, a genetic test for predicting human
eye (iris) color from DNA. This is something that`s very similar in the
complexities that one would find in human response to a drug ` how it
relates to the gene. So if you`re 50% or more Indo-European, which is
where eye color originates ` either blue, green or some shade of that in
combination with brown ` with 95% accuracy we can predict your eye color
from a DNA sample. Now, that`s really important for an investigator.
Again, remember that our DNA technology has nothing to do with your
political or social affiliations. It only has to do with where your
ancestors are from. That`s something you can`t hide. It`s like a
fingerprint. We actually screen 176 markers ` and if we do the Euro
we`re up to about 352 markers. In comparison, the Federal Bureau of
Investigation (FBI) has 16 loci, or points, that it uses to make a DNA
match. So we have a larger number of points that we look at.

TWST: How does DNAPrint`s technology work?


Mr. Gabriel: Our technology is based on single nucleotide polymorphisms
(SNPs), commonly called `snips.` Normal DNA screening may require the
analysis of millions of base pairs of genes to detect biological
patterns. DNAPrint`s technology for targeting SNPs eliminates the need
to screen irrelevant base pairs, saving time and money. Our technology
is proprietary and we have filed more than a dozen applications for
national and international patent protection. When we started out, we
had one of the first SNP machines ` a first-rate device that was
developed by Orchid. We actually had the beta version. We now have a
newer version made by Beckman Instruments, which bought the
manufacturing equipment from Orchid. The new machine is very accurate,
about 99.99%. With this technology we can identify the 2,000 or so
ancestry information markers in genes for our consumer and forensics
products. Looking down the road toward pharmaceutical development, we
think there is a need to understand how families are related, what a
genealogy of a family could be, if there is a disease component in a
family and whether a new drug can be specifically formulated to meet
their individual or group needs. Even though we have validated our
DNAWITNESS technology with blind test studies through police and crime
laboratories, we are looking toward certification from the American
Society of Crime Laboratory Directors (ASCLD). We need to either qualify
for certification on our own or obtain it through acquisition. So we`re
currently looking at acquisitions in general ` not only for the purpose
of obtaining ASCLD certification but we`re also shopping for clinical
laboratories that could enable us to do diagnostics for the FDA. We had
been focused on an acquisition that we had to terminate, and we now have
targeted a number of synergistic acquisition candidates we`re looking at
that will add revenue to the company.

TWST: What about the pharmaceutical prospects?


Mr. Gabriel: While we see our forensics business as an engine that will
generate revenues for the company, one of our fundamental goals is to
apply this technology to drug development. We recently took a big step
in that direction by acquiring an exclusive worldwide license from
Harvard Medical School`s Beth Israel Deaconess Medical Center (BIDMC).
This is a royalty bearing agreement that creates an opportunity for
DNAPrint genomics to develop a new, more potent and longer acting form
of the anemia drug Erythropoietin (EPO). EPO is currently commercialized
by Amgen, Johnson & Johnson and Roche in a worldwide market that exceeds
$10 billion and that has been growing at an average annual rate of 21%.
The human gene that produces EPO was cloned in 1985 and in 1989,
scientists at Amgen introduced to market a recombinant form under the
trade name EPOGEN`, a drug that many credit for the rise of Amgen in the
1990s as one of the world`s most successful biotechnology companies
ever. Erythropoietin has been approved by the Food and Drug
Administration as a treatment for anemia associated with renal failure,
cancer chemotherapy, and Zidovudine-treated HIV-infected patients and to
reduce blood transfusion in surgery patients. Our goal is to develop and
market a `super`-EPO, a more powerful form of the drug. This is a
perfect fit within the company`s overarching strategy to utilize recent
genomics and chemistry advances made by our researchers to develop next-
generation drugs that maximize efficacy and minimize side effects by
tailoring medication for specific individuals and well-defined
population sectors. In addition, we already have developed a product
called OVANOME_ in collaboration with the University of Florida and the
H. Lee Moffitt Cancer Center. OVANOME is a genomic-based diagnostic tool
for matching ovarian cancer patients with the most suitable form and
dose of chemotherapy. We`re particularly concentrating on patients being
treated with the drug Taxol. In previous FDA trials, Taxol-Carboplatin
drug combination therapy demonstrated efficacy in only about 60% of
patients treated. Our OVANOME therapeutic response tests have yielded
encouraging results so far. They were 96% effective in distinguishing
Taxol-Carboplatin responders from non-responders. Obviously, you do not
want to give a chemotherapeutic agent to a person unless you`re going to
get a positive response. We`ve been collecting samples all along, but we
just now are in the process of enrolling an additional 100 patients into
a trial at the Moffitt Center, and over the next six to nine months
we`ll be finalizing the data. Our goal is to be able to go to the FDA
and show them how important genetic ancestry is. When we originally
looked at the data on a prospective basis of patient populations, we
couldn`t make sense of it. That`s part of the problem with gene data, no
matter what technology you are using. If you don`t understand the
ancestry, or the genetic inheritance that goes along with that data,
it`s very difficult puzzle to solve because hundreds and hundreds of
genes need to be analyzed. We`re not claiming that we have the end-all-
and-be-all answer, but we certainly have what we think is a reasonable
tool for analyzing that very complex data. The second product in our
pipeline is STATINOME_. This is a test for the cardiac drug market to
determine whether patients will be good or poor responders to a class of
drugs called statins. The importance here is that statins are effective
in cholesterol reduction but adverse reaction can lead to liver damage
or kidney failure.

TWST: What does your business model look like at this point?


Mr. Gabriel: To summarize, one goal that we have is to develop our
business model so that we continue to generate revenues in the genealogy
area. We do not believe genealogy will be our biggest market
opportunity, but ANCESTRYbyDNA has taken off in the consumer products
area, and we certainly have gotten a lot of press out of that. The
technology has been highlighted on CBS Television, ABC`s 20/20 and
Nightline, and in The New York Times. So we actually plan on continuing
to expand it. We`re looking at subpopulations and constantly gathering
new samples on a volunteer basis. And we`re reorganizing our marketing
materials to be more consumer-oriented. In the forensics area, we`ve
done a tremendous job. We`re actually out teaching prosecutors about DNA
technology. We`ve been establishing contact with the Innocence Project
as well. In addition, there`s a significant opportunity here in New York
City for helping to identify all the unmatched samples of victims`
remains taken at the World Trade Center. We`ve been in contact with the
New York City Medical Examiner`s office in the hope of convincing them
that our DNAWITNESS technology ` possibly in conjunction with one of our
distributors, ReliaGene or Orchid ` could tackle the remaining 10,000
samples from the 9/11 disaster and possibly come up with the
identification of more victims, or at least classify those samples into
groupings. The case in point that I have (and again, these are only
cases that have gone public that we`re able to talk about) is of a young
girl`s remains that were found in Florida. Initially, the match for the
parents was about 5,000 families. After running DNAWITNESS, we narrowed
the number down to about 50 families. That`s the power of the
technology. If you`re an investigator and you`re looking at 5,000
families with one unknown, it becomes a daunting task. Even 50 families
is a daunting task, but at least you`re not dealing with an infinite
number. The technology really has a way of narrowing down, in the case
of a murder or a felony, the person-of-interest, or in a case of human
identification of remains, the list of potential families from which you
have to take DNA samples in order to do the match.

TWST: It sounds like, longer term, the real opportunity is on the
pharmacogenomics side.


Mr. Gabriel: Well, the same thing applies in pharmacogenomics. Think of
it this way: Take an African-American medical patient who enrolls in a
trial for a drug that works specifically, let`s say, for high blood
pressure. This is a condition that occurs more frequently in African-
Americans. But as it turns out, the patient`s ancestors were mostly
Native American or East Asian; perhaps there was an African-American
great, great grandfather somewhere along the line whose characteristics
the patient inherited. The patient lives in the African-American
community and cannot be expected to change his or her social or
political affiliations just because of a DNA sample. The real problem is
that the patient may not have inherited the required gene that is
beneficial for the drug treatment, and the drug might actually do more
harm than good. What we want to do is optimize the drug development
process with what we call `Theranostics` ` genetically tested drugs
appropriate for specific individuals and well-defined population
sectors. Our goal is to help insure that patients receive the
appropriate medicine and proper dosage the first time around. This takes
us back once again to the case in point where social/political
affiliations come into direct conflict with inherited ancestors. Your
genes have nothing to do with your political voice. As a matter of fact,
they don`t care. But understanding a person`s ancestry or genetic
inheritance is extremely important to the doctor and the patient. That`s
really what our focus is. We have taken up the banner and actually had
discussions with the FDA.

Dr. Frudakis wrote about this as part of a discussion panel for current
pharmacogenomics guidelines, which includes hints about ancestry and
genetic inheritance. We`re proponents of having an open dialogue with
the FDA and with the National Institutes of Health (NIH) about the
importance of genetic ancestry.

TWST: Is anybody else working in the same space?


Mr. Gabriel: Oh, certainly. The NIH itself has a pharmacogenomics
branch. The head of Human Genome Sciences has come forward on the
importance of genetic ancestry; the head of Celera Genomics has spoken;
Affymetrix and Perlegen Sciences are in this. There`s a lot of
competition in this field. We just happened to start early, and we
happen to believe that diversity is a human quality that is a wonderful
trait ` but that it also brings along inherited markers that maybe
aren`t so good from a medical standpoint. And for the medical field, we
think this is the only way to rationalize drugs.

TWST: Is there broad understanding and agreement on this?


Mr. Gabriel: There`s a lot of debate, mostly around geopolitical and
social concerns ` which are legitimate. There is absolutely no question
about the legitimacy of these concerns. We live in a democratic society,
and in order to have a debate we need to have an open dialogue about it.
There are already laws on the books that offer remedies for many of the
concerns. I would say that if an insurance company discriminates against
an individual because of an inherited marker and denies that person
insurance, it could result in hundreds of millions of dollars` worth of
lawsuits. At the same time, the federal government wouldn`t allow this
type of discrimination to begin with. So there`s plenty of legislation
in place to protect individuals. There are independent review boards at
hospitals, patients` bills of rights ` a lot of legislation is in place.
You cannot discriminate against individuals in the United States and get
away with it.

TWST: What type of standards does DNAPrint genomics set for itself?


Mr. Gabriel: We operate under the highest ethical standards and have a
strict code of ethics. DNAPrint genomics has a unique database that
gives us an understanding of families and how they`re related, but we
don`t divulge any of that information. Our customers` data is private.
If they ask us to destroy the DNA we do ` though some people ask us to
keep it because, for historical reasons, they want to make sure that if
they`re doing a family genealogy they`ll have DNA samples from all the
members of the family for comparison. And in that case we keep those
DNAs.

TWST: Is all that going to inhibit development?


Mr. Gabriel: Starting before Dr. Mark McClellan`s tenure at the FDA, but
really under his leadership, this issue has come to the forefront. I
have to say that the FDA has taken an absolutely stellar lead in
encouraging this dialog. And along with that, the NIH has been also a
strong promoter and will continue to be. I think it`s in the best
interest of all mankind to understand what your heritage is and what
diseases are inherited.

TWST: Tell us about the company`s management and its goals for the
future.


Mr. Gabriel: We`ve all been working at this for some time. I`ve been in
the pharmaceutical business for 20 years.

Dr. Hector Gomez, our Chairman and Chief Medical Officer, has been in it
all of his life. He has 11 drugs under his belt; I have four or five and
probably have been involved with 60 or 70 ` from discovery all the way
to approval ` over the course of my career. There are three or four
drugs on the market now that have gone through my previous company`s
hands. We`re dedicated individuals, and I thank our shareholders for
believing in our company. And that, quite honestly, is why we`re looking
for acquisitions. We want to build our revenue, and we either build our
revenue through sales, selling a new technology into a market, which is
hard, or we acquire it ` and we`re aggressively looking at both because
the goal is to boost shareholder value. I myself am a shareholder.

TWST: What are you looking for in the way of acquisitions?


Mr. Gabriel: Companies that bring accreditation to us in the
pharmaceutical area as well as in the forensics area. We are looking
across a broad spectrum of companies, both public and private.

TWST: Are there any milestones that you can set out for the next year or
two?


Mr. Gabriel: Our milestones have always been the same. They haven`t
changed from the first day I came onboard. The goal is to make the
company profitable as soon as possible, and we`re pursuing that by
developing products that we can get out into the market. Our new
DNAWITNESS test kit is just an example. We continue to build our
database. We have a 2,500 photo database and we collect samples. We`re
building our product portfolios to make our products attractive to the
customers in genealogy as well as in forensics, and we will continue to
do that. Pharmacogenomics is a longer haul, but it certainly offers a
much greater point of return when a product is approved and is accepted
by the market. So we look at it in a three-step fashion. We look at our
consumer products market, building our continued consumer base, and we
have probably sold, oh, I don`t know, 11,000 or 12,000 samples, or kits
into that market, and our long-term goal is to have, quite literally,
millions of those. So we will be a very unique company in that we will
have analyzed, literally, millions of DNA samples on a blind basis `
blind samples. We know nothing about the individuals; we just get a DNA
sample, and we report on it back to them. We also think there`s a
tremendous opportunity in forensics. In the investigation of cold cases
-` and there`s a backlog of hundreds, if not hundreds of thousands of
such cases ` our technology can be used to help categorize those cases.
Certainly categorizing DNA samples is important for the Innocence
Project. If a crime scene sample shows that the suspect is Caucasian and
the individual who`s incarcerated is African-American, obviously, you
move his DNA to the top of the pile and you do the match and you free
him. So there`s plenty of opportunity in those two markets for growth.
It`s steady and consistent growth. It will, however, not be the bell
ringer. The real bell ringer for this technology has always been in the
pharmaceutical area, really matching the patient with the doctor and
with the therapy through `Theranostics.` That`s what this technology can
do. It can actually put the doctor and patient back in control of the
pharmaceuticals that are being administered for the disease that`s being
treated. We can do this one step at a time, one drug at a time. We`ll
just proceed down that path and have an open dialog with the FDA, the
NIH and move our technology forward. In addition, we`re looking at
licensing opportunities for therapeutics as well ` in other words,
talking to people about drugs that we can bring in. We want to run
clinical trials of drugs along with our technology, and instead of
having 40% or 60% efficacy we could have up to 95% efficacy, which means
longer product life. That`s a novel concept, and an important one.
Especially when patents expire, the question always is, how you keep
generics out. Well, how you keep generics out is that you have a product
that is 95% efficacious. That builds brand loyalty, and people don`t
want to change. Aspirin has been around for a couple of hundred years,
and everybody knows Bayer aspirin; or Tylenol, anyone can make Tylenol,
but no one thinks of acetaminophen, people think of Tylenol. That`s
brand loyalty. It`s something that`s been around in the pharmaceutical
industry itself, and you do that by making a product that, when you take
it, the result is there. You take Bayer aspirin, you know what you get;
you take Tylenol, you know what you get. So if you have a disease and
you have a drug that treats the disease, the doctor knows that it`s an
efficacious drug, and if you match the patient to the drug and it works,
then that`s what`s going to happen. That`s how scrips are generated.

TWST: Thank you. (TJM)


RICHARD GABRIEL
President & CEO
DNAPrint genomics, Inc.
900 Cocoanut Avenue
Sarasota, FL 34236
[phone]
[phone]
www.dnaprint.com
e-mail: [e-mail]

Forward-Looking Statements
All statements in this interview that are not historical are forward-
looking statements. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from
those projected, including, but not limited to, uncertainties relating
to technologies, product development, manufacturing, market acceptance,
cost and pricing of DNAPrint`s products, dependence on collaborations
and partners, regulatory approvals, competition, intellectual property
of others, and patent protection and litigation. DNAPrint genomics, Inc.
expressly disclaims any obligation or undertaking to release publicly
any updates or revisions to any forward-looking statements contained
herein to reflect any change in DNAPrint`s expectations with regard
thereto or any change in events, conditions, or circumstances on which
any such statements are based.

Copyright 2005 The Wall Street Transcript Corporation
All Rights Reserved

[Michiko]

So! Ausgeschüttelt!!

Jetzt kann`s auf 2 Cent hoch gehen.

[Deggen]

#370

Dauert auch nicht mehr lange

Gewinnmitnahmen beendet und null Abgabedruck

Bid 0,0194
Ask 0,0195

[Michiko]

Deggen,

dem kann ich voll zustimmen.

Habe auch gerade so viel verkauft, dass ich jetzt mit Null Wertpapierkredit da stehe.
War ein schönes Zwischengeschäft, aber jetzt habe ich Null Abgabedruck.

[Deggen]

0,02 bezahlt!!!

[Deggen]

Explosionsgefahr!!!

Bid 0,021
Ask 0,0214

+40%

[Michiko]

Wer zu früh kommt, den bestraft das Leben!

Habe wieder mal zu früh verkauft! Aber zum Glück nur einen kleinen Teil

[Michiko]

Was meinen denn die Chart-Techniker zum heutigen Kursverlauf?

Könnte sich da mal der eine oder andere äußern?

Danke!

[Patsche]

ES GEHT WEITER

KURS: 0,0228

Bid 0,0227
Ask 0,0228

[Michiko]

Patsche,

war das jetzt ne Chart-Analyse?

[kai.hawaii]

hey, spannende aktie. bin seit wenigen tagen drin. guter tipp. vielen dank. als charttechniker UND bauchmensch sehe ich nur grün. ich kaufe nach.

gruß

[Deggen]

@kai.hawaii

Kann mich deiner Meinung nur anschließen

Bin auch kein Charttechniker hab die Aktie aber schon seit längerem auf der Watch gehabt und als letzten Freitag der Kurs Fahrt aufgenommen hat konnte ich einfach nicht anders und hab mir zu 0,015 welche ins Depot gelegt.

Der Chart (vor allem der Langfristchart) zeigt was hier möglich ist. Dann die Umsätze der letzten Wochen die Bodenbildung über der 1 Cent Marke, heute das Durchbrechen der 2 Cent Marke unter erneut hohen Umsätzen diese Faktoren sprechen für mich eine klare Sprache...

Wenn heute die 2 Cent Marke hält (wovon ich mal stark ausgehe) sehen wir am Ende der Woche Kurse über den 3 Cents

Kann nur jedem raten heute noch im Amiland um die 0,02 Cent einzusteigen

[MrRipley]

Hallo!

Jemand hatte nach meinem Einstiegskurs gefragt(Nachbarthread?).
Dieser befindet sich bei 0,016USD am Freitag.

Ich halte in nächster Zeit Kurse über 0,1 für möglich.
Bzgl. Prognosen bin ich normalerweise ziemlich zurückhaltend.
Da ich nur mit Spielgeld investiert bin, kann ich mir solche Aussagen erlauben.
(Wenn schon Schweinefleisch dann muss es triefen)
Meine Intuition sagt Gutes vorraus.

In diesem Sinne eine grüne Woche

R.R.

[kai.hawaii]

mist, in fra gabs praktisch keine mehr zu 0,018. obgleich der marketmaker ja mit seinen 0,012geld sehr schnell dabei war und evtl. für unsicherheit unter weicheiern gesorgt hat. gut, dass solche leute, die profi-maker sind gemeint, nur wenig verstehen und angesichts der vielzahl von bid-asks bei zigtausend aktien den überblick verlieren.

morgen geht´s hier weiter. der kurs in amiland ist wieder bei 0,022x.

spannend wird auch zb
- bankgesellschaft berlin (übernahme sparkasse etc)
- gameznflix (rennen gegen netflix)
... und viele andere, die ich noch nicht ansprechen möchte (bodenbildung abwarten).

gruß

[MrRipley]

welcher Anfänger kauft denn in FSE?

Gerade mal 3-4000€ Umsatz

[Menglovator]

Ob man das hier charttechnisch sehen muß, wage ich zu bezweifeln.
Ich denke eher an einen Hype durch noch unbekannte News, auf die ich allerdings noch warte....*nur meine bescheidene Meinung.

[Michiko]

Und schon wieder ein neues Tageshoch.

So langsam wird mir das ein wenig unheimlich.
Denn: So richtig fette News hatten wir doch noch nicht!?!

[kai.hawaii]

#383 mr ripley

hallo, geht´s noch?

als "anfänger", wie du mich netterweise bezeichnest, möchte ich doch sagen, dass es sich hier um nix als spielgeld handelt. es gibt zig aktien im nasdaqotc, gem, etc, die charttechnisch ähnlich aussehen wie dnaprint genomics. alles auf eine karte zu setzen - das wäre ein anfängerfehler. daher genügen "wenige tausend euro" erstmal. und us-orders kosten bei meinem broker mehr als das doppelte von deutschen.

um mit 100.000 euro reinzugehen, wie du es vermutlich anstrebst, fehlt mir zb charttechnisch noch so einiges - neben 8k-fillings etc. v.a. die überzeugung, warum gerade die um 10.000% steigen sollten, und nicht die zahlreichen anderen. ich bevorzuge eine streuung und bleibe dabei. dnaprint genomics gehört allerdings dazu.

gruß

[Michiko]

Ne Menge Leute haben da heute vermutlich ne Menge Hintergrundwissen, das uns fehlt!

Wir können leider nur im Dunkeln hinterher laufen.

[kai.hawaii]

0,024 plus x in amiland.

mann, jetzt geht´s ab.

bitte stellt doch einfach die news ein, die das begründet. charttechnisch und gefühlsmäßig gibt es nach oben kein limit mehr. alle grenzen sind durchbrochen.

morgen wird dann auch der deutsche handel nachziehen.

und ich idiot habe nicht in amiland nachgekauft, um ordergeld zu sparen. schön blöd.

gruß

[kai.hawaii]

... jetzt plus 72% !

[Michiko]

kai.hawaii

Mann, ich bin doch heftigst am Suchen.
Aber mehr als ich heute reingestellt habe, habe ich beim besten Willen nicht gefunden.

Schau Dir mal #349 an. Gestern habe ich Timburg genau vor dem gewarnt, was heute passiert ist.

Manchmal bin ich auch zu zögerlich.
Hinterher bleibt halt nur noch das Jammern

[Tho123]

Jetzt 0,0275 = 83% in Amerika.
Morgen kommen wir noch mal billiger rein, das wäre nicht das erste Mal, daß nach einem solchen Hype wieder die Verninft einkehrt, bzw. saftige Gewinnmitnahmen anstehen.
Wenn nicht, ist dies ein Zeichen,dass tatsächlich etwas
im Busch ist.

Gruß Tho123

[Tho123]

Aktuell 0,029 = 90%!!

[kai.hawaii]

teufel,

die grünen piks über 1 mio. volumen kommen zurück - zahlreich im intraday.

[Tho123]

0,0299 = 99,66%!!
Jetzt wollen sie mit Gewalt die 0,030 sehen.

[Leo02]

..übrigens Kai - hast ne´klasse neue Scheibe rausgebracht.
"Frieden" sei mit dir.
Für immer breit..
Gruß
Leo

[Tho123]

0,030 sind erreicht. Hundert Prozent sind voll!
Ja so ist das im Leben. Habe heute auf Neomedia gesetzt, die jetzt abbröckeln.
Meinen Kaufauftrag über 100000 DNAP bei 0,017 bei ETrade habe ich nicht weggeschickt.Habe dem Braten nicht getraut. Hätte ein guter Abend werden können .
Auf ein neues!
Dnap wird uns noch einige Chancen bieten.

[kai.hawaii]

... und ich idiot habe aus ordergebührengeiz nicht noch mehr nachgekauft ....

morgen ist dnaprint-genomics-tag.

[kai.hawaii]

der kaufpik war gerade bei über 2 mio...

[calibra21]

Heute BOOM Part III?

Die Eröffnung in Frankfurt müßte bei minimum 0,023 liegen

[Timburg]

@Michiko

Dass die Rakete aber so schnell startet hätte ich auch nicht gedacht. Und ich glaub, ich bin definitiv zu alt, um jetzt noch mit diesen OTC-Werten anzufangen. Hab gestern morgen noch überlegt, eine kleine Zocker-Posi aufzubauen; jetzt ist der Zug für mich aber definitiv abgefahren.

Was soll`s; wünsche Dir trotzdem weiter viel Spass und steigende Kurse. Sind ja einige hier (hab den Thread übers WE durchgelesen), welche in den letzten Jahren Ausdauer gezeigt haben und für das Durchhalten auch ein Erfolgserlebnis verdienen.

Good trades
TB

[marterpfahl]

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=3415…

Eine viel versprechende story wird fortgesetzt.
check it out.
marterpfahl

[ge4teilter]

0.03
+0.0150 (+100.00 %)
Volume: 75,745,432

Jetzt nur noch 300% bis Einstand!

Gruß ... g4

[hvs1]

G4,

nach meinen diversen Zukäufen bis auf 3M bin ich nun
im Plus.Einstand 0,0285
Mal sehen,was für News heute kommen.Verkaufen werde
ich trotzdem keine einzige Aktie,jedenfalls noch nicht.

Gruß hvs1

[ge4teilter]

you lucky hvs1-man!

[hvs1]

G4,

Deine 0,12 sehen wir schon bald.
Warum so grimmig,gönne es mir.

hvs1

[ge4teilter]

hvs1 >

Kleine Smilie-Kunde:

Grimmig sieht so aus:

Aber heißt Breites Grinsen bzw. im orschinohl biggrin


Ich gönne Dir selbstverständlich alles!!!!!

Gruß ... g4

[corfutown]

Wer kann mir die WKN von 3M sagen ?

Danke !

[Menglovator]

Na, wer hat die ersten (Vor-) Zahlen aus Amiland ?

[Beginner77]

DNAPrint genomics CEO Richard Gabriel Interviewed by Wall Street Transcript
Monday April 25, 10:21 am ET


SARASOTA, Fla.--(BUSINESS WIRE)--April 25, 2005--The Wall Street Transcript has published an in-depth interview with Richard Gabriel, President and Chief Executive Officer of DNAPrint(TM) genomics, Inc. (OTCBBNAP - News), in which he discusses how the Company is applying its proprietary DNA technology to the development of new drugs, as well as the law enforcement and consumer markets.
The interview is available free on line at the Transcript`s Web site (www.twst.com/ceos.htm).

Mr. Gabriel provides examples of how DNAPrint genomics` DNAWITNESS(TM) forensics technology for the law enforcement market is utilized in crime scene investigations. He also went into detail about the Company`s ANCESTRYbyDNA(TM) product for the consumer market, which targets individuals who want to trace their family heritage.

Mr. Gabriel also discussed the Company`s recently announced exclusive worldwide license from Harvard Medical School`s Beth Israel Deaconess Medical Center (BIDMC) for a project to develop a new, more potent and longer acting form of the anemia drug Erythropoietin (EPO), which currently has a worldwide market that exceeds $10 billion.

"Our goal is to develop and market a `Super`-EPO, a more powerful form of the drug," Mr. Gabriel said. "This is a perfect fit within the Company`s overarching strategy to utilize recent genomics and chemistry advances made by our researchers to develop next-generation drugs that maximize efficacy and minimize side effects by tailoring medication for specific individuals and well-defined population sectors."

The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800-246-7673.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company`s ANCESTRYby DNA(TM) is a consumer product for individuals interested in learning their family heritage. DNAWitness(TM) is a forensics market tool for analyzing DNA evidence recovered at a crime scene. DNAPrint is also developing products in the pharmacogenomic market including OVANOME(TM), a genomic-based diagnostic tool that matches ovarian cancer patients with the most suitable form and dose of chemotherapy, and STATINOME(TM), a test for the cardiac drug market to determine whether patients will be good or poor responders to statins, which are effective in cholesterol reduction. For more information about the company, please visit www.dnaprint.com.

[hvs1]

G4,

danke für die Aufklärung.War auch nicht ernst gemeint
von mir.

hvs1

[Michiko]

Filing! Lesestoff in Massen:

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=3415…

[Michiko]

Lustig:

Momentan bid 0,032 - ask 0,0305

[Michiko]

Jetzt bid 0,0325 - ask 0,0328

[Michiko]

RUMMS!!

Jetzt wird sofort im Millionentakt geschi§§en!

[Michiko]

GUTE GÜTE! Da geht die Post ab!!

18 Millionen in 7 Minuten!!!

[Beginner77]

@Michiko

Hast du Realtime-Kurse? Wie steht der Kurs?

[Michiko]

Beginner

bid 0,028 - ask 0,0285

ändert sich aber ständig.

Momentane Tendenz: Eher nach unten.

[Michiko]

Jetzt werden sie ersäuft wie Nachbars junge Kätzchen:

Momentan minus 17%

[corfutown]

die armen kätzchen, hoffentlich überleben sie.

die sind mir wichtiger als die aktie !

[Michiko]

corfutown,

das ist ein Bild aus meiner Jugendzeit. Ich war ein Bauernkind; da gab`s für Sentimentalitäten keinen Raum.

[ge4teilter]

Holla!

Halbe Stunde rum und schon 31 Mio. Shares gehandelt!

Aber leider auch 30% runtergekommen

Bin ja mal gespannt!

g4

[Deggen]

Gewinnmitnahmen beendet!!!

Dreht wieder

Aktuell 0,024

[Michiko]

Ich äußere jetzt mal eine Vermutung aus dem Bauch heraus, also völlig ungesichert:

Das war eben eine klasse Swing-Trade-Gelegenheit.

Gestern zum Börsenschluss oder heute bei Beginn verkauft, eben wieder rückgekauft und den weiteren Anstieg abwarten.

Schade, dass mein Broker zu lahm für so was ist.

[Michiko]

Ich vermute, jetzt entscheidet sich die kurzfristige Entwicklung.

War der kurze Anstieg in der letzten Viertelstunde eine Hoffnung der Swing-Trader auf einen schnellen Zock und überwiegt die Abstiegs-Tendenz oder geht es nach den Verkäufen wieder stabil aufwärts?

[corfutown]

Der Absturz hat es aber in sich.

Zocker-Wert, hin und her .

[Deggen]

Der Anstieg gestern hatte es auch in sich

Haben jetzt schon fast soviel wie gestern umgesetzt

Würde mich nicht wundern, wenn wir heute Abend noch leicht im Plus schließen...

[ge4teilter]

Na, sieht doch schon wieder etwas freundlicher aus!

Quote (del. 15 min.)
10:07 AM ET
0.0250
-0.0050 (-16.67 %)
Volume: 47,999,952

[ge4teilter]

Auch interessant:

Beiträge: 427
Gelesen gesamt: 15167
Gelesen heute: 1221

[babe_in_the_woods]

RT-Demo

NAP" target="_blank" rel="nofollow ugc noopener">http://finance.lycos.com/qc/livecharts/default.aspx?symbols=BBNAP

noch DNAP einfügen

könnt auch regristieren lassen!

[Michiko]

g4

spricht doch eindeutig für die Qualität Deines Threads!

Michi

[Beginner77]

@ babe_in_the_woods

DANKE!!!

[babe_in_the_woods]

@B77

Bitte

[Deggen]

Mittlerweile schon 60 Mio. Stück umgesetzt!!!

Wahnsinn

[Tho123]

Aktuell 0,024.

Gehts noch weiter runter heute?

[jenbroke]

Also ich habe ein Abstauberlimit zu 0,02 - ich denke das
ist adäquat! Vielleicht kommt DNAP heute noch dahin, um dann wieder in Richtung 0,03 zu gehen

[Deggen]

Die 0,02 wird gerade das zweite Mal getestet. Denke der Kurs wird hier wieder abprallen. Müsstest also welche bekommen haben...

[Michiko]

Ich denke, inzwischen ist die Tendenz klar zu erkennen Nach unten!

Vielleicht hat jenbroke mit seinem Abstauber-Limit Recht.

Es könnte aber noch deutlich tiefer liegen.

News oder nicht News (und zwar echte!)
Das ist die Frage.

[HenryR.Mandell]

Nee,ich habe heute in F zu €.0025 geschmissen - es ist immer wieder das gleiche...

Für 1 cent gehts wieder rein

Croko

[Beginner77]

Ja, so wie es aussieht, haben die Amis bei 2 cent den Boden gefunden.
Charttechnisch war es die letzten Tage der erste Ausbruch nach mehr als einem Jahr.
Fragt sich nur wie es weitergeht.

[kai.hawaii]

spannend. jetzt weiss ich ja auch, wer mir in f zuvorgekommen ist. egal - ich hab ja wieder gekauft.

[Michiko]

Dachlatte!

Das mit den Zahlen ist anscheinend bei Dir immer noch nix!

Schau mal in Deiner Abrechnung nach; ich bin sicher, dass Du nicht zu 0,0025 geschmissen hast

Wie auch immer, wenn Du sie für 0,01 zurückkaufen kannst, haste vermutlich ein gutes Geschäftle gemacht.

Gruß

Michi

[Tho123]

Aktuell 0,021.

Es ist doch immer wieder das gleiche Spiel.
Die, die long sind, brauchen sich dabei keine großen Gedanken zu machen.
Aber die anderen:
DNAP wird immer wieder nach dem gleichen Muster hochgezogen. In den Boards wird Stimmung gemacht, irgendwelche mehr oder weniger ( eher weniger) bedeutsamen News werden benutzt, um den Wert hochzuziehen.
Dann erfolgt der jähe Absturz.Einige machen Kohle und lauern schon wieder auf die nächste Chance .
Übel ist dran, wer gestern im späten Geschäft euphorisch
eingestiegen ist.
Bei 80 Millionen gehandelter Aktien (trotz des geringen
Gegenwerts) sitzen eine nicht unbedeutende Anzahl von Zockern an den PC`s un lauern auf ihre Chance.
Bei DNAP ist es äußerst gefährlich bei einem solchen Anstieg im späten Geschäft einzusteigen.

Bis zum nächsten Hype! Hoffentlich seid Ihr dabei.

[Michiko]

Tho123

ich gebe Dir Recht:

Bei dieser Aktie zu spät aufzuspringen ist tödlich.

Entweder Du bist ganz frühzeitig dabei oder Du bleibst besser draußen.
Oder Du bist absolut long und kümmerst Dich zwischenzeitlich um garnix.

Oder aber, Du steigst irgendwann ein und hoffst auf den ganz großen Big Bang, der hier durchaus nicht ausgeschlossen ist.

Langjährige Erfahrung meinerseits.

[HenryR.Mandell]

#442

Ja die longs...

Bin eigentlich auch einer - seit bald 4 Jahren hänge ich an DNAP - mal mehr, mal weniger...

Nur denke ich mittlerweile anders - im Frühjahr 2003 habe ich laufend eingesammelt - für ca.2000 Euronen im Schnitt zu 3 cent...

Dann ging es los bis fast auf 20 cent - was meinst Du wann ich raus bin ???

exakt 0,074 cent.....

Das zum Thema "Long"...

Croko

[FCHennes]

0,021 USD hat gehalten. Jetzt geht es nach oben!Am besten im Amiland
ordern, da in Deutschland die Taxe viel zu groß ist!

[HenryR.Mandell]

Michi,das genau ist das Problem mit DNAP - wenn Neeinsteiger wie jedes Mal regelmäßig wieder auf die Nase fallen fassen sie das Teil nicht mehr an - aber wer nach 400% in so kurzer Zeit noch auf den Zug will sollte wissen was er tut....

Nur wenn DIE news kommt wird in NY dann bei 20 cent eröffnet - deshalb versuche ich immer mit einem Teil drin zu bleiben...

Was machen die anderen Zocks ?

Croko

[HenryR.Mandell]

Kaufe ein u

[hvs1]

all,

mit 3M long

hvs1

[Eurofuchs2]

...hier mal ein Beitrag eines "Dummen",

in Fra für 0,012 gekauft, in Fra für 0,025 verkauft!
War ein reiner Zock! .. mit fun.
Aber was läuft über dem Teich.
- Umsatz 71k
- Trades 1,1 k
= Umsatz pro trade schlappe 65 US$

... ist doch auch nur zocken oder?

Bei 0,005 bin ich wieder dabei!

good luck
Eurofuchs

[Michiko]

croko

ich habe eigentlich nur noch einen anderen Zock.

Und das ist CMKX.
Aber der ist brandheiß.

Ich bin mit 55 Millionen drin. Bleib mal tuned.

Michi

[HenryR.Mandell]

@Eurofuchs

Hat mit dumm nix zutun - ist meist besser so....

Bisher kamen sie immer wieder runter - GANZ runter...

Wenn er wirklich 70000 da drin hat, sind es in zwei Wochen vielleicht nur noch 15000 - im RB liefen schon Wetten auf $.oo1...

Ich für meinen Teil warte auch ab

so long,

Croko

[kai.hawaii]

wieder einer, der zu 0,025 verkauft hat. kein wunder, dass ich zu spät kam. aber egal. die 0,020 in amiland sind nach unten durchbrochen. nicht so prickelnd.

hier gibt es ein interview von gestern (von WO gemeldet)
SARASOTA, Fla.--(BUSINESS WIRE)--April 25, 2005--The Wall StreetTranscript has published an in-depth interview with Richard Gabriel,President and Chief Executive Officer of DNAPrint(TM) genomics, Inc.(OTCBB DNAP), in which he discusses how the Company is applying itsproprietary DNA technology to the development of new drugs, as well asthe law enforcement and consumer markets.
The interview is available free on line at the Transcript´s Website (www.twst.com/ceos.htm).

[Eurofuchs2]

[posting]16.461.989 von Michiko am 26.04.05 19:31:17[/posting]wartest Du auf den Juni 05?
Juni 04 lief ja wirklich gut, aber was soll jetzt kommen?
Der Chart der letzten 6 Mon. ist doch nur fun, ohne Perspektive.
100% rauf 50% runter usw.

Weisst Du mehr? Bitte nur wirklich Gutes.

Euer(O)fuchs2

[corfutown]

0,015 nur noch in Frankfurt.

[HenryR.Mandell]

Juni 2004 war nix - war 2003...

croko

[kai.hawaii]

na, schmeisst keiner mehr in fra? ach doch - gerade wieder 0,015. ich glaub, in amiland kaufen ist doch nicht so schlecht...

[HenryR.Mandell]

Wie war das mit dem fallenden Messer ?



Croko

[HenryR.Mandell]

Fällt wie ein Stein, grausam aber das ist DNAP...

- ohne Worte -

croko

[MrRipley]

Ich habe gerade eben meine 61000Stk(2 Käufe) wieder in den USA verkauft, das wurde mir zu blöd...


Jetzt kommt das Kuriose:
Ohne Gebühren habe ich 10 Cent Gewinn gemacht, ich bin also mit einem lachenden Auge wieder raus gekommen aus der Geschichte.

Auch Glück muss man haben, und die ca. 50€ Gebühr verbuche ich unter "Lehrgeld beim Handel an der OTC"!

[Der Papst]

Hallo Mandell,

was meinst du mit dem Post:

Nur wenn DIE news kommt wird in NY dann bei 20 cent eröffnet - deshalb versuche ich immer mit einem Teil drin zu bleiben...

Amen

Papst

PS: Sollte man jetzt einsteigen?

[Menglovator]

Läuft bis jetzt doch ganz gut

[Michiko]

Falls es sich noch nicht rumgesprochen hat:

DNAP hat im letzten Filing einen Resplit angekündigt.
Irgendwas zwischen 1 für 10 und 1 für 20.

Dürfte einer der wesentlichen Gründe für den Rückfall gestern sein.

[alex1975]

ich persönlich finde die Begründung im Filing für diesen RS schlüssig und unterm strich positiv, ist aja auch noch ein bißchen zeit bis zur entscheidung.

mal schauen, wie es gleich weitergeht...!

[HenryR.Mandell]

@Der Papst

Ich lasse immer 20000 im Depot liegen - die aber habe ich fast alle schon um die 5 cent gekauft...

Was DIE news bedeutet ?

Wenn DNAP endlich/bald mal/irgendwann/was weiss ich GELD verdient...

Nicht anderes - zum Zocken sind immer 300% drin - nur wie schon erwähnt würde ich nach 400% und mehr nicht mehr reingehen !!!!

Und wann Du einsteigst musst Du selbst entscheiden - ich habe unter .005 versucht reinzukommen - leider ohne Erfolg

Und bis dahin warte ich ab (nur meine persöhnliche Meinung - die ist keine Aufforderung zum Kauf oder blablabla....)

Immer an die Masse denken,die Sie rauswerfen dürfen (kenne mich nicht mehr so aus - 1,3 Milliarden?) und an den (wohl kommenden)Split...

Croko

[Michiko]

croko, Du sagtest: Immer an die Masse denken, die sie rauswerfen dürfen (und an den wohl kommenden Split).

Dieser RS ist SEHR entscheidend für die Masse, die sie rauswerfen dürfen!

Zahlenbeispiel:
Die Zahl der autorisierten Shares AS beträgt momentan 1,5 Milliarden.
Die Zahl der ausgegebenen Shares OS beträgt momentan cirka 1,1 Milliarden.

Ergo: Momentan haben sie noch ca. 400 Millionen Aktien im Tresor.

Wenn der RS z.B. 1:10 getätigt wird (das ist der allerdezenteste Fall), dann beträgt das OS plötzlich nur noch 110 Millionen.
Da sich das AS von 1,5 Milliarden aber nicht ändert, haben sie dann noch 1,39 Milliarden Shares in der Hinterhand. 1 390 Millionen nachher statt 400 Millionen vorher!

Wenn der RS 1:20 beträgt (wovon ich ausgehe), dann ist das OS plötzlich nur noch 55 Millionen.
Also noch weitere 1 445 Millionen Shares, die ausgegeben werden können!
Was das an Dilution (Verwässerung) bedeutet, kannst Du Dir vielleicht vorstellen.

Ich bin sehr am Diskutieren mit meinem Alter Ego, wie ich darauf reagieren soll.

RS ist immer Schei§§e, weil meistens eine letzte Verzweiflungstat des Managements vor der Zahlungsunfähigkeit.

Das alles sind natürlich nur unausgegorene Gedanken meinerseits und sollen niemanden und nichts gar niemals nicht von irgendeiner Kauf- oder Verkaufentscheidung abhalten oder Ihn/Sie/Es dazu bewegen!

Mit Grummelbauch

Michi

[HenryR.Mandell]

Michi,danke das Du das mal erklärt hast - ich kenne doch die Zahlen eh nicht mehr....

Wie gesagt, ich gehe jetzt nicht mehr rein - das Ding kommt wieder runter, da bin ich mir sicher - war schon immer so...

Und nach Split geht es eh erstmal abwärts, und das heftigst denke ich ??

Es sei, denn.....................................

Croko

[HenryR.Mandell]

UHhhhhhhhhhhhhhhhhhhhhhhhhh...........

Michi,denkst Du noch an
AMJY

Ein Split nach dem anderen....

Neenee,

Croko

[kai.hawaii]

# 465 michiko

erstmal danke für deine erläuterung.

vielleicht der grund, warum im otc praktisch kaum volumen seit 1 std. vorhanden ist bei ca 0,145. oder mein broker spinnt - schliesse ich mal aus. dnap halte ich momentan keine mehr und hatte noch glück mit dem verkauf gestern in fra, wenn auch nicht zu 0,025. die kauforder heute zu 0,010, natürlich in fra, hat auch nicht gegriffen. für mich bleibt dnap äusserst interessant und ein kauf.

kurz zu den gebühren:
comdirect kostet pro trade bis 5000 eur in deutschland ca 10-15 eur, in amiland zwischen mind. 7,90 plus 0,25% des ordervolumens, also zwischen 12,90 und 62,90 pro trade PLUS 15 eur zuschlag pro us-order. bei spielgeld-zocks, also 1-3 teur, lohnt sich der kauf in amiland für mich daher weniger, ausser die kursspanne ist in deutschland sehr hoch und es findet kaum handel statt. sorry, das wollte ich noch mal kurz gesagt haben.

broadvision wird ja jetzt auch interessant.

gruß

[Eurofuchs2]

[posting]16.471.923 von kai.hawaii am 27.04.05 20:08:02[/posting]Hai Kai,

etwas mehr Geduld! 0,04 ist ne echte Chance!

EF2

[kai.hawaii]

# 469 ef2

danke für den tipp.

gruß

[alex1975]

und grün !

[Corner]

Grün ist gar kein Ausdruck !

Ich sehe + 30 % !!!

[kai.hawaii]

mein us-limit wurde nicht ausgeführt, obwohl es hätte ausgeführt werden müssen. toll. trödel-broker. jetzt steigen die natürlich. ach, es ist doch zum ... dann kaufe ich halt morgen wieder in fra. natürlich zu überhöhten kursen.

[jenbroke]

Hat jemand aktuellen Rt

[kai.hawaii]

bid 0,0190
ask 0,0191

ohne gewähr und eh vor minuten

[Tho123]

Just in Time 0,0185 = 15% plus

[kai.hawaii]

# 476 tho123

darf ich fragen, woher du diesen kurs hast? und falls ich fragen darf, wo stand der? bei mir war ask 0,0190 bid 0,0191.

[Eurofuchs2]

oh, oh,

40,5$ pro trade, da geht was!!!
Mitnehmen was mitzunehmen ist.
Übern Teich wird doch verar.....!
EF2

[alex1975]

so, +19,37% bei 0,0191 - sieht gut aus !

[kai.hawaii]

# 479

beides ist richtig; hat halt geschwankt zwischen 0,0185 und 0,0191. jetzt zittert der kurs um 0,190. ich warte ab.

[Menglovator]

Ab 21.00 Uhr :

DNAPRINT GENOMICS INC
Börse: NASDAQ OTC BBS
Datum: 27.04.05

Zeit Kurs Volumen

21:59:28 0,0191 71000
21:59:26 0,0190 71000
21:59:19 0,0189 200000
21:59:18 0,0190 200000
21:59:04 0,0190 62300
21:59:04 0,0187 62222
21:57:36 0,0187 140000
21:57:04 0,0190 100000
21:57:02 0,0190 34000
21:56:38 0,0187 1200
21:56:22 0,0187 5000
21:55:50 0,0190 8000
21:55:00 0,0187 50000
21:54:12 0,0192 8000
21:53:06 0,0190 100000
21:53:03 0,0188 37000
21:52:14 0,0187 30000
21:52:11 0,0187 100000
21:51:13 0,0190 3000
21:51:05 0,0187 50000
21:50:43 0,0189 10000
21:50:19 0,0189 25000
21:49:59 0,0190 150000
21:49:59 0,0190 100000
21:49:12 0,0190 5000
21:48:58 0,0191 199999
21:48:50 0,0191 600000
21:48:50 0,0191 100000
21:48:49 0,0191 100000
21:48:25 0,0192 200000
21:48:24 0,0190 200000
21:47:35 0,0190 150000
21:47:27 0,0193 100000
21:46:54 0,0193 95000
21:46:46 0,0192 80000
21:46:45 0,0193 100000
21:46:44 0,0193 5000
21:46:04 0,0193 90000
21:46:01 0,0193 100000
21:45:56 0,0193 20000
21:44:21 0,0190 469500
21:44:11 0,0190 200000
21:44:10 0,0190 75000
21:43:43 0,0190 60000
21:43:23 0,0190 10000
21:43:11 0,0190 5000
21:43:10 0,0189 5000
21:42:25 0,0190 22500
21:42:25 0,0190 22500
21:42:08 0,0189 5000
21:41:43 0,0186 5000
21:41:12 0,0185 20000
21:40:59 0,0185 5000
21:40:54 0,0185 50000
21:40:36 0,0185 21605
21:39:47 0,0185 50000
21:39:45 0,0183 50000
21:39:38 0,0185 20000
21:39:35 0,0185 95000
21:38:52 0,0185 6598
21:38:52 0,0183 6600
21:38:34 0,0183 50000
21:38:32 0,0185 50000
21:37:21 0,0188 50000
21:36:55 0,0185 53600
21:36:54 0,0185 100000
21:36:33 0,0188 4999
21:34:16 0,0190 95000
21:34:13 0,0192 95000
21:34:11 0,0192 5000
21:34:10 0,0190 100000
21:34:01 0,0191 85000
21:33:37 0,0190 15000
21:33:32 0,0191 200000
21:33:27 0,0192 20000
21:33:22 0,0190 30000
21:33:20 0,0191 100000
21:33:07 0,0193 10000
21:33:06 0,0194 140000
21:33:04 0,0193 3900
21:32:59 0,0193 295000
21:32:59 0,0194 295000
21:32:58 0,0193 5000
21:32:50 0,0194 50000
21:32:49 0,0194 5700
21:32:41 0,0193 50000
21:32:40 0,0194 5000
21:29:46 0,0190 50000
21:29:41 0,0192 50000
21:28:50 0,0190 50000
21:28:31 0,0190 10000
21:28:06 0,0190 5000
21:28:05 0,0190 1630000
21:27:53 0,0190 8000
21:27:25 0,0186 25000
21:25:51 0,0182 170000
21:25:40 0,0181 2300
21:25:40 0,0182 100000
21:25:39 0,0181 500000
21:25:39 0,0181 100000
21:25:34 0,0182 35000
21:25:33 0,0181 35000
21:24:58 0,0181 53500
21:24:57 0,0181 92143
21:24:56 0,0182 145600
21:23:52 0,0181 5000
21:23:16 0,0182 12000
21:22:56 0,0183 100000
21:22:54 0,0181 1667400
21:22:35 0,0185 10000
21:22:22 0,0186 25000
21:22:20 0,0185 45000
21:22:12 0,0185 5000
21:21:42 0,0185 10000
21:20:51 0,0190 100000
21:20:37 0,0185 46800
21:20:37 0,0190 46800
21:20:32 0,0191 5000
21:20:28 0,0190 5000
21:20:04 0,0190 67000
21:19:39 0,0190 11500
21:19:39 0,0191 11500
21:19:07 0,0190 5000
21:18:56 0,0191 11500
21:18:56 0,0191 3500
21:18:54 0,0190 15000
21:18:12 0,0191 48500
21:18:12 0,0192 48500
21:17:35 0,0191 40000
21:17:02 0,0197 60000
21:16:56 0,0198 60000
21:16:44 0,0197 7500
21:16:44 0,0198 7500
21:16:42 0,0197 5000
21:16:25 0,0197 5000
21:15:29 0,0199 5000
21:15:29 0,0199 50000
21:15:25 0,0200 49000
21:15:22 0,0197 50000
21:15:22 0,0199 50000
21:15:18 0,0199 45000
21:15:15 0,0197 55000
21:15:09 0,0197 5000
21:15:02 0,0195 46500
21:15:02 0,0195 53500
21:14:58 0,0195 46500
21:14:43 0,0199 50000
21:14:37 0,0200 105000
21:14:22 0,0199 5000
21:14:04 0,0199 51000
21:14:03 0,0200 51000
21:14:00 0,0199 2500
21:13:46 0,0199 200000
21:13:30 0,0200 62222
21:13:22 0,0200 160000
21:13:09 0,0200 18000
21:13:04 0,0200 5000
21:13:00 0,0200 25000
21:12:54 0,0200 100000
21:12:54 0,0200 100000
21:12:51 0,0200 172500
21:12:51 0,0200 6500
21:12:48 0,0200 100000
21:12:45 0,0200 150000
21:12:38 0,0200 25000
21:12:35 0,0200 50000
21:12:22 0,0200 50000
21:11:57 0,0197 5000
21:11:33 0,0195 201000
21:11:14 0,0193 50000
21:11:11 0,0195 50000
21:09:30 0,0192 5000
21:09:14 0,0192 150000
21:09:13 0,0195 77000
21:09:13 0,0194 60000
21:09:13 0,0190 13000
21:09:09 0,0195 10000
21:08:57 0,0194 23000
21:07:47 0,0192 70000
21:07:30 0,0185 28500
21:07:29 0,0190 28500
21:07:22 0,0192 165000
21:07:22 0,0192 5000
21:07:09 0,0185 40000
21:07:09 0,0183 235000
21:07:03 0,0185 5000
21:07:00 0,0185 70000
21:06:59 0,0181 70000
21:06:48 0,0181 25000
21:06:48 0,0190 25000
21:06:33 0,0190 45000
21:06:24 0,0190 5000
21:06:17 0,0190 40800
21:06:15 0,0180 40800
21:06:15 0,0190 50000
21:06:14 0,0180 50000
21:06:06 0,0199 19000
21:06:04 0,0199 195000
21:06:03 0,0191 20000
21:05:53 0,0191 5000
21:05:42 0,0190 7000
21:05:42 0,0190 38500
21:05:26 0,0190 25000
21:04:53 0,0195 30000
21:04:52 0,0195 5000
21:04:46 0,0198 95000
21:04:39 0,0195 15000
21:04:30 0,0198 25000
21:04:29 0,0195 25000
21:04:27 0,0195 50000
21:04:27 0,0195 8000
21:04:26 0,0198 5000
21:04:13 0,0198 6200
21:04:11 0,0195 6200
21:04:05 0,0195 110500
21:04:05 0,0198 155000
21:04:05 0,0195 44500
21:04:03 0,0198 5000
21:03:59 0,0198 10000
21:03:59 0,0195 25000
21:03:56 0,0195 15000
21:03:54 0,0195 20000
21:03:46 0,0195 95000
21:03:44 0,0195 150000
21:03:44 0,0195 100000
21:03:44 0,0199 13165
21:03:43 0,0199 29700
21:03:39 0,0195 25000
21:03:37 0,0200 20000
21:03:37 0,0200 25000
21:03:37 0,0200 2400
21:03:36 0,0200 25000
21:03:35 0,0200 16150
21:03:35 0,0200 50000
21:03:34 0,0200 50000
21:03:34 0,0200 45000
21:03:34 0,0200 16200
21:03:34 0,0199 300000
21:03:34 0,0200 5000
21:03:34 0,0199 5000
21:03:13 0,0199 5000
21:03:05 0,0200 60000
21:03:05 0,0200 75000
21:03:03 0,0200 5000
21:02:53 0,0200 18500
21:02:52 0,0199 50000
21:02:52 0,0199 18500
21:02:51 0,0200 50000
21:02:49 0,0200 42000
21:02:49 0,0199 42000
21:02:43 0,0200 25000
21:02:43 0,0199 25000
21:02:39 0,0199 100000
21:02:36 0,0200 15000
21:02:25 0,0199 140000
21:02:25 0,0200 140000
21:02:21 0,0200 190000
21:02:21 0,0200 310000
21:01:58 0,0199 10000
21:01:42 0,0195 240000
21:01:37 0,0195 201000
21:01:28 0,0190 5000
21:00:58 0,0193 10000
21:00:54 0,0193 25000
21:00:51 0,0193 50000
21:00:50 0,0192 30000
21:00:49 0,0192 50000
21:00:49 0,0193 50000
21:00:39 0,0193 20000
21:00:39 0,0192 20000
21:00:32 0,0192 30000
21:00:31 0,0192 100000
21:00:24 0,0192 8450
21:00:05 0,0193 10000

[Menglovator]

Und wo lag jetzt der Grund des letzten Hypes ?

[HenryR.Mandell]

Gab keinen...

Zocken eben...

Croko (der auf 0,005 wartet)

[Michiko]

Hey Latte!

Mach keinen Ärger von wegen 0,005!!

Ich bin nämlich dicke drin!!!

Michi

[hvs1]

Hallo Michi,

was heißt dicke drin in Zahlen?

hvs1

[Michiko]

hvs1

das heißt, dass ich gegen Dich ein Waisenkind bin.

Habe einige 100k beim letzten Anstieg verkauft und halte jetzt noch 1,3 Millionen.
Ist für mich aber viel Geld.

Michi

[hvs1]

Michi,
Glückwunsch zum Verkauf.
Ich werde ja nicht klüger und halte nach wie vor noch alle.
Aber wer weiß wozu das gut ist.
Irgendwann muß ja mal der Durchbruch kommen.Die Gefahr ist
ja immer,wenn es knallt,dann fangen die in den USA schon
mit einem Kurs an,zu dem man nicht mehr rein will.

Also alles Gute für Dich und Dein Investment.

hvs1

[luto9]

Go dnap!! Form 8-K/A for DNAPRINT GENOMICS INC


--------------------------------------------------------------------------------

5-May-2005

Entry Material Agreement, Financial Obligation Matter, Financial Statemen



Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
Beth Israel Deaconess Medical Center License Agreement

Effective April 4, 2005, the Registrant entered into a License Agreement (the Agreement) with Beth Israel Deaconess Medical Center, a Massachusetts nonprofit corporation (Beth Israel) to develop a new, more potent and longer acting form of the anemia drug Erythropoietin (EPO).

EPO is a glycoprotein naturally made by the body to stimulate red blood cell production; the currently marketed forms are manufactured using recombinant DNA technology and are used to treat anemia or low blood cell count. Under the Agreement, Beth Israel has granted the Registrant an exclusive license to United States and foreign patents related to certain forms of EPO. The Registrant has the right to develop, use, market and sell products derived from the licensed patents.

In exchange for the license, the Registrant paid Beth Israel a $25,000 signing fee and agreed to make certain milestone payments linked to its progress in developing marketable products from the licensed technology. The total of payments, if all milestones are reached, is $2,150,000. The milestone payments are nonrefundable. Up to $200,000 of this amount is creditable against future royalties. In addition to the milestone payments, the Registrant must also pay Beth Israel an annual royalty of 4% of the net sales of all products developed from the licensed technology. A minimum royalty payment of $100,000 a year is due upon the commencement of commercial sales in any territory worldwide.





Item 2.03 CREATION OF A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT.
See Item 1.01 above.





Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits:

10.1 License Agreement with Beth Israel Deaconess Medical Center dated April 4, 2005

[Michiko]

Da wir ja ein langes Wochenende haben; lest Euch einfach mal schnell das folgende Lizenz-Abkommen zwischen Beth Israel und DNAP durch:

THIS AGREEMENT is made as of April 4, 2005(the "Effective Date") by and between The Beth Israel Deaconess Medical Center, a Massachusetts nonprofit corporation, having its principal place of business at 330 Brookline Avenue, Boston, MA 02215 ("Licensor"), and DNAPrint Genomics, Inc. a for-profit corporation having its principal place of business at 900 Cocoanut Avenue, Sarasota, Florida 34236 ("Licensee").


Licensor owns the rights to the Licensed Technology, as defined below.


Licensee wishes to obtain a license, under the Licensed Technology, to make, have made, use and sell Licensed Products, as defined below.


Licensor wishes to grant such a license to Licensee on the terms and conditions of this Agreement.


Licensor and Licensee have therefore agreed as follows.


I. DEFINITIONS


The following terms shall have the meanings indicated in this Agreement:


1.1 Agreement shall mean this Agreement, including all schedules and attachments hereto.


1.2 Affiliate shall mean any company, corporation, business or entity controlled by, controlling, or under common control with either Licensee or Licensor. For this purpose, "control" means direct or indirect beneficial ownership of at least fifty percent (50%) interest in the voting stock (or the equivalent) of such corporation or other business or having the right to direct, appoint or remove a majority or more of the members of its board of directors (or their equivalent), or having the power to control the general management of such company, corporation, business or entity, by contract, law or otherwise.


1.3 Applicable Percentage -- see Schedule 3.1(ii) attached hereto.


1.4 Commercial Sale shall mean any sale where any Licensed Product is sold or commercially disposed of for value in an arm`s length sale to an independent third party in the Licensed Territory after Licensee has received full regulatory approval for such sale from the appropriate jurisdiction. Commercial Sale shall not include sales for purposes of testing, or research, including clinical studies, or sales in limited numbers for the purpose of introducing a Licensed Product as part of a promotion.


1.5 Confidential Information shall mean any and all information of or about a Party including all information relating to any technology, product, process or intellectual property of such Party (including, but not limited to, owned or licensed intellectual property rights, data, knowhow, samples, technical and non-technical materials and specifications) as well as any business plan, financial information or other confidential commercial information of or about such Party. Notwithstanding the foregoing, information of or about a Party shall not be considered Confidential Information with respect to such Party to the extent that the Person possessing such information can demonstrate by written record or other suitable physical evidence that:



2
--------------------------------------------------------------------------------


(a) such information was lawfully in such Person`s possession or control prior to the time such information was disclosed to such Person by the Party to whom the information relates;


(b) such information was developed by such Person independently of and without reference to Confidential Information, provided, however that without limiting the generality of the foregoing, the Confidential Information of Licensor shall not become the Confidential Information of Licensee by virtue of this Agreement;


(c) such information was lawfully obtained by such Person from a third party under no obligation of confidentiality to the Party to whom such information relates; or


(d) such information was at the time it was disclosed or obtained by such Person, or thereafter became, publicly known otherwise than through a breach by such Person of such Person`s obligations to the Party to whom such information relates.


1.6 Effective Date -- See Preamble.


1.7 Federal Patent Policy shall mean 35 U.S.C. § 200 et seq. and all regulations promulgated thereunder, as amended, and any successor statutes or regulations.


1.8 FDA shall mean the United States Food and Drug Administration.


1.9 Licensed Field shall mean the field described in Schedule 1.8.


1.10 Licensed Patent shall mean any of those patents and patent applications described on Schedule 1.10 and any divisional, continuation, continuation-in-part (only to the extent that the continuation in part covers the original information in the initial patent application which is the subject of this License), reissue, renewal or extension thereof or substitute therefor, or any patent issuing therefrom.


1.11 Licensed Technology shall mean the Licensed Patents.


1.12 Licensed Territory shall mean the territory described in Schedule 1.12.


1.13 Licensed Product shall mean:



3
--------------------------------------------------------------------------------


(a) any product the manufacture, use or sale of which would, absent the license granted by Licensor to Licensee herein, infringe any valid claim included in any Licensed Patent or any portion thereof; or


(b) any product developed in whole or in part through use of a process which is covered by a valid claim included in any Licensed Patent or any portion thereof.


1.14 Net Sale shall mean:


(a) in any case where any Licensed Product is sold or commercially disposed of for value in an arm`s length sale to an independent third party, the gross invoice price for such Licensed Product, less the following permitted deductions to the extent that such items are reflected in the price charged and do not exceed reasonable and customary amounts in the country in which the transaction occurs: (a) trade and quantity discounts or rebates actually taken or allowed, (b) credits or allowances given or made for rejections or return of any previously sold Licensed Product actually taken or allowed, (c) any tax or government charge (including any tax such as a value added or similar tax or government charge, but not including any tax levied with respect to income) levied on the sale, transportation or delivery of the Licensed Product and born by the seller thereof, (d) any charges for freight or insurance billed to the final customer and (e) any sale previously taken into account as a Net Sale to the extent that it is subsequently deemed a bad debt by Licensee in accordance with GAAP.


(b) in any case where any Licensed Product is sold, leased or otherwise commercially disposed of (including, without limitation, disposition in connection with the delivery of other products or services) in a transaction that is not an arm`s length sale to an independent third party, the greatest of: (a) the Net Sale amount for such transaction determined as provided in (i) above or (b) if there has been any arm`s length sale of a similar Licensed Product to an independent third party, the Net Sale amount, determined as provided in (i) above, for the most contemporaneous such sale or (c), if there has been no such arm`s length sale, the gross sales asking price for the Licensed Product.


1.15 Party shall mean each party to this Agreement and their respective successors and permitted assigns.


1.16 Person shall mean any natural person or legal entity.


1.17 Sublicensee shall mean any Person to whom Licensee grants a sublicense of some or all of the rights granted to Licensee under this Agreement.



4
--------------------------------------------------------------------------------


II. LICENSE


2.1 Grant of License. Licensor hereby grants to Licensee an exclusive, royalty-bearing license, including the right to grant sublicenses, under the Licensed Technology, to make, have made, use, offer to sell and sell Licensed Products in the Licensed Territory in the Licensed Field.


2.2 Licensor’s Representation of Title. Licensor represents to Licensee that Licensor is the assignee of the rights granted by this License.


2.3 Federal Patent Policy. To the extent that any invention included within the Licensed Technology has been partially funded by the United States Government, the United States Government retains certain rights in such research as set forth in the Federal Patent Policy. As a condition of the license granted hereby, Licensee shall comply with all aspects of the Federal Patent Policy applicable to the Licensed Technology in the Licensed Territory in the Licensed Field. Nothing contained in this Agreement obligates or shall obligate Licensor to take any action which would conflict in any respect with its past, current or future obligations to the U.S. Government under the Federal Patent Policy with respect to the Licensed Technology in regard to work already performed or to be performed by Licensor. Licensor shall, however, use its reasonable best efforts to take all necessary action to reserve for Licensee exclusive rights to the Licensed Technology in the Licensed Territory in the Licensed Field to the extent permitted under the Federal Patent Policy.


2.4 Pre-existing Third Party Rights. There are no pre-existing third party rights in the License granted by Licensor to Licensee under this Agreement.


2.5 Licensor`s Retained Rights/Publication. All rights granted by Licensor to Licensee hereunder are subject to Licensor`s retained rights which are as follows:


(i) Notwithstanding the exclusive rights granted to Licensee hereunder, Licensor retains, for itself and its Affiliates, a royalty-free right to make and use Licensed Products or use Licensed Technology solely for research, teaching or other scientific or academic purposes.


(ii) Licensor also retains for itself, its employees and its Affiliates and their employees the right to present at symposia, national, regional or professional meetings (a "Presentation") and to publish in scientific journals or otherwise (a "Publication") scientific findings from research related to the Licensed Technology provided that the Presentation or Publication does not violate any confidentiality provision found in this Agreement, is not proprietary to the Licensee, Confidential Information or otherwise encumbered.



5
--------------------------------------------------------------------------------


2.6 Sublicensing. Licensee shall have the right to grant sublicenses consistent with the terms and conditions of this Agreement provided that Licensee shall be responsible for the operations of any Sublicensee relevant to this Agreement as if such operations were carried out by Licensee itself, including (without limitation) the payment of any royalties or other payments provided for hereunder, regardless of whether the terms of any Sublicense provides for such amount to be paid by the Sublicensee directly to Licensor. Except as Licensor may in its discretion otherwise agree in writing, any sublicense granted by Licensee under this Agreement shall provide for termination upon termination of this Agreement. The standard form of any sublicense agreement shall be consistent with the foregoing terms and other applicable provisions of this Agreement and shall be subject to prior approval by Licensor, which approval shall not be unreasonably withheld. Once Licensee obtains Licensor’s pre-approval of a standard form sublicense agreement, Licensor’s prior approval of sublicensing agreements is not required; provided, however, Licensee shall obtain Licensor`s prior written approval of each sublicensee’s identity, which approval shall not be unreasonably withheld. Licensee shall provide to Licensor a copy of all sublicense agreements within thirty days of executing the same.


2.7 Restriction on other Rights. No license is granted to any right not specifically listed or referenced in this Agreement.


III. CONSIDERATION, RECORD-KEEPING AND PAYMENTS


3.1 Payments and Other Consideration.


3.1.a Licensing Fees. Licensee shall pay to Licensor those licensing fees specified in Schedule 3.1(i), at the time and in the manner specified therein.


3.1.b Running Royalties. Licensee shall pay or cause to be paid to Licensor a running royalty equal to the Applicable Percentage of all Net Sales of any Licensed Product sold by Licensee or any Sublicensee as specified in Schedule 3.1(ii), at the times and in the manner specified therein.


3.1.c. Minimum Royalties. Licensee shall pay to Licensor the minimum royalty payments specified on Schedule 3.1(iii), at the times and in the manner specified therein.


3.1.d. Milestone Payments. Licensee shall pay or cause to be paid to Licensor those milestone payments specified in Schedule 3.1(v), on the terms and conditions specified therein.


3.1.e. Sublicensing and Partnering. Licensee shall pay or shall cause to be paid to Licensor those sublicensing and partnering fees specified in Schedule 3.1(vi), on the terms and conditions specified therein.


3.1.f. Records. During the term of this Agreement and for three (3) years thereafter, Licensee shall keep complete and accurate records of Licensee`s and any Sublicensee`s sales of Licensed Products and such other matters as may affect the determination of any amount payable to Licensor hereunder in sufficient detail to enable Licensor or Licensor`s representatives independent authority to determine any amounts payable to Licensor under this Agreement. Licensee shall permit Licensor or its representatives, at Licensor`s expense (except as provided below), to examine periodically its books, ledgers, and records during regular business hours for the purpose of and to the extent necessary to verify any report required under this Agreement or the accuracy of any amount payable hereunder. Licensee shall also permit Licensor or its representatives to examine periodically any documents relating to its sublicensing of the Licensed Technology during regular business hours. Should any examination conducted by Licensee or its representatives pursuant to the provisions of this paragraph result in an increase of more than 10% in any payment due Licensor hereunder, Licensee shall be obligated to pay any out of pocket expenses incurred by Licensor with respect to such examination. In the event any examination conducted by Licensee or its representatives reveals any overpayment made to Licensor by Licensee, the overpayment will be returned to Licensee and Licensee is not obligated to pay any out-of-pocket expenses incurred by Licensor with respect to such examination.



6
--------------------------------------------------------------------------------


3.2. Reports. Within 60 days after March 31, June 30, September 30 and December 31 of each year, Licensee shall deliver to Licensor a true and accurate report, giving such particulars of the business conducted by Licensee and any Sublicensees during the preceding three (3) calendar months under this Agreement as are pertinent to an accounting for any royalty or other payments hereunder. If no payments are due, it shall be so reported.


3.3 Form of Payment; Taxes. All amounts payable to Licensor hereunder shall be payable in United States funds without deductions for taxes, assessments, fees, or charges of any kind. Licensee shall be responsible for the payment of all withholding taxes imposed by any country on any royalty or other payment payable to Licensor hereunder and the percentage or other amounts payable to Licensor hereunder shall not be reduced to reflect the payment of any such withholding tax. All amounts payable to Licensor hereunder shall be payable in United States dollars in Boston, Massachusetts, or at such other place as Licensor may reasonably designate, provided, however, that if the law of any foreign country prevents any payment payable to Licensor hereunder to be made in Boston, Massachusetts, or as otherwise designated by Licensor or prevents any such payment to be made in United States dollars, Licensor agrees to accept such royalty in form and place as permitted, including deposits by Licensee in the applicable foreign currency in a local bank or banks in such country designated by Licensee. If any currency conversion is required in connection with any payment to Licensor hereunder, such conversion shall be made at the buying rate for the transfer of such other currency as quoted by The Wall Street Journal on the last business day of the applicable accounting period, in the case of any payment payable with respect to a specified accounting period, or, in the case of any other payment, the last business day prior to the date of such payment.


3.4 Interest. In the event that any payment due hereunder is not made when due, the payment shall accrue interest beginning on the first day following the calendar quarter to which such payment relates calculated at the annual rate of the sum of (a) two percent (2%) plus (b) the prime interest rate quoted by The Wall Street Journal on the date said payment is due, or on the date the payment is made, whichever is higher, the interest being compounded on the last day of each calendar quarter, provided that in no event shall said annual rate exceed the maximum interest rate permitted by law in regard to such payments. Such royalty payment when made shall be accompanied by all interest so accrued. Said interest and the payment and acceptance thereof shall not negate or waive the right of Licensor to any other remedy, legal or equitable, to which it may be entitled because of the delinquency of the payment.



7
--------------------------------------------------------------------------------


IV. PROTECTION OF INTELLECTUAL PROPERTY RIGHTS

4.1 Patent Prosecution/Patent Costs. Licensor and Licensee shall prosecute and maintain the Licensed Patents as provided in Schedule 4.1.


4.2 Confidential Information. Each Party shall maintain the Confidential Information of the other Party in confidence to the same extent that such Party maintains and protects its own Confidential Information, and shall not disclose, divulge or otherwise communicate such Confidential Information to others, or use it for any purpose, except pursuant to, and in order to carry out, the terms and objectives of this Agreement or with the express written consent of the Party who provided such Confidential Information. Each Party also hereby agrees to take reasonable and customary steps to prevent and restrain the unauthorized disclosure of such Confidential Information by any of its directors, officers, employees, consultants, sub-contractors, sub-licensees or agents. The provisions of this paragraph shall not apply to any Confidential Information of a Party which is required to be disclosed by another Party to comply with any lawfully issued subpoena or court order, or applicable laws or regulations, but only to the extent required by such subpoena, court order, law or regulation and further provided that the Party making any disclosure pursuant to the provisions of this sentence shall provide prior written notice of such disclosure to the other Party sufficiently in advance of such disclosure to allow such other Party to respond and to take reasonable and lawful action to avoid and/or minimize the degree of such disclosure.


4.3 Enforcement of Intellectual Property Rights. In the case of any infringement of any Licensed Patent or any violation of any other intellectual property right contained in the Licensed Technology by any third party (an "Infringer") in the Licensed Field in the Licensed Territory during the term of this Agreement, Licensee shall have the right and the obligation, at Licensee`s expense, to cause such third party to cease such infringement and to otherwise enforce such Licensed Patent or such other intellectual property right. Licensor shall assist Licensee as reasonably requested, at Licensee`s expense, in taking any such action against any such Infringer. Any amount recovered as a result of any action taken by Licensee hereunder shall be first applied to reimbursing Licensee for its out-of-pocket expenses incurred in connection therewith and the remainder, if any, shall be divided appropriately between Licensee and Licensor with reference to the relative monetary injury suffered by each of them by reason of the infringement for which said amounts are recovered. If, following reasonable notice from the Licensor, Licensee shall fail to take any action against any Infringer which Licensor may reasonably deem necessary or desirable to prevent such infringement or violation, or to recover damages therefor, in addition to any other remedy available to it, Licensor may, upon notice to Licensee, take any steps Licensor may deem appropriate against such Infringer at Licensor`s own expense. Licensee shall assist Licensor, at Licensor`s expense, as reasonably requested in taking any such action against any such Infringer. Any amount recovered as a result of any such action taken by Licensor shall be first applied to reimbursing Licensor for its out-of-pocket expenses incurred in connection therewith and the remainder, if any, shall be divided appropriately between Licensor and Licensee with reference to the relative monetary injury suffered by each of them by reason of the infringement for which said amounts are recovered. This paragraph shall survive the termination or expiration of this Agreement.



8
--------------------------------------------------------------------------------


4.4 Infringement of Third Party Rights. Licensee shall promptly advise Licensor in writing of any notice or claim of any infringement and of the commencement against it of any suit or action for infringement of a third party patent made or brought against Licensee and based upon or arising under the license granted under this Agreement. In such event, Licensee shall have at all times the right to immediately suspend commercialization and the right either to:

a. request that Licensor enter into negotiation with such third party to obtain rights for Licensee under the third party patent; or

b. request that Licensor defend such claim, suit or action at Licensor`s expense; or

c. terminate this Agreement.


Licensor shall not be obligated to enter into negotiations with such third party to obtain rights for Licensee under the third party patent nor obligated to defend such claim, suit or action. If Licensor, in its sole discretion, elects to enter into negotiations with such third party to obtain rights for Licensee under the third party patent or if Licensor, in its sole discretion, elects to undertake at its own expense the defense of any such claim, suit or action, Licensee shall render Licensor all reasonable assistance that may be required by Licensor in the negotiations or in the defense of such claim, suit or action. Licensor has the primary right to control the defense of any such claim, suit or action by counsel of its own choice. The Parties agree to cooperate reasonably in any such defense.


Notwithstanding the foregoing, if Licensor has not within ninety (90) days (or such lesser period of time as is necessary to avoid entry of a default judgment against Licensor or Licensee) from the date of receipt of a request from Licensee, either entered into negotiations with such third party to obtain rights for Licensee under the third party patent or initiated legal action to defend such claim, suit or action, it shall, upon written request of Licensee, grant to Licensee the right to enter into such negotiations or defend such claim, suit or action. Licensee shall be entitled to deduct from royalties due Licensor, all reasonable costs and expenses (including, but not limited to, legal fees, expert witness fees, and trial consultants’ fees) incurred in entering into such negotiations or defending such claim, suit or action. Licensee shall not settle or compromise any such suit or action without the Licensor’s written consent, which consent shall not be unreasonably withheld or delayed.



9
--------------------------------------------------------------------------------


V. OPERATIONS UNDER THE LICENSE


5.1 Due Diligence.



5.1.1. General Obligation. Licensee shall use commercially reasonable efforts, which efforts shall not be less than efforts expended by biopharmaceutical companies of similar size, scale, and capacity in connection with similar development projects, to diligently commercialize the Licensed Technology. In the event that Licensor believes Licensee has failed to comply with its general due diligence obligations under this paragraph, Licensor shall provide written notice to Licensee stating, in detail, the basis for Licensor’s belief. Within 60 days of Licensee`s receipt of a detailed written notice from Licensor, Licensee shall provide to Licensor either (i) a response detailing the basis for the Licensee’s position that the Licensor’s belief is in error, or (ii) a commercially reasonable plan to remedy such failure within a time period not to exceed 210 days from the date of Licensee`s receipt of such notice. In the case of (ii), the Licensee shall cure such failure in accordance with such plan within the time provided for under such plan.

5.1.2. Specific Due Diligence Obligations. Licensee shall also comply with each of the more specific due diligence requirements specified in Schedule 5.1.

5.2 Reports. Licensee shall provide to Licensor at least once per year a report of its activities and efforts toward commercialization of the Licensed Technology in sufficient detail to allow Licensor to monitor Licensee`s compliance with the due diligence provisions of this Agreement and shall provide to Licensor those additional reports, if any, specified in Schedule 5.1.


5.3 Compliance with Law. Licensee shall comply with and shall insure that any Sublicensee complies with all government statutes and regulations that relate to Licensed Products, including, but not limited to, FDA statutes and regulations and the Export Administration Act of 1979 (50 App. U.S.C. §2401 et.seq.), as amended, and the regulations promulgated thereunder, and any applicable similar laws and regulations of any other country. Without limiting the generality of the foregoing, Licensee agrees that all Licensed Products used or sold in the United States shall be manufactured substantially in the United States to the extent required by and in compliance with the Federal Patent Policy.


5.4 Marking. Licensee shall cause all Licensed Products sold in the United States to be marked with all applicable U.S. Patent Numbers, to the full extent required by United States law. Licensee shall similarly cause all Licensed Products shipped to or sold in any other country to be marked in such a manner as to conform with the patent laws and practice of such country.


5.5 Publicity. Except as required by law, Licensee shall not use the name of the Licensor nor Licensor`s Affiliates, nor that of any staff member, employee, or student of Licensor or its Affiliates, or any adaptation thereof, in any advertising, promotional or sales literature, offering materials, business plan or any other form of publicity without Licensor’s prior written consent, and the consent of the individual staff member, employee or student if such individual`s name is so used.



10
--------------------------------------------------------------------------------


A. Licensor Policies. Licensee acknowledges that Licensor`s employees and the employees of Licensor`s Affiliates are subject to the applicable policies of Licensor and such Affiliates, including, without limitation, policies regarding conflicts of interest, intellectual property and other matters. Licensee shall provide Licensor with any agreement it proposes to enter into with any employee of Licensor or any of Licensor`s Affiliates (including, without limitation, any member of the medical or research staff of Licensor or any Affiliate of Licensor) for Licensor`s prior review and shall not enter into any oral or written agreement with any such employee which conflicts with any such policy. Licensor shall provide Licensee, at Licensee`s request, with copies of any such policies applicable to any such employee.


B. Research Agreement. Licensee and Licensor shall enter into a Research Agreement, as more specifically described in Schedule 5.6.


C. Clinical Trials. Licensee hereby grants to Licensor, on behalf of Licensor and its Affiliates, those rights in regard to clinical trials of Licensed Products described on Schedule 5.7.


VI. INDEMNIFICATION; INSURANCE; WARRANTY DISCLAIMER


6.1. Indemnification


a. Licensee shall indemnify, defend and hold harmless Licensor and its trustees, officers, medical and professional staff, employees, and agents and their respective successors, heirs and assigns (the "Licensee Indemnitees"), against any liability, damage, loss or expense (including reasonable attorney`s fees and expenses of litigation) incurred by or imposed upon the Licensee Indemnitees or any one of them in connection with any claims, suits, actions, demands or judgments arising out of any theory of product liability (including, but not limited to, actions in the form of tort, warranty, or strict liability) concerning any product, process or service made, used or sold pursuant to any right or license granted under this Agreement.


b. Licensees indemnification under (i) above shall not apply to any liability, damage, loss or expense to the extent that it is directly attributable to the negligent activities, reckless misconduct or intentional misconduct of the Licensee Indemnitees.


c. Licensee agrees, at its own expense to defend against any actions brought or filed against any party indemnified hereunder with respect to the subject of indemnity contained herein, whether or not such actions are rightfully brought.



11
--------------------------------------------------------------------------------


This entire Section 6.1 shall survive expiration or termination of this Agreement.


6.2. Insurance


a. Beginning at the time as any such product, process or service is being commercially distributed or sold (other than for the purpose of obtaining regulatory approvals) by Licensee or by a Sublicensee, Affiliate or agent of Licensee, Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts not less than $2,000,000 per incident and $2,000,000 annual aggregate and naming the Indemnitees as additional insureds. Such commercial general liability insurance shall provide (a) product liability coverage and (b) contractual liability coverage for Licensee`s indemnification under Section 6.1 of this Agreement. If Licensee elects to self-insure all or part of the limits described above (including deductibles or retentions which are in excess of $250,000 annual aggregate) such self-insurance program must be acceptable to the Licensor and the Risk Management Foundation of the Harvard Medical Institutions, Inc. The minimum amount of insurance coverage required under this Section 6.2 shall not be construed to create a limit of Licensee`s liability with respect to its indemnification under Section 6.1 of this Agreement.


b. Licensee shall provide Licensor with written evidence of such insurance upon request of Licensor. Licensee shall provide Licensor with written notice at least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance; if Licensee does not obtain replacement insurance providing comparable coverage within such fifteen (15) day period, Licensor shall have the right to terminate this Agreement effective at the end of such fifteen (15) day period without notice of any additional waiting periods.


c. Licensee shall maintain such commercial general liability insurance during (a) the period that any such product, process or service is being commercially distributed or sold (other than for the purpose of obtaining regulatory approvals) by Licensee or by a Sublicensee, affiliate or agent of Licensee and (b) a reasonable period after the period referred to in (iii) (a) above which in no event shall be less than fifteen (15) years.


d. This Section 6.2 shall survive expiration or termination of this Agreement. Any Sublicensee shall maintain insurance in favor of Licensor under the same terms as set forth above.


6.3 Warranty Disclaimer


LICENSOR MAKES NO EXPRESS OR IMPLIED WARRANTY INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY OR ANY IMPLIED WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY OF THE LICENSED TECHNOLOGY OR ANY LICENSED PRODUCTS AND HEREBY DISCLAIMS THE SAME.



12
--------------------------------------------------------------------------------


LICENSOR MAKES NO EXPRESS OR IMPLIED WARRANTY THAT THE MANUFACTURE, USE OR SALE OF ANY LICENSED PRODUCT WILL NOT INFRINGE ANY PATENT OR OTHER RIGHT OF ANY PARTY AND HEREBY DISCLAIMS THE SAME.




VII. TERM AND TERMINATION


7.1 Term. Unless terminated earlier under the provisions of this Agreement, this Agreement will expire when Licensee has no further obligation to make or cause to be made any royalty or other payment under Section 3 of this Agreement.


7.2 Termination by Licensor. Licensor shall have the right to terminate this Agreement and the license granted hereunder upon the happening of any of the following events:


a. Licensee fails to pay or cause to be paid any royalty or other material payment which has become due to Licensor under Section 3 of this Agreement, within thirty (30) days after receiving a written request from Licensor to make such payment or to cause such payment to be made;


b. Licensee fails to comply with any due diligence requirement provided for in Section 5.1; or


c. Licensee is in breach of or default under any other material provision of this Agreement and has not cured such breach or default within sixty (60) days after written notice from Licensor to Licensee specifying the nature of such breach or default


7.3. Termination by Licensee. Licensee shall have the right to terminate this Agreement in the event that Licensor is in breach of or has defaulted under any provision of this Agreement and has not cured such breach or default within thirty (30) days after written notice from Licensee to Licensor specifying the nature of such breach or default.

7.4. Effect of Termination.

a. Upon termination of this Agreement for any reason, nothing herein shall be construed to release either Party from any obligation that matured prior to the effective date of such termination.


b. Upon any termination of this Agreement by Licensor, Licensee shall permit Licensor to purchase and otherwise have the benefit of all regulatory approvals of, or clinical trials or other studies conducted on, and all filings made with regulatory agencies in connection with, the Licensed Technology (“R&D Materials”) in order to assist Licensor or its licensees in developing the Licensed Technology and obtaining any approvals required to make, have made, use, offer to sell or sell Licensed Products. In the event Licensor desires to purchase the R&D Materials, it shall provide written notice of same to Licensee within a reasonable time following termination of the Agreement. Upon Licensee’s receipt of the written notice, Licensee and Licensor shall mutually select a valuation expert knowledgeable in the valuation of the R&D Materials. The expert shall provide an appraisal of the R&D Materials within sixty (60) days of his or her selection, which appraisal shall be binding on all parties. In the event the Licensor and the Licensee cannot mutually agree on the selection of an appraiser within thirty (30) days following Licensee’s written notice to Licensor, Licensee and Licensor shall each select a valuation expert knowledgeable in the valuation of the R&D Materials. The two experts selected by the Licensor and the Licensee shall evaluate and provide an appraisal of the R&D Materials within sixty (60) days of their selection, which appraisal shall be binding on all parties. In the event the valuation experts selected by the parties cannot agree on an appraisal, they shall select a third valuation expert, who shall review all relevant information and shall issue a final appraisal within thirty (30) days of his selection, which shall be binding on Licensor and Licensee. Each party shall bear its own costs in connection with the valuation process, including the fees associated with its own valuation expert. In the event a third valuation expert is required, the Licensor and the Licensee shall each pay one-half of all associated expenses.


13
--------------------------------------------------------------------------------


c. The provisions of Sections 4.2 (Confidential Information), 4.3 (Enforcement of Intellectual Property Rights), 6.1 (Indemnification), 6.2 (Insurance), 6.3 (Warranty Disclaimer), and 8 (Dispute Resolution) shall survive termination of this Agreement for any reason.

i. Licensee and any Sublicensee may, after Termination, sell all Licensed Products which are in inventory at the time of termination, and complete and sell Licensed Products which Licensee can clearly demonstrate were in the process of manufacture at the time of such termination, provided that Licensee shall pay to Licensor any royalties due on the sale of such Licensed Products and shall submit reports, in accordance with this Agreement.



14
--------------------------------------------------------------------------------


VIII. DISPUTE RESOLUTION


8.1 Arbitration. Any controversy, claim or other dispute arising out of this Agreement or relating to the subject matter hereof shall be decided by binding arbitration. Each party shall select an arbitrator from a list of qualified arbitrators practicing in the Boston metropolitan area, and these two arbitrators shall select a third arbitrator. The arbitrators together shall agree on customary rules and procedures, and may, but are not obligated to, adopt the rules employed by the American Arbitration Association. Nothing contained herein shall subject the parties to the jurisdiction of the American Arbitration Association or its fee structure. This agreement to arbitrate shall be specifically enforceable under the prevailing arbitration law. The award rendered by the arbitrator shall be final and binding on all parties, and judgment may be entered thereon in any court having jurisdiction thereof. The arbitration shall be held in the Boston, Massachusetts metropolitan area. All costs and fees associated with the arbitrators and the arbitration shall be shared equally by the parties. In addition, each party shall pay its own attorney’s fees.


IX. GENERAL


9.1 Assignment. This Agreement shall be binding upon and shall inure to the benefit of each Party and each Party`s respective transferees, successors and assigns, provided, however, that neither Party shall have the right to assign this Agreement or its rights and obligations hereunder to any other Person without the prior written consent of the other Party, except as expressly provided in this paragraph. Each Party may assign or otherwise transfer this Agreement and the License granted hereby and the rights acquired by it hereunder in connection with a sale or other transfer of such Party`s entire business or that part of such Party`s business to which the License granted hereby relates, provided, in all such cases, that any such assignee or transferee has agreed in writing to be bound by the terms and provisions of this Agreement or is so bound by operation of law. Any purported assignment in violation of the provisions of this paragraph shall be null and void.


9.2 Entire Agreement/Amendments This Agreement constitutes the entire and only agreement between the Parties relating to Licensed Invention, and all prior negotiations, representations, agreements and understandings are superseded hereby. No agreements amending, altering or supplementing the terms hereof may be made except by means of a written document signed by a duly authorized representative of each Party.


9.3 Notices. Any notice, communication or payment required or permitted to be given or made hereunder shall be in writing and, except as otherwise expressly provided in this agreement, shall be deemed given or made and effective (i) when delivered personally; or (ii) when delivered by telex or telecopy (if not a payment); or (iii) when received if sent by overnight express or mailed by certified, registered or regular mail, postage prepaid, addressed to parties at their address stated below, or to such other address as such party may designate by written notice in accordance with the provisions of this Section 9.3.


15
--------------------------------------------------------------------------------


LICENSOR:

Chief, Business Ventures

Technology Ventures Office

Beth Israel Deaconess Medical Center

330 Longwood Avenue

Boston, MA 02215



With a copy to: General Counsel

Legal Department

CareGroup, Inc.

109 Brookline Ave.

Boston, MA 02215



LICENSEE: Richard Gabriel

DNAPrint Genomics, Inc.

900 Cocoanut Avenue

Sarasota, FL 34236



With a copy to: Thomas P. McNamara, P.A.

2909 Bay to Bay Blvd., Suite 309

Tampa, FL 33629


9.4 Governing Law. This Agreement shall be construed and enforced in accordance with the domestic substantive laws of Massachusetts without regard to any choice or conflict of laws rule or principle that would result in the application of the domestic substantive law of any other jurisdiction other than (i) United States federal law, to the extent applicable and (ii) in regard to any question affecting the construction or effect of any patent, the law of the jurisdiction under which such patent is granted.

9.5 Headings. Headings included herein are for convenience only, and shall not be used to construe this Agreement.

9.6 Independent Contractors. For the purposes of this Agreement and all services to be provided hereunder, each shall be, and shall be deemed to be, an independent contractor and not an agent, partner, joint venturer or employee of the other party. Neither party shall have authority to make any statements, representations or commitments of any kind, or to take any action which shall be binding on the other party, except as may be explicitly provided for herein or authorized in writing


9.7 Severability. If any provision of this Agreement shall be found by a court of competent jurisdiction to be void, invalid or unenforceable, the same shall either be reformed to comply with applicable law or stricken if not so conformable, so as not to affect the validity or enforceability of this Agreement.


16
--------------------------------------------------------------------------------


9.8 No Waiver. Failure of either party to enforce a right under this Agreement shall not act as a waiver of that right or the ability to later assert that right relative to the particular situation involved or to terminate this Agreement arising out of any subsequent default or breach.

9.9 Limitation of Liability. Neither Party shall be liable to the other Party for indirect, incidental or consequential damages arising out of any of the terms or conditions of this Agreement or with respect to its performance or lack thereof.

9.10 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall constitute an original document, but all of which shall constitute the same agreement.


[THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK]


17
--------------------------------------------------------------------------------



IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives as of the date first set forth above.



THE BETH ISRAEL DEACONESS MEDICAL CENTER [LICENSEE]



By: By:

--------------------------------------------------------------------------------
Paul F. Levy
--------------------------------------------------------------------------------
Richard Gabriel
Title: President Title: President


18
--------------------------------------------------------------------------------


Schedule 1.8


LICENSED FIELD


All fields of use.


19
--------------------------------------------------------------------------------


Schedule 1.10


LICENSED PATENTS


The following patents and patent applications:


APPENDIX A:


Recombinant Fusion Dimers:


US Patents:


1. US Patent Application Serial No. 08/890,929, issued 6/05/01, entitled “Production and use of Recombinant Protein Multimers with Increased Biological Activity”


2. US Patent Application Serial No. 6,187,564 CIP, issued 2/03/98, entitled “Production and use of Recombinant Protein Multimers with Increased Biological Activity”

Foreign Patents:

1. PCT/US98/13944(EPO, CA, AU, JP), filed 7/10/98, entitled “Production and use of Recombinant Protein Multimers with Increased Biological Activity”

Chemically Cross-Linked Dimers:


US Patents:

1. U.S. Patent Application Serial No.5,747,445, issued 5/05/98, entitled “Modified Polypeptides with Increased Biological Activity”



2. U.S. Patent Application Serial No.5,919,758, issued 7/06/99, entitled “Modified Polypeptides with Altered Biological Activity”



3. U.S. Patent Application Serial No.6,107,272, issued 8/22/00, entitled “Modified Polypeptides with Increased Biological Activity”



Foreign Patents:

1. PCT/US95/03242(EPO, AU, CA, JP), issued 3/15/95, entitled “Modified Polypeptides with Increased Biological Activity”



2. PCT/US97/22503(EPO, AU, CA, JP), pending, entitled “Modified Polypeptides with Increased Biological Activity”



20
--------------------------------------------------------------------------------


Schedule 1.12


LICENSED TERRITORY


All territories, worldwide


21
--------------------------------------------------------------------------------


Schedule 3.1(i)


LICENSING FEES




Upon execution of this Agreement, Licensee shall pay to Licensor $25,000 as a license signing fee.


Each of the fees specified in this Schedule are non-refundable and shall not be credited against any other payments due to Licensor under this Agreement, unless otherwise stated in this Agreement or subsequent amendments of this Agreement.



22
--------------------------------------------------------------------------------


Schedule 3.1(ii)


RUNNING ROYALTIES


Licensee shall pay or cause be paid, to Licensor a running royalty equal to the Applicable Percentage of Net Sales of Licensed Products, as follows:


The running royalty shall equal 4% of Net Sales.

AND:


Licensee shall pay any applicable withholding taxes.


Licensee`s obligation to pay a running royalty with respect to the Net Sale of any Licensed Product shall terminate on a country-by-country basis, upon the later of (i) the last to expire of any Licensed Patent applicable to the manufacture, use or sale of such Licensed Product and (ii) the date that is [15] years from the First Commercial Sale in such country. First Commercial Sale shall mean, with respect to any country, the first bona fide arm`s-length sale of Licensed Product in such country following receipt of all regulatory approvals necessary to commence regular, commercial scale sales of Licensed Product in such country. Any sale prior to receipt of all approvals necessary to commence commercial sales, such as any so-called "named patient sale" or "compassionate use" sale, shall not be a First Commercial Sale.

By way of example, if seventeen years after the First Commercial Sale of a Licensed Product in Country Z, a Licensed Product is manufactured in Country X, where such manufacture would, but for the license granted hereby, infringe a valid claim of an unexpired Licensed Patent, Licensee shall pay or cause to be paid to Licensor a running royalty on the Net Sales of such product in Country Z as compensation to Licensor for the license to manufacture such product in Country X, even if the sale of such product in Country Z would not infringe any valid claim of any Licensed Patent.


Within 60 days of the end of each calendar quarter in which any Net Sales occur, Licensee shall calculate the running royalty amount owed to Licensor and shall remit to Licensor the amount owed to Licensor. Such payment shall be accompanied by a statement showing the calculation of the amount owed for each country, the total Net Sales of Licensed Product by country for that quarter, the exchange rate used to convert any royalty amounts into United States dollars and the total Net Sales for that quarter in all countries. For purposes of determining when a sale of a Licensed Product occurs, the sale shall be deemed to occur on the date the Licensee invoices the purchaser in a Commercial Sale. Notwithstanding any language contained herein, any Commercial Sale that is subsequently deemed a bad debt by Licensee in accordance with GAAP shall no longer be considered a Net Sale for purposes of calculating Licensee’s royalty obligations under this License. Any royalty paid by Licensee in connection with a Net Sale subsequently deemed a bad debt shall reduce, dollar for dollar, any future royalty payment due Licensor.



23
--------------------------------------------------------------------------------


Schedule 3.1(iii)

MINIMUM ROYALTIES




Upon commencement of Commercial Sales anywhere, Licensee shall pay $100,000 per year.


The foregoing minimum royalties shall be non-refundable to Licensee and shall be creditable against any royalties subsequently due during the next year.


24
--------------------------------------------------------------------------------


Schedule 3.1(v)


MILESTONE PAYMENTS




Licensee shall make the following payments to Licensor within 15 days of the initial occurrence of each of the following events:






Event Amount

Initiation of the first Phase I trial of Licensed Product (either chemically linked or recombinant fusion EPO dimers) $ 150,000 *

Initiation of first Phase II trial of a Licensed Product (either chemically linked of recombinant fusion dimers) $ 250,000 *

Regulatory approval by Asian or [South American Country] for EPO dimers $ 150,000

First commercial sale of Licensed Product of EPO dimers in [Asian or South American Country] $ 150,000

Regulatory approval by US FDA of recombinant fusion or chemically linked EPO dimers $ 450,000

Regulatory Approval by EMEAA of recombinant fusion or chemically linked EPO dimers $ 500,000

First commercial sale of a Licensed Product in the United States or Europe of recombinant fusion or chemically linked EPO dimers $ 500,000





The foregoing milestone payments shall be non-refundable to Licensee and are not creditable against any other payments payable to Licensor under this Agreement.




* 50% to be credited against future product royalties


25
--------------------------------------------------------------------------------


Schedule 3.1(vi)


SUBLICENSING AND OTHER FEES




In the event Licensee shall receive, in connection with the grant to any third party or parties of a sublicense or other right, license, privilege or immunity to make, have made, use, offer to sell, sell or otherwise dispose of Licensed Products, any of the following forms of consideration, Licensee shall pay to Licensor within 30 days of Licensee`s receipt of any such consideration the specified amount:


BIDMC to receive 20% of fees, earned royalties (if earned royalties percentage is greater than those end-sales net royalties as above), and lump sum or milestone payments attributable to sublicenses of Recombinant Fusion Dimer Licensed Patent Rights; And,

BIDMC to receive 15% of fees, earned royalties (if earned royalties percentage is greater than those end-sales net royalties as above), and lump sum or milestone payments attributable to sublicenses of Chemically Cross-Linked Dimer Licensed Patent Rights, including but not limited to technology access fees, license issue fees, but excluding research support received by DNAP.



26
--------------------------------------------------------------------------------


Schedule 4.1

PATENT PROSECUTION




Licensor shall be responsible for prosecuting and maintaining all Licensed Patents. Without limiting the generality of the foregoing, Licensee shall reimburse Licensor for all costs incurred as of and following the Effective Date, in connection with the preparation, filing, prosecution and maintenance of any patent applications and patents included in the Licensed Patents. Licensee shall cooperate with Licensor in regard to such maintenance and prosecution. Licensor shall provide Licensee with copies of all filings and relevant documentation and an opportunity to comment thereon prior to their submission. Should Licensor determine to abandon prosecution of, or to cease to maintain, any Licensed Patent, in any jurisdiction, Licensor shall so notify Licensee and shall permit Licensee, should Licensee choose to do so, at Licensee’s expense, to continue to prosecute or maintain such Licensed Patent in such jurisdiction, and Licensor shall cooperate with Licensee in regard thereto.



27
--------------------------------------------------------------------------------


Schedule 5.1


SPECIFIC DUE DILIGENCE OBLIGATIONS


Prior to execution and delivery of this Agreement, Licensee shall produce a development and commercialization plan acceptable to Licensor. Such plan shall indicate (to the extent practicable and on a product-by-product basis, if appropriate) Licensee`s currently expected research and development budget; regulatory approval, patent prosecution, marketing and manufacturing strategies; and expected sources of funding. In addition, Licensee shall adhere to the following diligence milestones:




Event: Date:

Production of GMP grade EPO dimers 03/2006

First commercial sale of a Licensed Product in Asia or S. America 12/2011

First commercial sale of Licensed Product in US/Western Europe 12/2012



28
--------------------------------------------------------------------------------





Copyright © 2005 QuoteMedia. All rights reserved. Terms of Use.
Financial data powered by QuoteMedia, www.quotemedia.com, SEC filings by 10kWizard.

[Menglovator]

http://dnap.1hwy.com/welcome.html

http://www.investorshub.com/boards/board.asp?board_id=113

[MichiMischtMit]

Ich habe heute 10.000 Stück gekauft,
und warte bis die mind. 1 Dollar kosten

Träumen wird ja erlaubt sein

[MichiMischtMit]

Und außerdem ist dieser Traum ja billig wie sonst was
Gerade mal 90 €

[hvs1]

MichiMischtMit,

Deine Träume gefallen mir,auch wenn ich nicht so billig
reingekommen bin.

hvs1

[luto9]

bis DNAP bei $1 angekommen ist, brauchst Du wahrscheinlich
noch nicht mal mit der Eichel teilen

[MichiMischtMit]

Ich habe nochmal nachgelegt.
Jetzt habe ich 20.000

[kai.hawaii]

# 491

na, meine 100k zu 0,0100 fse haben ja auch gegriffen, nachdem ich mein limit von 0,009 leider gestern heraufsetzen musste. in amiland geht´s ja wieder ab. schade, dass ich dort nicht längst zusätzlich gekauft habe. dnap ist und bleibt spannend und meine wenigkeit ist auch nur mit spielgeld drin.

wenn die jetzt noch einmal auch nur kurz stark anziehen, glaube ich, es ist an der zeit, auch mal mit grösseren summen reinzugehen. da wir nahe dem allzeittief sind, kann ja so wirklich viel nicht schiefgehen. und fantasie ist auch reichlich vorhanden - auch für längerfristiges liegenlassen und nachkaufen. ein blick auf den 3-jahres-chart und das volumen der letzten wochen ist ja vielversprechend.

ich will ja nicht pushen. aber mein intradaychart hat gerade 0,15 in amerika angezeigt. vermutlich ein technischer ausreisser. oder wer bietet über 1000% ??? na, jedenfalls scheint dnap 30% im plus zu sein - bis jetzt...

[Optimierer]

Hi,

DNAP ist und bleibt eine Träumerbude wie damals Mark Hoffman
von Commerceone, heute pleite.
Bin Laden läßt grüßen.........!!!



Gruß Opti.....

[kai.hawaii]

# 497

hi optimierer,

du scheinst zu vergessen, dass commerceone von 0,04 auf über 0,18 nach dem knall gestiegen ist. hierbei habe ich immerhin 320% nutzen können. und dnap sperrt nicht mitarbeiter aus und ist nicht insolvent, sondern hat fantasie. und kostet nur 0,014 gerade.

viel glück weiterhin.

[alex1975]

mittagspause rum? über 30.000.000 stücke gehandelt und wieder 0,016 - man bedenke, dass freitag ist und solche werte freitags ganz gern abgestoßen werden!

aktuell aber +29% - sieht nach einer interessanten nächsten woche aus ! weiterhin viel erfolg den investierten!

[Michiko]

HEY!

WASN DAS FÜR NE ID???